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MOTIVATION AND CONTEXT 
 
According to the American Cancer Society, the prostate cancer (PCa) is the most frequent 
malignancy in men. After lung cancer, the PCa is the second leading oncological cause of death. 
Despite many years of research, the main current treatments are still surgery, radiation and androgen 
deprivation therapy. The androgen ablation ultimately leads to the development of a more advanced, 
hormone-refractory (castration-resistant) form of prostate cancer, which responds poorly to standard 
chemotherapy and is considered to be terminal. It is evident that there is an urgent need for the 
discovery of alternative targets and the development of new therapeutic approaches for prostate 
cancer treatment. 
The design of new therapeutic agents against prostate cancer depends critically on our 
knowledge of the molecular mechanisms of cancer origin and progression. In 2007 the term “non-
oncogene addiction” was proposed by Elledge and co-authors to explain the increased dependency 
of cancer cells on the function of normal genes. The phenomenon is based on increased cellular 
stresses experienced by cancer cells (mitotic, proteotoxic, metabolic, etc.), making them more 
dependent on stress support systems. Among these, the ubiquitin-proteasome system (UPS), as a 
major mediator of key cellular functions, represents a perfect model for a loss-of-function screen to 
search for potential drug targets based on non-oncogene addiction. 
This work was carried out in the Biomics laboratory, which is specialized in functional 
genome-wide screens and biomarker discovery targeting prostate cancer. In the course of the project, 
we applied a novel systematic approach to the loss-of-function screen of the UPS. Our strategy was 
to employ the cascade organization of the UPS and its hierarchical mode of function. Compared to 
standard genome-wide screens, this "cascade profiling" results in a rather compact and more targeted 
screen, which facilitates hits identification. Using this approach we have identified components of 





LIST OF ABBREVIATIONS 
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AIDS – acquired immune deficiency syndrome 
AJs – adherens junctions 
AKT – v-Akt murine thymoma viral oncogene homolog 1 
AMACR - alpha-methylacyl-coa racemase 
AR – androgen receptor 
ATCC - American Type Culture Collection 
ATG12 – autophagy 12 
ATG8 – autophagy 8 
ATM – ataxia telangiectasia mutated 
bp – base pair 
BPH – benign prostatic hyperplasia 
BRCA – breast cancer 
BSA – bovine serum albumin 
CAND1 – cullin-associated and neddylation-dissociated 1 
Caspase – cysteine-aspartic proteases 
CHD1 – chromodomain helicase DNA binding protein 1 
ChSM – DMEM supplemented with the charcoal/dextran stripped FBS 
c-Myc – v-Myc avian myelocytomatosis viral oncogene homolog 
COP1 – constitutive photomorphogenesis protein 1 homolog 
CR – castration resistant 
CRL – Cullin-RING-Ligase 
CUL1-7 – cullins 1-7 
DAPI – 4'6-diamidino-2-phenylindole 
DDR – DNA-damage response 
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DMEM – Dulbecco’s Modified Eagle's Medium 
DMSO – dimethyl sulfoxide 
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DSB – double stranded breaks 
dsRNA – double-stranded RNA 
DUB – deubiquitylating enzyme 
E1 – ubiquitin-activating enzymes 
E2 – ubiquitin-conjugating enzymes 
E3 – ubiquitin-protein ligases 
EdU – 5'-ethyl-2'-deoxyuridine 
EGFR – epidermal growth factor receptor 
EMT – epithelial-to-mesenchymal transition 
ERG – ETS-related gene 
ETS – v-Ets avian erythroblastosis virus E26 oncogene homolog 1 
ETV1-5 - Ets variants 1-5 
FACS – fluorescent activated cell sorting 
FAK – focal adhesion kinase 
FAs – focal adhesions 
FAT10 – HLA-F adjacent transcript 10 
FAU – Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) ubiquitously expressed
FBS – fetal bovine serum 
GS – Gleason Score 
gSD – global Standard Deviation 
HIF1α – hypoxia-inducible factor-1 alpha 
IRS-1 - insulin receptor substrate 1 
ISG15 – interferon-stimulated gene product of 15 kDa 
IκB – inhibitor of NF-κB 
LAP – leukemia associated protein 
Lys – lysine 
MDM2 – mouse double minute 2, human homolog of; p53-binding protein 
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miRNA – micro RNA 
mRNA – messenger RNA 
MSMB – microseminoprotein, Beta- 
MW – molecular weight 
NAE – NEDD8 activating enzyme E1 subunit 1 
NEDD8 – neural precursor cell expressed, developmentally down-regulated 8 
NF-κB – nuclear factor kappa B 
NKX3-1 – NK3 Homeobox 1 
nt – nucleotide 
Opti-MEM – reduced serum modification of eagle's minimum essential media 
p21 – cyclin-dependent kinase inhibitor 1A 
p27 – cyclin-dependent kinase inhibitor P27 
p53 – tumor protein p53 
PBS – phosphate buffered saline 
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PCa – prostate cancer 
PCA3 – prostate cancer antigen 3 
PDGFRβ – platelet-derived growth factor receptor, beta polypeptide 
PFA – paraformaldehyde 
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PSMA – prostate-specific membrane antigen 
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Rb – retinoblastoma 1 
RBR – ring between ring 
RBX1/2 - RING-box 1/2, E3 Ubiquitin Protein Ligase 
RdRP – RNA-dependent RNA-polymerase 
RING – Really Interesting New Gene 
RISC – RNA-induced silencing complex 
RLC – RISC loading complex 
RNA – ribonucleic acid 
RNAi – RNA interference 
siRNA – small interfering RNA 
SPOP – speckle-type POZ protein 
StdM – DMEM supplemented with standard FBS 
SUMO – small ubiquitin-like modifier 
TGFβ – transforming growth factor beta 
TICs – tumor-initiating cells 
TJs – tight junctions 
TMPRSS2 – transmembrane protease, serine 2 
TMPRSS2:ERG – genetic fusion of TMPRSS2 and ERG genes 
Ub – Ubiquitin 
UFM1 – ubiquitin-fold modifier 1 
ULM – Ubiquitin-like modifiers 
UPS – Ubiquitin-proteasome system 
URM1 – for ubiquitin-related modifier 1 
UTR – untranslated region 
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CHAPTER 1. PROSTATE CANCER 
 
While in developing countries respiratory infections and AIDS are the most 
mortal diseases, in developed countries, medicine and technology allow people to 
overcome these health problems and live longer, which make heart disease and cancer the 
leading causes of death (http://www.who.int/). Prostate cancer (PCa) is the most often 
diagnosed malignancy (1 in 6 men is diagnosed with PCa during their lifetime) and the 
second leading cause of death from cancers (Jemal et al., 2011; Siegel et al., 2012; 
Stewart & Wild, 2014). Despite high incidence of PCa, the prognosis is usually positive – 
only 1 of 100 men will have progression to an aggressive form during the 5 years 
following diagnosis, and the best treatment option in this case – is watchful waiting. 
Nevertheless, in some patients PCa progresses to terminal disease with extremely fast 
metastasis that requires intensive therapy. Apart from that, current treatment options 
(radio-, chemo- and androgen-deprivation therapy) ultimately lead to the development of 
more advanced forms of prostate cancer - castration-resistant and metastatic PCa. 
Metastatic cancer is considered to be incurable and only 1/3 of patients with metastatic 
PCa survives the 5 years following diagnosis. Better understanding of prostate cancer 
biology would allow clinicians to distinguish relatively indolent forms of prostate cancer 
from aggressive ones. In our research we are searching for proteins involved in the 
viability of prostate cancer cells thus giving an insight in prostate cancer biology. In this 
chapter I describe: (I) epidemiology of prostate cancer, (II) major biomarkers that 
clinicians currently use to determine disease stage and prognosis, and (III) the prevalent 
mutation in prostate cancer, TMPRSS:ERG, and its influence on prostate cancer 
development. 
1.1 STRUCTURE AND FUNCTION OF PROSTATE 
The prostate is a little (3 cm diameter, about 20 grams) auxiliary exocrine gland of 
the male reproductive system located in the anteroinferior part of the pelvis where it 
encloses the urethra and bladder neck. An adult human prostate consists of 3 concentric 
zones (transition/periurethral, central, peripheral), and an anterior fibro-muscular zone 
(Figure 1). The majority of cancers are found in the peripheral zone of the prostate, the 
transition zone in the second place, and almost none in the central zone (De Marzo et al., 
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2007). In contrast, benign prostatic hyperplasia (BPH), a common nonmalignant 
condition found in older men, arises mostly from the transition zone. The prostate is both 
a glandular and muscular body. About a half of the volume of the prostate is taken up by 
30-50 small glands (usually thin branching tubules), forming wedge-shaped slices 
draining into the urethra. The second half of the gland is distributed evenly between fibro-
elastic stroma and randomly orientated smooth muscle bundles that help expel semen 
during ejaculation and form the involuntary urethral sphincter (Shen & Abate-Shen C., 
2010). 
At the histological level, the glandular epithelium of the prostate is mainly 
pseudostratified, comprising tall columnar luminal cells, basal and neuroendocrine cells. 
Tall columnar cells express high levels of androgen receptor (AR), and are responsible for 
the secretory functions of the prostate. They are controlled by the endocrine system and 
respond by the production of unique complex of secretions involved in the fertilization of 
the egg. Basal cells, comprising about 10% of prostatic epithelium, are almost devoid of 
secretory products. They lie on the basal membrane and are wedged between columnar 
cells. It is believed that these cells function as stem cells and are ancestors of luminal 
cells (Merk et al., 1982; Shen & Abate-Shen, 2010). Finally, neuroendocrine cells are 
singular cells producing growth-support secretions (Davis, 1987; Abrahamsson & Lilja, 
1989). 
There is a large variety of types of sensory nerve receptors in the prostate: Vater-
Pacini corpuscles (lamellar bodies), Krause’s end bulb, etc. An extensive network of 
nerve ganglia and nodes around the prostate is so large that relatively small pathological 
changes often lead to severe disorder. Nerve fibers are connected with other nerves of the 
pelvic organs, primarily with the bladder, seminal vesicles, rectum, vas deferens, and 
corpus cavernosum. The close interweaving of the pelvic nerves may facilitate the 
transmission of stimuli (e.g., inflammation) to other pelvic organs. Because of this effect, 






Figure 1. Structure of the prostate. http://teachmeanatomy.info/pelvis/the-male-reproductive-system/prostate-gland/ 
 
1.2 EPIDEMIOLOGY OF PROSTATE CANCER 
The main risk factors for the development of prostate cancer are: aging, family 
history, race (for African-Americans this type of cancer is diagnosed more frequently and 
more often leads to death), hormonal changes, genetic mutations and lifestyle (Reiter & 
de Kernion, 2002). The prevalent form (95%) of prostate cancer is adenocarcinoma 
originating from columnal cells in the acini and glandular part of the ducts. Other 
categories of prostate cancer – such as ductal adenocarcinoma, mucinous carcinoma, and 
signet ring carcinoma – are extremely rare. 
As it was mentioned before, PCa is one of the most often diagnosed malignancies 
in men. Since the introduction of prostate specific antigen (PSA) screening, the rates of 
prostate cancer mortality and incidence began to stabilize and then decline since 1990s. 
PCa incidence decreases 2.4% per year, and the number of PCa-related deaths declines by 
3.4% per year (Figure 2). Despite high incidence of this type of cancer, the prognosis is 
usually positive: PCa is usually confined within the gland and progresses slowly. The 
percentage of patients surviving 5 years comprises 98.9% (Edwards et al., 2014). 
Nonetheless, long-term survival is not as good, because the main treatments often lead to 
the development of highly aggressive metastatic form of PCa (Elledge, 2010). 
The clinical course of localized untreated prostate cancer is still unclear. 
Progression of the disease to the metastatic form within 10-15 years following diagnosis 
is not frequent (5% of all PCa cases according to American Cancer Society), but the 
further follow-up has shown that even primarily indolent localized prostate cancer can 
proceed to a more aggressive form, invading surrounding tissues and giving metastases in 
the lymph nodes and the bones as the major sites (McNeal JE, 1992). To prevent 
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overtreatment, it is necessary to understand the prolonged natural history of the disease 
(McNeal, 1969; McNeal, 1992; Johansson et al., 2004; Shen MM & Abate-Shen C., 
2010). 
 
Figure 2. Number of new cases and deaths from prostate cancer per 100,000. Figure from Edwards et al., 2014 
 
Therapeutic decisions based on correct diagnosis and accurate staging of prostate 
cancer is critically important for the fate of the patient. Early diagnosis of prostate cancer 
includes three main options: (1) measurement of PSA in blood, (2) digital rectal 
examination and (3) ultrasound-guided transrectal biopsy of the prostate with further 
immunostaining for specific markers (anti-p63, cytokeratin 5 and 14). The most important 
prognosis factors are the initial (pre-therapeutic) level of total serum PSA and the 
Gleason score (G2-G10, discussed below in more details). Patients are also diagnosed by 
the status of their primary tumors, from organ-confined to fully invasive (T1–T4), with or 
without lymph node involvement (N0 or N1), and the presence and degree of distant 
metastases (M0 and M1a–c). Prostate cancer is often preceded by a stage of pre-cancer, 
and timely identification of this condition significantly helps to determine prognosis and 
treatment. To date, Prostatic Intraepithelial Neoplasia (PIN) remains as the only well-
proven preneoplastic condition with clinical significance (Armah & Parwani1, 2008; 
Shen & Abate-Shen, 2010). 
For early diagnosed organ-confined prostate cancer current treatment options 
include watchful waiting, surgery (radical prostatectomy) and radiotherapy - external or 
brachytherapy (implantation of radioactive “seeds”). This type of PCa is curable with 
very good survival and cure rates, but the disease relapses in approximately 25% of 
patients. Nevertheless, choice of treatment option is very questionable – localized cancer 
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rarely progresses to a fatal form and some patients receive overtreatment while others die 
during prostatectomy. For more malignant forms, combined therapy regimens 
(brachytherapy, hormone therapy and chemotherapy) are applied specifically according to 
the disease’s stage, patient’s age and personal choice. In the case of advanced cancer, 
these regimens are usually followed or substituted by androgen deprivation therapy 
(chemical or surgical castration), which initially will reduce tumor burden, but inevitably 
leads to the development of a more destructive form of prostate cancer - androgen-
independent (or castration-resistant, CR-PCa) prostate cancer (Bardan et al., 2007; Shen 
& Abate-Shen, 2010). This recurrent disease has a median survival rate of less than 2 
years. For CR prostate cancer, the only approved therapy is with docetaxel and provides a 
modest survival benefit of 2 to 3 months. 
To explain the emergence of CR-cancer, Isaacs and Coffey proposed that 
androgen withdrawal results in the natural selection of the androgen-refractory cells 
initially present in heterogeneous prostate tumor (Isaacs & Coffey, 1981). Indeed, several 
observations suggest that prostate tumor-initiating cells (TICs) do not express androgen 
receptor (AR) (Gu et al., 2007; Kasper, 2009). In addition, prostate neuroendocrine cells, 
which have been implicated in CR-PCa, are androgen-independent (Cindolo et al., 2007). 
Despite this evidence, however, it is widely established that in the majority of CR tumors, 
AR remains the key driver of cancer progression. Notably, castration-resistant tumors 
express AR as well as AR target genes such as PSA, indicating that pathway activity is 
intact (Gregory et al., 1998). Androgen ablation has been shown to select for TIC clones 
with aberrant, androgen-independent AR signaling (Wang & Shen, 2011). This arises 
through a variety of mechanisms, including mutations that change AR function, 
inactivation of tumor suppressors, activation of oncogenes, increase in autocrine 
stimulation, and rearrangement of cell signaling pathways (Knudsen & Penning, 2010; 
Feldman & Feldman, 2001). As a result, in CR malignant cells, AR executes a 
transcriptional program distinct from that in androgen-responsive cells resulting in 
increased cell survival and androgen-independent growth (Wang et al., 2009). 
It should be noted that in more than 50% of metastatic prostate tumors AR is not 
mutated (Heinlein & Chang, 2004; Knudsen & Penning, 2010). This suggests that the 
aberrant function of AR in androgen-refractory cells results mainly from the changed 
cellular context, i.e. a variety of cellular factors, which define and complement AR 
activity in CR prostate cancer. Comparative genomic analysis of prostate cancer, CR 
tumors and normal prostate cells has revealed numerous genetic alterations and abnormal 
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gene expression profiles in cancer cells (Varambally et al, 2005; Taylor et al, 2010; 
Berger et al, 2011). However, though very valuable for cancer classification and 
prognosis, genomic data tell less about molecular mechanisms of prostate cancer 
progression. A complete understanding of cancer biology requires knowledge of principal 
actors regulating protein interactions and activities. 
1.3 SIGNIFICANT PROGNOSTIC FACTORS 
2.3.1 Gleason score 
To assess the prognosis of patients, clinicians use Gleason Score based on the 
architecture of the prostate glands and the relationship between the tumor cells and the 
surrounding stromal tissue. The Gleason grading system has five levels of tumor 
progression, grade 1 being the least aggressive, while grade 5 is the most anaplastic. 
Usually, prostate tumors are not homogenous. Gleason Score is a sum of Gleason grades 
of the two most typical tumor samples. Thus, it can range from 2 (1 +1) to 10 (5 +5) 
(Bardan et al., 2007). 
In general, the higher the Gleason Score, the more "malignant" the tumor is. 
However, this rule should be used wisely. Generally, the patients with GS ≥ 7 means a 
greater risk for the patient and that it should be treated intensively. Nevertheless, some 
studies using surrogate end points have shown that the prognosis of GS 7 cancers varies 
considerably (Stark et al., 2009). On the other hand, tumors with GS below 4 are 
considered to be indolent and almost never progress to the advanced stage, thus the best 
treatment option in this case – local therapy and watchful waiting. However, after 
universal introduction of routine PSA diagnostics, it became clear that small fraction of 
these “indolent” tumors could progress rapidly and require immediate treatment. 
Consequently, the major clinical challenge is the current inability to readily distinguish 
between indolent and aggressive tumors in prostate cancer patients with a low Gleason 
Score (Shen & Abate-Shen, 2010). 
2.3.2 Prostate specific antigen 
PSA is an organ-specific marker produced by a healthy prostate, and released into 
the blood only in the case of impairment of normal prostate architecture (Lilja et al., 
2008). Thus, while the blood PSA is not a sign of a certain disease or condition, its 
increased level can indicate the presence of a destructive disease, such as adenoma or 
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tumor. This helps to diagnose and monitor PCa progression. PSA in blood serum exists in 
three forms: free, associated with either α-1-antichymotrypsin or with α-2-macroglobulin. 
Two forms of PSA are routinely used in diagnostics: free and α-1-antichymotrypsin-
binded, which add up to a "total PSA". In healthy conditions, PSA is present in serum at a 
very low level, which is age-dependent: 
40-49 years - 2.5 ng/ml 
50-59 years - 3.5 ng/ml 
60-69 years - 4.5 ng/ml 
Over 70 years - 6.5 ng/ml 
Nevertheless, it has been shown that some PCa cases can exist at normal level of 
PSA (Thompson et al., 2004). Men with increased PSA level (10 ng/ml) are 
recommended for prostate biopsy to verify the presence of cancer. To make a decision 
about biopsy in these cases, when serum PSA level is below 10 ng/ml, the ratio of free 
PSA to total PSA becomes crucial: prostate cancer was shown to be associated with the 
formation of protein-bound PSA. “PSA velocity” (the rate of PSA increase) and PSA 
density (the ratio of PSA to prostate volume) are also important prognostic factors 
(Carter, 2006). 
2.3.2 Other potential biomarkers 
Routine PSA screening provides a 20% mortality reduction, because it helps in 
early detection of clinically unapparent, localized tumors with a low GS. However, the 
clinical course of localized untreated prostate cancer is still unclear. Progression to the 
metastatic form in 10-15 years following diagnosis is not frequent, but a further follow-up 
has shown that even primarily indolent localized prostate cancer can proceed to a more 
aggressive form. To prevent overtreatment, it is necessary to understand the prolonged 
natural history of the disease. In order to improve specificity and sensitivity of detection, 
many efforts are being made to identify novel biomarkers. Some of them are already at 
early stages of development and are being evaluated in clinical trials (Duskova & Vesely, 
2014). Examples of such biomarkers are PCA3, PSMA, AMACR, MSMB, etc. One of 
the promising urine biomarkers is TMPRSS2:ERG fusion transcripts. In contrast to PSA, 
which often gives false-negative and false-positive results, TMPRSS2:ERG appears only 
in malignant conditions, which greatly increases the specificity of the test. Some other 
researchers show the efficiency of a multiplexed approach, where the set of markers is 
followed simultaneously that make detection more sensitive and specific. These 
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prominent results could be adjusted for clinical use and would increase the efficiency of 
routing testing for prostate cancer (Rubin, 2012). 
1.4 REARRANGMENTS OF ETS (E26 TRANSFORMATION SPECIFIC) 
TRANSCRIPTION FACTORS 
Localized prostate cancer usually contains histologically and genetically distinct 
areas and thus is regarded as multifocal malignancy. In contrast, despite phenotypical 
differences of metastases in diverse sites, genomic analysis demonstrates their clonal 
origin. During the last few decades, there has been an accumulation of data on molecular 
alterations in PCa, shedding light on the mechanisms of prostate cancer initiation and 
progression. The frequent characteristic mutations have been identified, which include: 
(1) ETS-rearrangements found in more than half of prostate cancer cases (discussed in 
details below); (2) mutations of SPOP component of cullin-RING E3 Ub-ligase complex, 
which are present in up to 15 % of PCa cases; (3) deletion of CHD1 gene (substrate 
recognition component of the transcription regulatory histone acetylation complex 
SAGA) found in up to 15 % of PCa cases. There are also some other less frequent 
mutations/deletions/rearrangements involving PTEN, AR, NKX3-1, p27, p53, Rb and etc. 
(Tomlins et al., 2005; Shen & Abate-Shen, 2010; Yoshimoto et al, 2012; Wyatt et al., 
2014; Yadav et al., 2015). 
The ETS (E26 transformation-specific) family of transcription factors includes 30 
proteins unified by the presence of evolutionarily-conserved ETS domain responsible for 
DNA binding. Also, they contain an N-terminal regulatory domain. The ETS family of 
proteins participates in the regulation of many key cellular processes including 
proliferation, differentiation and apoptosis. In prostate cancer, rearrangements that 
activate ERG, ETV1, ETV4 and ETV5 members of the ETS family have been identified 
(John et al., 2012; Kumar-Sinha et al., 2008; Tomlins et al., 2005; Tomlins et al., 2007b). 
The most frequently rearranged gene in prostate cancer is ERG (ETS related gene) 
(Tomlins et al., 2005). Under normal conditions ERG is constitutively expressed in 
endothelial cells where it regulates angiogenesis and endothelial apoptosis by affecting 
expression of many genes, including eNOS, HO-1, ICAM-2, VE-cadherin, von 
Willebrand's Factor, etc. (Birdsey et al., 2008; Nikolova-Krstevski et al., 2009). The 
major ETS translocation in PCa is TMPRSS2:ERG. TMPRSS2 is a prostate specific, 
androgen responsive transmembrane serine protease (Figure 3). TMPRSS2:ERG fusion 
leads to the ERG expression under control of androgen sensitive promoter elements of 
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TMPRSS2 (St John et al., 2012). There are multiple other 5’ fusion partners of the ETS 
family in PCa (Figure 3). 
Interestingly, these chromosomal rearrangements may be caused by AR function. 
Studies in androgen-responsive LNCaP cells have shown that AR binding induces 
chromosomal proximity between the TMPRSS2 and ERG loci that can lead, upon DNA 
damage, to the formation of TMPRSS2:ERG fusions. In addition, androgen signaling 
recruits topoisomerase II to AR-binding sites, leading to the induction of double-stranded 
breaks even in the absence of genotoxic stress (Shen MM & Abate-Shen C, 2010). Thus, 
ETS fusions could be induced in cells, which, initially, do not harbor these translocations. 
Combined treatment of prostate cancer LNCaP cells or non-cancerous PNT2 cells with 
DHT and γ-irradiation leads to the appearance of cells with ETS rearrangements (Lin et 
al., 2009; Mani et al., 2009; Bastus et al., 2010; Chiu et al., 2012). Unfortunately, the fate 
of these cells has not been followed, and there is no data on whether this rearrangement 
gives some survival advantages to the cells. 
TMPRSS2:ERG is most likely a driver mutation in prostate cancer. The first piece 
of evidence is the enrichment of this translocation during cancer progression. 
TMPRSS2:ERG fusion is found only in 20% of prostatic intraepithelial neoplasia (PIN) 
lesions (Tomlins et al., 2008), and in up to 50% of confined cancers (Taylor et al., 2010), 
suggesting that this rearrangement is often acquired after cancer initiation, or, instead, it is 
an early event in cancer development and predisposes cells to progression to malignant 
state (Tomlins et al., 2005). The second piece of evidence comes from molecular biology: 
the appearance of this translocation in prostatic cells results in overproduction of various 
N-truncated ERG isoforms (Figure 4). ERG, in its turn, causes transcriptional activation 
of oncogenic pathways including Wnt/β-catenin, NF-κB, c-MYC and disruption of AR-
dependent signaling (Birdsey et al., 2015; Yu et al., 2010; Sun et al., 2008; Wang et al., 
2011). This could lead to the development of PIN but is not sufficient to produce invasive 
adenocarcinoma (Klezovitch et al., Tomlins et al., 2008; Zong et al., 2009). Additional 
factors (e.g., AKT activation, enhanced AR signaling and PTEN loss resulting in aberrant 
phosphoinositide 3-kinase (PI3K) pathway) are required for the development of prostate 




Figure 3. ETS rearrangements. This diagram represents all published ETS-fusions grouped by ETS members. 
http://oncofusion.com/pipelines/erg-inhibitors/ 
 
Figure 4. ETS fusions in prostate cancer. Fusion places transcriptional factor ERG (or any other ETS family member, 
i.e. ETV1, ETV4, and ETV5) under the control of AR-responsive promoter that results in overproduction of more or 
less N-truncated ERG protein. ERG, in its turn, activates its own transcriptional program. Acquisition of additional 




The third piece of evidence comes from follow-up studies. Most studies following 
the natural history of the disease show strong correlation between the presence of 
TMPRSS2:ERG fusion and cancer progression to more aggressive forms, metastases and 
a reduced survival rate (Demichelis et al., 2007; Attard et al., 2008; Hägglöf et al., 2014; 
Berg et al., 2014). Interestingly, expression of ERG protein has been shown to correlate 
with markers previously associated with bad prognosis, such as PDGFRβ, hyaluronan, 
Caveolin-1 and von Willebrand factor (Hägglöf et al., 2014). Unfortunately, none of these 
studies addressed the clinical outcome of different TMPRSS2:ERG isoforms, while in in 
vivo cancer models different isoforms were shown to have antagonistic behavior (Rastogi 
et al., 2014). However, the T1E4 isoform (fusion of 1
st
 exon of TMPRSS2 with 4
th
 exon 
of ERG) seems to be the most frequent and clinically relevant. A study, published in 2011 
by Markert and colleagues, takes into account several molecular signatures, including 
TMPRSS2:ERG, and shows that the presence of this translocation is associated with poor 
prognosis, even though the most aggressive phenotype is defined as stem cell-like with 
P53−/PTEN− genotype (Markert et al., 2011). 
High incidence of these gene fusions in prostate cancer and their cancer-driving 
behavior makes them attractive drug targets. However, direct inhibition of ERG protein 
does not give expected results: inhibition of ERG expression in VCaP cells diminishes 
invasiveness, but has no effect on the viability of the cells (Tomlins et al., 2008). Another 
study on VCaPs has shown a slight decrease of cell proliferation under ERG-deprived 
conditions, but only where a high concentration of siRNA was used (starting from 50 
nM), despite that the decrease of ERG protein level starts from 2.5 nM concentration 
(Urbinati et al., 2015). Thus, this effect on viability could be due to some off-target 
effects. Hence, targeted therapy might benefit from using pathways altered in ERG-
expression tumors (Chatterjee et al., 2015; Mancarella et al., 2015) or identification of 





CHAPTER 2. UBIQUITIN-PROTEASOME SYSTEM (UPS) 
 
In this thesis we describe siRNA screening of the ubiquitin-proteasome system 
(UPS) and ubiquitin-like modifiers (ULMs) pathways to identify individual components 
required for the functioning of PCa cells. We chose to investigate UPS and ULMs 
pathways because of the previous success of proteasome inhibitors in the treatment of 
tumors. It should be noted, that despite the documented anti-cancer effect, proteasome 
inhibition is generally toxic and, thus, may be detrimental for healthy cells. We wanted to 
benefit from targeting individual components of UPS or ULM, which could make therapy 
more selective toward tumor cells. Our screens and subsequent validation experiments 
using a small molecule inhibitor of neddylation revealed that the inhibition of the 
components of the CRL/NEDD8 pathway can have a complex outcome on the viability of 
PCa cells. In this chapter I describe the organization and function of the UPS, and of the 
CRL/NEDD8 pathway as a part of the UPS. 
2.1 UBIQUITIN AND UBIQUITIN-LIKE MODIFIERS 
It has been estimated that bacteria with an average genome size of few thousands 
genes produces about 250,000 individual proteins packed so tight that the space between 
them does not exceed a few molecules of water. Most likely, the eukaryotic cell has more 
or less the same level of compaction (Petsko & Ringe, 2004). The cell interior is 
extremely crowded, but also very mobile: the proteins are separated into different 
compartments and organelles with permanent exchange between them. Complexity is 
increased by a flow of newly synthesized proteins and their constant degradation. In such 
a crowded and mobile environment, precise regulation of protein function is essential to 
avoid chaos. Protein function in vivo can be regulated at transcriptional level via control 
of gene expression. Other levels of control include regulation of translation, post-
translational modification, localization of the protein, covalent or noncovalent binding of 
effector molecules, and the lifetime of the active protein (Petsko & Ringe, 2004; Cooper, 
2000).  
Although it was known that, despite the exergonic nature of peptide-bond 
cleavage protein, degradation is energy-dependent and proteins have different life-time, 
for many decades protein degradation was believed to be non-specific and thus was never 
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really studied (Ravid & Hochstrasser, 2008). At that time lysosome-mediated protein 
degradation was the only pathway known, in accordance with this paradigm. The 
discovery of the ubiquitin-proteasome system made a revolution and was awarded by the 
Nobel Prize in Chemistry in 2004. Specific labeling of intracellular proteins, by small 
protein ubiquitin (Ub), which targets them for degradation by a multienzymatic complex 
called the proteasome, was identified as the main function of this system. Later it was 
shown that ubiquitination also has regulatory functions and does not necessarily lead to 
the degradation of proteins (Glickman & Ciechanover, 2002; Herrmann et al., 2007). 
Ubiquitin, a highly conserved, 76-amino acid protein, is ubiquitously present in 
eukaryotes, but absent in the Eubacteria and the Archaea. Characterization of ubiquitin 
was followed by the discovery that it is a member of a group of protein tags, which share 
similar structure and mechanism of attachment. Ubiquitin and Ubiquitin-Like Modifiers 
(ULMs) have a similar three-dimensional core structure, the β-grasp fold, but otherwise 
are distinct (Figure 5). There are 17 known ubiquitin-like proteins (UBLs) belonging to 
nine phylogenetically distinct classes (Table 1): NEDD8 (RUB for bacteria and plants), 
SUMO (for small ubiquitin-like modifier), ATG8 (for autophagy 8) and ATG12, Ufm1 
(for ubiquitin-fold modifier1), URM1 (for ubiquitin-related modifier 1), ISG15 
(interferon-stimulated gene product of 15 kDa), FAT10 (HLA-F adjacent transcript 10), 
FAU and a diverse assortment of proteins which harbor structurally related folds fused 
translationally to other domains (Watson et al., 2011; Hochstrasser, 2009; Vierstra, 2012). 
 
 
Figure 5. Characteristic ubiquitin-fold. a. Ribbon representation of 3D fold of Ub and ULMs. b. Superposition of their 




Table 1. Known ULMs (modified figure from Hochstrasser, 2009). E1 and E2 - enzymes, involved in modification of 
proteins with a given modifier: E1 – Ub-activating enzyme, E2 – Ub-conjugase (discussed in details below in 2.2 UPS 
MACHINERY) 
Modifier Identity with Ub (%) E1 E2 Roles 
Ub 100 UBA1 & UBA6 >30 Multiple, including protein homeostasis, 
cell receptor signaling, endocytic 
trafficking, transcriptional regulation and 
cell cycle progression 
NEDD8 59 Uba3/NAE1 UBE2M & 
UBE2F 
Activation of cullin-based E3s 
SUMO 18 SAE1/UBA2 Ubc9 Multiple, including protein stability and 
localization, transcriptional regulation and 
cell cycle progression 
Atg12 5 Atg7 Atg10 ATG5–ATG12 conjugate forms complex 
with ATG16 that functions as an E3 ligase 
for autophagic vesicle formation 
Atg8 8 Atg7 Atg3 Autophagic vesicle formation 
Urm1 ~0 UBA4 dimer – Antioxidant pathways; tRNA uracil 
thiolation 
ISG15 32/37 UBA7 UBE2H Antiviral functions; possibly cell growth 
and differentiation 
UFM1 14 UBA5 dimer UFC1 Unknown 
FAU 38 – – Regulation of immune response 
FAT10 32/40 Uba6 USE1 Antiviral functions 
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2.2 UPS MACHINERY 
Ubiquitin and ULM became attached to target molecule in multistep reaction. 
More time will be given to the description of the machinery and organization of the 
ubiquitin-ligation pathway, but the principles are the same for other modifiers. 
Ubiquitin is conjugated to target proteins by the formation of an iso-peptide bond 
between the C-terminal carboxyl group of ubiquitin and a lysine side-chain of the target 
protein. Ub can also be attached by peptide bond to the N-terminus of the protein. This 
process, termed ubiquitylation, occurs through a cascade reaction and requires three 
classes of enzymes: ubiquitin-activating enzymes (E1), ubiquitin-conjugating enzymes 
(E2), and ubiquitin-protein ligases (E3) (Figure 6). E1 activates ubiquitin by forming a 
high-energy thiol ester bond between an E1 active site-located cysteine and a C-terminal 
glycine of ubiquitin in a reaction that requires the hydrolysis of ATP. Activated ubiquitin 
is then transferred to a speciﬁc Cys residue of one of ~30 E2s via a thioester linkage. The 
E3 ubiquitin ligases (E3s) recruit ubiquitin-loaded E2s, recognize speciﬁc substrates, and 
facilitate (or directly catalyze) ubiquitin transfer to either the Lys residues (in most cases) 
or the N terminus of their molecular targets with the formation of (iso-) peptide bonds. 
E3s are the key determinants of substrate specificity and are capable of recognizing a few 
or multiple substrates through specific degradation signals. A single E2 may function 
with multiple E3s (and vice versa) to provide specificity in a combinatorial way. To date, 
>500 E3s have been identified. There are several mechanistically distinct classes of E3 
enzymes: many of these E3s contain the Homologous to E6-associated protein (E6-AP) 
Carboxy Terminal (HECT) domain or the Really Interesting New Gene (RING) finger 
domain. Recently, four RING-like domains, the U-box, the Leukemia Associated Protein 
(LAP) finger proteins, the Plant Homeo Domain (PHD) and the Ring Between Ring 
fingers (RBR)-domain family, have also been shown to have E3 activity (Figure 7) 
(Bernassola et al., 2008; Deshaies & Joazeiro, 2009; Chen et al, 2006; Metzger et al., 





Figure 6. Enzymatic cascade of UPS. (a) Activation of Ub-moiety by activating enzyme (E1) in energy-dependent 
reaction. (b) Transthiolesterification reaction between E1 and E2 (conjugating enzyme). (c) E3 ubiquitin ligase transfer 
Ub from E2~Ub thioester on target protein. (d) Ubiquitin mark can be eliminated by deubiquitylating enzymes (DUBs). 
Monoubiquitylated substrate can then acquire additional Ub moieties in the form of multiple single attachments (not 
shown) or an ubiquitin chain (e). After depending on the nature of the chain protein can change its function (common 
for mono- multi-ubiquitylation and also for poly-Lys63-cahains) (f) or undergo proteasomal degradation (typical for the 




Figure 7. Classification of E3 ubiquitin ligases by mechanism of action. Two major types of E3 are illustrated. The 
PHD domain, LAP and U-box E3 have the similar mechanism as RING-ligases. S, substrate of an E3. I. For HECT-
ligases, ligation involves an obligate thioester intermediate with the active-site cysteine of the E3. II. Ring-ligases 




The fate of ubiquitylated proteins is determined by its nature (mono-, multi- or 
poly-ubiquitylation) and the type of isopeptide linkage of Ub (chains formed through 
lysine 6, 11, 27, 29, 33, 48, 63 or mixed are found in vivo and seem to target proteins to 
different fates). Monoubiquitylation and the formation of multiubiquitin chains by 
isopeptide bonds other than Lys48, such as Lys6, Lys29/33 and Lys63, perform both 
proteolytic as well as regulatory function. Poly-ubiquitylation through Lys48 represents a 
standard signal for proteasome-mediated degradation (Bernassola et al., 2008). Lys63-
poly-ubiquitin chains are involved in protein/protein interaction important for kinase 
signaling activation, receptor endocytosis, protein trafficking, and DNA damage repair 
(Wertz et al., 2004). Lys6 and Lys11 polyubiquitin linkages have been identiﬁed in vivo, 
and their accumulation correlates with the pathogenesis in neurodegenerative disorders 
(Bernassola et al., 2008). In addition, recently discovered linear polyubiquitylation 
through Methionine (Met1) is involved in nuclear factor-κB signaling and cell death, and 
dysfunctions in linear ubiquitylation underlie chronic inflammation (Iwai et al., 2014). 
Like many other dynamic posttranslational protein modification, ubiquitylation is 
a reversible process. Ub cleavage is performed by deubiquitylating proteins (DUBs). The 
human genome encodes for nearly 100 Ub-specific DUBs, divided in six families: the 
UCH, USP, OTU, MJD, MCPIP and JAMM families (Reyes-Turcu et al., 2009). 
2.3 PROSTATE CANCER & UPS 
The UPS conjugation pathways have multiple essential biological roles. Even if 
we focus our attention only on cancer-related processes of UPS, the variety of 
downstream effects is extraordinary (Table 2). Ubiquitin-mediated proteasomal 
degradation controls cell-cycle progression, protein quality control, signal transduction, 
and circadian rhythms. The non-proteolytic way of regulation is applied to membrane 
trafficking, control of genome integrity, and the assembly of signaling complexes 
(Hochstrasser, 2009). ULM also regulates multiple biological functions. For example, 
SUMO plays an important role in DNA repair and maintenance of genome stability 
(Bergink & Jentsch, 2004; Nagai et al., 2011). NEDD8 regulates the Ub-pathway and 
degradation of some individual proteins including p53. ISG15 modification is part of the 
cellular response to infection and inflammation (Hochstrasser, 2009). In this light it is not 
surprising that their function, and often malfunction, are important factors in various 





Table 2. Biological roles of UPS in cancer. 
 
In prostate cancer, E3 ubiquitin ligase adaptor SPOP (speckle-type POZ protein) 
is probably the most often deregulated component of UPS. It is specifically down-
regulated or mutated in 10-15% of all PCa cases, but not in other types of cancer 
suggesting tissue-specific mechanism of action (García-Flores et al., 2014). Indeed, it was 
shown that the wt-SPOP protein provides ubiquitylation and degradation of androgen 
receptor, while mutant isoforms lack this activity (An et al., 2014). Moreover, SPOP 
mutation is associated with genomic instability (Boysen et al., 2015). Interestingly, 
mutation of SPOP and the presence of TMPRSS2:ERG translocation are mutually 
exclusive events (Berger et al., 2011). COP1 (constitutive photomorphogenesis protein 1 
homolog) is another tumor suppressor E3-RING gene, which is frequently affected by 
loss-of-function mutations in cancer (Migliorini et al., 2011). This Ub-ligase controls 
degradation of such oncoproteins as c-Jun and ETS transcription factor Etv1. In the 
majority of prostate cancers ETS factors are overproduced because of TMPRSS2:ETS 
gene fusions (Tomlins et al., 2008). Interestingly, truncated Etv1 encoded by prostate 
cancer translocation TMPRSS2:ETV1 lacks the critical COP1 binding motifs and is 
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fiftyfold more stable than wild-type Etv1 (Vitari et al., 2011). As a result, almost all 
clinically-relevant translocations result in COP1-insensitive Etv1, implying that COP1 
loss-of-function confers a selective advantage to prostate cancer cells. In contrast to 
COP1, the gene for E3-HECT Ub-ligase WWP1 is frequently amplified in prostate 
cancer. WWP1 induces degradation of several components of the TGFβ pathway as well 
as the Klf5 protein. The latter is one of the key tumor suppressor transcription factors, 
which are down-regulated in PCa (Chen et al., 2007). Mutations of some UPS genes have 
been associated with elevated incidence of sporadic cancer as well as with hereditary 
prostate cancer. For example, the risk of prostate cancer is increased two- to fourfold in 
men with BRCA1/2 mutations (Agalliu et al., 2009). These tumor suppressor genes code 
for E3-RING Ub-ligases, which control DNA repair as well as G2/M and DNA 
replication checkpoints. The most frequent mutations result in truncated BRCA proteins, 
which have lost E3-ligase activity. 
The global alterations of UPS in prostate cancer can also be seen on the protein 
level. Immunostaining of prostate tissues reveals that upon cancer progression sub-
cellular localization of Ub-conjugates is shifted from the nucleus to the cytoplasm 
(Bataineh & Habbal, 2006). This may result from the accumulation of Ub-rich 
cytoplasmic protein aggregates caused by defective protein synthesis and degradation. 
Indeed some UPS components implicated in protein quality control are specifically 
downregulated in PCa (Tomlins et al., 2007b; Lapointe et al., 2004). Other ULMs also 
demonstrate global changes in conjugation and intracellular localization. For example, 
both SUMO and ISG15 pathways are upregulated in PCa cells (Moschos et al., 2010; 
Kiessling et al., 2009), while the NEDD8 pathway is believed to be significantly inhibited 
(Meehan et al., 2002). The critical role of the UPS in prostate cancer is thus well 
recognized and may result from direct control of stability and function of androgen 
receptor and/or regulation of other cancer-related proteins such as oncoproteins and tumor 
suppressors. However, though very important for development of new therapeutic 






3.4.1 NEDD8 as an ubiquitin-like protein 
Among ubiquitin-like modifiers NEDD8 is one of the best studied. NEDD8 is the 
closest to Ub in sequence and structure, but they also have a non-overlapping function. 
NEDD8 was mainly characterized in the context of its function in the regulation of the 
biggest class of E3 ubiquitin-ligases – CRLs (cullin-RING-ligases). However, new 
studies show that NEDD8 probably have other target proteins and functions, the most 
well-studied being the regulation of p53 protein (Harper et al., 2004; Enchev et al., 2014). 
Like in the Ub-pathway, neddylation requires a cascade of reactions performed by 
E1, E2 and E3 enzymes. Neddylation can be reversed by NEDD8-specific proteases. The 
NEDD8-conjugating cascade starts from the NEDD8-activating enzyme (NAE). NAE is a 
heterodimer comprising NAE1 and UBA3 subunits. Activated NEDD8 is subsequently 
transferred to the E2-conjugating enzyme. In metazoans, two NEDD8-specific E2 
conjugating enzymes have been described: UBE2M (also known as UBC12) and UBE2F 
(Huang et al., 2009). Finally, E3 ligases transfer NEDD8 to one of the Lys or N-terminus 
of the target protein. NEDD8-E3-ligases, with one exception, belong to the RING (really 
interesting new gene) finger proteins. 
The best characterized NEDD8-E3-ligases are RBX1 (RING-box protein 1, 
neddylates cullins 1-4 and 7) and RBX2 (RING-box protein 2, specific to cullin 5). 
Neddylation of cullins by RBX1/2 accompanied by DCUN1 proteins (defective in cullin 
neddylation protein 1-like proteins; there are 5 of them in human). Both RBX1 and RBX2 
are part of the multi-subunit complexes Cullin-RING-E3-Ub-Ligases (CRLs), and 
neddylation of cullins leads to activation of CRLs. Other described NEDD8-E3-ligases 
from the RING family are MDM2 (which neddylates p53 and p73 and attenuates its 
transactivation function), c-CBL (which neddylates receptor tyrosine kinases, e.g. EGFR 
and TGFIIβ, and targets them to cell compartments), RNF111 (which neddylates histone 
H4 during DNA-damage response), and DIAP1 (which neddylates caspases and thus 
prevents apoptosis) (Harper, 2004; Watson et al., 2006; Oved et al., 2006; Yang et al., 
2007; Broemer et al., 2010; Ma et al., 2013; Zuo et al., 2013). Recently, the HECT-
domain family of E3 ligase, SMURF1, was shown to be auto-neddylated at multiple sites, 
which increases its activity (Enchev et al., 2014). A few deneddylases have been 
identified, including the CSN5, NEDP1, USP21, Ataxin-3, UCH-L1, and UCH-L3 
(Watson et al., 2011). CSN5 and NEDP1 are selective to NEDD8, whereas the other 
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above mentioned NEDD8 ligases also cleave Ub. The principal cullin deneddylase is 
CSN5, which is active only being a part of 8-subunit COP9 signalosome complex (CSN). 
NEDP1 complements the activity of CSN and ensures maturation of the NEDD8 
precursor (Enchev et al., 2014). 
Normally, both Ub and NEDD8-pathway enzymes are highly specific (Souphron 
et al., 2008), but in conditions of increased ratio of NEDD8:Ub, ubiquitylating enzyme 
E1 UBA1 can activate NEDD8, and redirect it to Ub-conjugation pathway. Unfortunately, 
the biological role of this effect is unclear. One possibility is that formation of mixed Ub-
NEDD8 chains mediates specific stress-response pathways (Leidecker et al., 2012; 
Hjerpe et al., 2012). 
 
 
Figure 8. Architecture of Cullin-RING-ligases. http://biology.ucsd.edu/research/faculty/e1bennett 
3.4.2 NEDD8 targets 
The best-known function of neddylation is regulation of the activity of Cullin-
RING ligases (CRLs), the biggest class of E3 ubiquitin ligases. CRLs are multisubunit 
complexes which consist of the cullin scaffold, a conjugating apparatus represented by 
E2-conjugase and RING-E3-ligases RBX1/2 and an adaptor module, which determines 
specificity to substrate protein (Figure 8). There are a few subclasses of CRLs, depending 
on the type of cullin and adaptor protein involved. In mammals, 7 cullins have been 
identified (1, 2, 3, 4A, 4B, 5 and 7), forming about 300 distinct CRL complexes. Two 
other proteins, CUL9 (also known as PARC) and APC2 (anaphase promoting complex 
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subunit 2), also have significant sequence homology to cullins over a ~180 a.a. region and 
bind RBX1 or a homologous small RING protein, APC11. 
The major regulator of CRLs’ function is neddylation. Modification of the cullin 
by NEDD8 causes change of its conformation, stimulating binding to Ub-loaded E2, 
bringing together E2 and substrate, and facilitates transfer of Ub from the E2 active site. 
Upon substrate exhaustion, deneddylation by CSN5 turns off CRL activity and allows 
changing of substrate specificity (Figure 9, C-E). Another key regulator of CRL is the 
protein CAND1. Binding of CAND1 is mutually exclusive with neddylation and the 
adaptor complex of proteins (Figure 9, A-C). CAND1 helps to change the adaptor unit 
and thus change substrate specificity (Merlet et al., 2009; Duda et al., 2011; Pierce et al., 
2013; Abidi & Xirodimas, 2015). 
Other ubiquitin E3 ligases reported to be neddylated include VHL, parkin, 
BRCA1-associated protein 2 (BRAP2) and MDM2. These are all members of the RING 
domain family. Apart from E3 ligases, other proteins modified by NEDD8 include p53, 
NF-κB, L11, HIF1α, E2F1 and APP (Hjerpe et al., 2012; Enchev et al., 2014). 
 
Figure 9. CRLs regulation. CAND1 works as an exchange factor for substrate-recognition unit (A-C), while 
neddylation stabilizes substrate- and E2- conjugated state of the complex (D-E). Ubiquitylated substrate can be 





Figure 10. Involvement of CRLs and their substrates in promoting (green boxes/arrows) or inhibiting (red 
boxes/arrows) growth and survival of cancer cells, thus impacting oncogenesis. Figure from Lee J & Zhou, 2010. 
 
3.4.3 Role of CRL/NEDD8 pathway in cancer 
Proteins involved in the regulation of the CRL/NEDD8 pathway are not 
conventional oncoproteins because their effect depends on their targets. Nevertheless, 
there are well-established roles in tumor biology for some final effectors (Figure 10). 
Therefore, the CRL/NEDD8 pathway can function both in promotion and in suppression 
of cancer development (Lee J & Zhou, 2010). In addition, different sorts of NEDD8-
pathway deregulations have been found in cancer. For example, overexpression of NAE 
and UBC12 and global hyper-neddylation are found in a variety of cancers, including 
lung adenocarcinomas and squamous-cell carcinomas (Chairatvit & Ngamkitidechaku, 
2007; Li et al., 2014), while in prostate cancer the pathway is thought to be down-
regulated (Meehan et al., 2002). Another CRL regulatory protein, DCUN1D1, is 
amplified in cancer, particularly in squamous cell carcinoma. Targeting the expression of 
DCUN1D1 by short hairpin RNA induces apoptosis, while another member of DCNL 
family, DCUN1D3, functions as a tumor suppressor by antagonizing the neddylation 
activity of DCUN1D1 (Sarkaria et al. 2006). NEDD8 was reported to cause an anti-
proliferative effect through degradation of Estrogen Receptor-alpha (Fan, 2003). 
Neddylation of pVHL can also inhibit proliferation because it results in pVHL binding to 
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fibronectin and the assembly of extracellular fibronectin. The fibronectin matrix promotes 
differentiation and suppresses the proliferative and metastatic potentials of transformed 
cells in various model systems (Stickle et al., 2004). On the other hand, in its 
deneddylated form pVHL becomes a part of ECV complex (Elongin B/C-CUL2-VHL) 
and participates in the destruction of hypoxia-inducible factor which in turn plays an 
essential role in tumor angiogenesis (Russell & Ohh, 2008). 
Collectively, these data demonstrate the important role of NEDD8-pathway in 
tumorigenesis and suggest that inhibition of neddylation may be a valid therapeutic 
approach for cancer treatment. The development of a potent small molecule inhibitor of 
NAE, MLN4924, was reported in 2009 by Millennium Pharmaceuticals. MLN4924 is 
structurally related to adenosine 5′-monophosphate (AMP), a product of the NAE 
reaction. MLN4924 forms covalent NEDD8-MLN4924 adduct within the active site of 
NAE. MLN4924 is a potent inhibitor of NAE (half-maximal inhibitory concentration 
IC50 = 4 nM), and does not affect related pathways (SUMO, Ub, etc.) or other ATP-
dependent enzymes (Soucy et al., 2009). Treatment of cells with MLN4924 resulted in a 
dose-dependent stabilization of known CRL substrates (Soucy et al., 2009). 
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CHAPTER 3. RNA INTERFERENCE 
 
In this project RNA interference (RNAi) was used to perform loss-of-function 
screening of the UPS components. The discovery of RNA interference made a revolution 
in the field of molecular biology and created a powerful tool for the modulation of gene 
expression. Compared to other methods, RNAi is easy to perform, cost-effective, specific 
to a selected gene and also low in toxicity. As a result, RNAi currently is the most used 
method for gene knockdown. After the development of this technology, genome-wide 
functional screenings became a standard research method, helping to identify the function 
of a gene, the involvement of a protein in a certain process, and, therefore also potential 
new drug targets. Most likely, RNAi will also be used in medicine to treat viral infections 
and cancer, even though there are still some difficulties related to its non-specific effects 
and its delivery system. RNAi and major aspects of its application for molecular biology 
research are discussed below. 
3.1 DISCOVERY OF RNAi 
The term RNAi describes the phenomenon when a double stranded RNA 
(dsRNA) initiates a cellular response, leading to sequence-dependent recognition of a 
target mRNA and thus causes modulation of its function (degradation of mRNA, 
temporary stimulation or inactivation). It has been known by many names, including co-
suppression, post-transcriptional gene silencing (PTGS) and quelling. Only after the 
underlying mechanisms were understood well enough was it given with its current name 
“RNA-interference”, or RNAi. 
The first piece of evidence comes from the 1970s with experiments showing that 
the introduction of oligonucleotides complementary to the target RNA causes the 
formation of RNA-RNA duplexes and interferes with the function of the target RNA. 
First this phenomenon was shown for the E. coli 16s rRNA where antisense RNAs 
inhibited translation. Later the same effect was shown for many other nucleotide 
sequences, and sometimes this interaction has regulatory, but not inhibitory effect. One 
such example is the regulation of the E. coli mobile genetic element Tn10. Hybridization 
of a small anti-sense transcript of Tn10 to its mRNA contributes to the regulation of Tn10 
transposition. Finally, the same effect was shown for mRNAs, where the expression of 
sequences complementary to the herpes simplex virus I (HSV) thymidine kinase (TK) 
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diminishes activity of the enzyme fivefold (Izant & Weintraub, 1984). However, it has 
since been shown that not only can complementary (antisense) RNA cause such a 
silencing, but so can sense oligonucleotides, too. 
In 1990 three reports described a similar phenomenon. To make petunia have 
brighter flowers, petunia genes responsible for flowers coloration (chalcone synthase 
CHS and dihydroflavonol-4-reductase DFR) were overexpressed in transgenic plants. 
Unexpectedly, ¼ to ½ of resultant petunias had completely white flowers or had 
uncolored patterns on the naturally-colored violet flowers. None of transgenic plants had 
flowers darker than the parental genotype. It was found that the level of the introduced 
mRNA was extremely low. Likewise, the level of mRNA of the corresponding 
endogenous gene was very low, too (Napoli et al., 1990; van der Krol et al., 1990). 
Similar results were reported for the tomato polygalacturonase gene. This phenomenon 
was named “co-suppression” (Smith et al., 1990). In 1994 it was shown that, despite the 
strong decrease of CHS mRNA, the transcription of this gene was unchanged (de Lange 
et al., 1994). This suggested that co-suppression was a posttranscriptional event. The next 
important step was made in 1997 by Metzlaff and colleagues, who showed that at least in 
some cases the introduced genes could cause formation of dsRNA, which induces 
silencing. For example, the petunia CHS mRNA forms dsRNA region at the 3’-end of 
transgenic mRNA. 
Andrew Fire and Craig C. Mello brought all this evidence together and proved 
that double stranded RNAs are up to 100 times more efficient comparing to single-
stranded antisense RNA (Fire et al., 1998). For this discovery they were awarded with the 
Nobel Prize in Physiology or Medicine in 2006. This work, performed on nematode C. 
Elegans, stimulated research in the field, leading to the discovery of RNAi mechanisms 
and key RNAi enzymes. It was shown also, that RNAi is evolutionarily conserved and is 
used by many eukaryotes, from protozoa to animals, for gene regulation and for 
protection from viruses. Recently RNAi has become widely used in molecular biology as 
a tool for analyzing gene function. 
3.2 MECHANISM OF RNAi 
As mentioned before, RNAi is initiated by the exogenous or endogenous dsRNA. 
For all vertebrates the efficiency of the interference correlates with the length of dsRNA: 
the longer dsRNA is, the greater the amount of siRNA produced and the greater number 
of target sites recognized on the mRNA molecule. The minimal size of dsRNA sufficient 
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for inducing interference is 19 bp. Most likely this limitation prevents degradation of the 
cell’s own mRNA with short intramolecular self-complementary structures (Elbashir et 
al., 2002). At the same time, in vertebrates, the large dsRNAs cause non-specific effects, 
such as the activation of the interferon response, which leads to suppression of protein 
synthesis and cell death. These non-specific responses can be avoided using small 
interfering RNAs (siRNAs) less the 30 bp long (Caplen et al., 2001). 
The first step in RNAi is the formation of short double stranded RNA fragments 
of 21-28 nt (depending on the species) with 2-nt overhangs at the 3’ ends; the 3’-ends are 
finished an –OH group, and 5’-ends have a phosphate group (Tomari et al., 2004; Lima et 
al., 2009). These small dsRNAs are produced by the enzyme called Dicer, a type III 
RNase, which selectively binds to and cleaves dsRNA. The sequence of this protein is 
highly conserved through evolution (Chiu & Rana., 2002). Dicer contains the following 
domains (Figure 11): PAZ with a “platform”, which recognizes 3’-overhangs on dsRNA; 
double RNase domains, which form intramolecular dimer with a functional RNase active 
site (Vermeulen et al., 2005); dsRBD responsible for the recognition and binding to 
dsRNA (Ketting et al., 2001). At the N-terminus, Dicer has a predicted helicase domain, 
but the helicase function has not yet been demonstrated. Instead, this domain has been 
shown to have some regulatory function – for example, it can function as an 
autoinhibitory module essential for Dicer processivity. The role of the DUF domain 
(Domain of Unknown Function) is still controversial, but it has been suggested that it can 
bind dsRNA and Dicer’s co-enzymes (Dlakic, 2006; Ma et al., 2008; Sawh & Duchaine, 
2012). 
The dsRNA produced by Dicer is transferred to an Ago protein, which uses one 
strand of this RNA as a template for recognition and cleavage of target RNAs. Ago is the 
major protein of RISC (RNA-induced silencing complex), a multisubunit enzyme 
responsible for RNA interference. The RNA strand used as a template for silencing is 
called the “guide chain”, while the remaining “passenger strand” is eliminated. The 
choice of the chain and the loading of this chain onto Ago protein are performed by 
RISC-loading complex (RLC). RLC is formed by the binding of Dicer to a specific 
protein (TRBP in human and R2D2 in D. Melanogaster) with a few cofactors (Figure 12). 
The positioning of RNA in this complex seems to play a crucial role: the favorable 
position is when R2D2 is attached to the end with the higher melting temperature, while 
Dicer is still attached to the opposite end (Song et al., 2004). After the attachment of Ago 







 nt from the 5′-end of the guide chain by one of the domains of Ago 
and eliminated from the complex; the second chain then becomes the guide (Leuschner et 
al., 2006). 
The highest assortment of proteins involved in RNAi is found in plants. For 
example, Arabidopsis thaliana has 4 types of Dicer and 10 of Ago, each with its unique 
function. This diversity probably reflects the need of immobile organisms to struggle 
against biotic and abiotic stresses. Drosophila has 2 Dicers: one works with miRNAs and 
the second with siRNAs (described below). This is due to the fact that Drosophila 
actively use RNAi to regulate the activity of its own genes, but also to protect against 
viruses; thus, this separation of function could decrease the concurrence for the enzymes 
between these two processes. This hypothesis is consistent with the observation that Dicer 
and Ago have a very high rate of evolution which may reflect evolutionary pressure from 
viruses. For mammals, silencing of viral genes is not crucial because they developed a 
highly efficient protein-based immune system, and, for them, one type of Dicer is enough 
(Ghildiyal et al., 2009). 
The small RNAs that guide RISC have been given a variety of similar sounding 
names, including siRNA, miRNA, piRNA, rasiRNA, tasiRNA, tncRNA, hcRNA, and 
scnRNA. These molecules are virtually indistinguishable biochemically and functionally, 
and thus they are classified based on the biosynthetic pathway of the precursors or on the 
type of RISC in which the RNA is found. But all of them have the same function: to be a 
template for the recognition of target RNA transcripts for silencing (Pratt & MacRae, 
2009). Nevertheless, there are two major classes of these regulatory RNAs: siRNAs 
(small interfering RNAs) of 21-23 nucleotides in length formed from longer dsRNA; and 
microRNAs (miRNAs) formed from intramolecular double-stranded structures (hairpins) 
of RNA precursors (Vilgelm et al., 2006; Kim et al., 2009b). 
 
 





Figure 12. Formation of RISC-loading complex and destruction of the passenger chain. 
http://helicase.pbworks.com/w/page/17605619/Emily-Devol 
 
miRNAs. miRNA were found to be involved in the regulation of gene expression 
in both plant and animal kingdoms. Genes of miRNA are often clustered into 
polycistronic units and thus transcribed together; nevertheless it has been shown that they 
also can have their own promoter. Moreover, they have been shown to be inserted into the 
introns or exons of coding and non-coding RNAs. Genes of miRNAs are usually 
transcribed by RNA-polymerase II (or, rarer, RNA-pol III) (Borchert et al., 2006); the 
resulting transcripts have self-complementary regions forming “hairpin” structures 
(Figure 13). Those transcripts are cleaved (most likely, co-transcriptionally), by 
microprocessor complexes, into smaller fragments of pre-miRNA (Denli et al., 2004). 
The microprocessor complex comprises two major proteins: Pasha (for C. Elegans; 
human analogue: DGCR8) which binds dsRNA, and Drosha which has RNase activity 
(Lee et al., 2003). These pre-miRNAs are then transported to the cytoplasm by Exportin-
5, where they are processed by Dicer (which cuts off the loop) and Ago (as described 
above). As a result, the mature RISC complex is formed (Khvorova et al., 2003). The 
40 
 
next step depends on the level of homology between miRNAs and the target RNA. For 
most animals these sequences are not completely complementary, and they have been 
shown to bind 3’-UTR of target mRNA and inhibit its translation (Grosshans & Slack, 
2002; Kim et al., 2009b). Plant mRNAs more often have full complementarity to target 
RNAs and thus more often cause their degradation (Llave et al., 2002). 
siRNAs. This type of regulatory RNAs is most often formed from complementary 
transcripts encoded by transposable elements of the genome or from partially 
complementary transcripts of mRNA from different genes. These transcripts are also 
produced in the nuclei and then transported into the cytoplasm where they are processed 
by Dicer and Ago (Kim et al., 2009b). The highest diversity of endogenous siRNA, and 
of proteins involved in their processing, is found in plants. The distinctive feature of plant 
siRNA is methylation of the 3’-end by the enzyme HEN1. In plants, production of 
siRNAs depends on the activity of RNA-dependent RNA-polymerase (RdRP). 
The genomes of mammals and Drosophila do not encode RdRP, and the discovery 
of endogenous siRNA in these organisms was unexpected. The first discovered mammal 
siRNA was targeted against one of the transposable element of the genome – LINE1 
(long interspersed nuclear element 1). LINE1 has promoters for the sense and antisense 
chains which produce complementary transcripts forming dsRNA. Soon afterward, 
endogenous siRNAs targeting transposons were also found in C. Elegans and D. 
Melanogaster (Ghildiyal et al., 2009). 
RNAi is also used by plants and fungi as a protective mechanism against viruses. 
Very often viruses, during their replication, go through a stage of dsRNA. These dsRNAs 
are then processed by cellular machinery and transformed into siRNAs that have 
complete complementarity with target RNAs, which usually result in their degradation 




Figure 13. Biogenesis of miRNA. Figure from Vilgelm et al., 2006 
 
3.3 RNAi AS A TECHNOLOGY 
To induce RNAi in mammal cells synthetic siRNA are used, having a 19 bp 
dsRNA core with a 2 nt 3’-overhang (21 bp total). It is very important to design siRNA to 
be fully complementary to the targeted mRNA, because even 1 nt difference may 
significantly decrease or even abolish the activity of the siRNA. The second important 
factor to consider is the region of the target mRNA corresponding to the sequence of 
siRNA. The secondary structure of the mRNA or its attached regulatory proteins could 
decrease its availability for RISC, and thus significantly diminish the efficiency of RNAi. 
For this reason it is not recommended to target 5’-UTR or the first exon of mRNA, 
because most likely there will be some regulatory sequences and binding sites for 
proteins. Despite all these precautions, the design of siRNA goes through “trial-and-
error” methods: usually 3-4 siRNA sequences, which are complementary to the different 
regions on the target RNA, are chosen and synthesized, and then the most efficient are 
experimentally selected (Kim, 2003; Vilgelm et al., 2006). There are many commercial 
42 
 
organizations who offer synthesis of custom siRNA sequences; very often they also 
provide programs for siRNA design. 
Despite world-wide use of RNAi, there are still some limitations in this approach: 
1) Stability. The effect of RNAi is based on the degradation of target mRNA, 
but protein is not affected by RNAi and is instead degraded by natural mechanisms. Time 
of the half-life for each protein is different, thus usually the effect of siRNA on phenotype 
can be detected after the first day, but in case of long-living proteins it develops later. A 
related problem is that the effect of RNAi is transient and lasts until siRNA is present in 
high enough concentrations: after 3-5 mitoses transfected siRNA usually loses its activity. 
To overcome these difficulties it is possible to make additional transfections or to 
introduce into the cells constructions which stably express the necessary siRNA. For 
stable transformation the siRNA is often expressed in the form of shRNAs (Figure 14), 
where sense and anti-sense chains are separated by a short (9 nt) spacer. During 
maturation this spacer loop is cleaved by Dicer as it occurs in the case of miRNA 
(Vilgelm et al., 2006). 
2) Delivery. RNA has a negative charge due to the phosphate groups, which 
makes it difficult to enter the cell through the negatively-charged membrane. Currently, 
there are three major methods for siRNA delivery: electroporation, transfection, and 
stable transformation using DNA-incorporated vectors. Electroporation can be used in the 
case of difficult-to-transfect cells, such as primary and suspension cultures. This method 
was shown to be highly efficient, but harmful, causing up to 50% mortality in cell culture. 
Transfection using lipophilic molecules is currently the most used method for siRNA 
delivery. The most used particles for delivery are liposomes, but there are still 
considerable efforts to find better ways for siRNA delivery (Figure 15). For example, 
polymeric nanoparticles are promising delivery systems because they offer stability and 
controlled release, have the capacity to encapsulate large amounts of genetic material, 
allow for co-delivery, and can readily be surface-modified to enhance stability, transport 
properties, targeting, or uptake. Polymers that are biodegradable, biocompatible, and non-
toxic make attractive candidates for constructing in vivo delivery vehicles. Chitosan, 
cyclodextrin, polyethyleneimine (PEI), poly(lactic-co-glycolic) acid (PLGA), dendrimers, 
and metallic core nanoparticles are becoming popular for delivery, although none of these 
materials possess all of the desirable properties (Vilgelm et al., 2006; Gavrilov & 
Saltzman; 2012). Moreover, self-assembling virus-like particles can be used to deliver 
siRNA into the cells (Kimchi-Sarfaty et al., 2005). 
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As it was said before, for stable inhibition of gene expressing shRNA is often 
used, which can be delivered in the form of plasmids or using virus-based systems 
(lentiviral, adenoviral, adeno-associated or synthetic viruses). These viral vectors have 
been engineered and optimized to facilitate the entry of siRNA into difficlt to transfect 
cells. (http://www.sabiosciences.com/pathwaymagazine/pathways9/sirna-delivery-
methods-mammalian-cells.php) 
3) Off-target effects. Highly-specific RNAi has been converted into a tool for 
molecular biology resulting in a method that has unexpectedly high level of off-target 
effects. siRNAs are designed to have full complementarity to the target and, thus, to have 
no off-target effects. Unfortunately, many studies have shown that siRNA can behave like 
miRNA and regulate expression of RNAs with partial complementarity, which leads to 
appearance of non-specific effects. Considering the amount of these non-target mRNA 
(several hundred), the side-effects can be very strong (Laganà et al., 2014). It appeared 
that the transcripts with sequences complementary to the seed region (nucleotide 
positions 2–8 from the 5′ end of siRNA guide strand), are usually sufficient to yield a 
significant repression of the target (Figure 16). The seed-dependent off-target effect can 
be eliminated by chemical modifications (Ui-Tei et al., 2012). Another approach to the 
off-targeting problem employs pools of siRNAs targeting a single gene in multiple sites. 
This approach may be more specific because such pools combine the effects of individual 
siRNAs on a specific target, while decreasing siRNA effective concentrations and, thus, 
potential off-target effects (Laganà et al., 2014). 
 
 











Figure 16. Schematic representation of downregulation of transcripts with seed-complementary sequences. In the left 
panel, transcripts possessing 3′UTR complementarity to a given 7-nt-long guide strand sequence were divided into 15 
groups based on the position of the complementary sequence in the siRNA guide strand. Transcripts labeled with “1” 
and “7” at both ends possess complementarity to nucleotides 1–7 of the siRNA guide strand and vice versa. The 
horizontal arrow indicates a transcript group with seed complementarity. In the right panel, changes in gene expression 
levels are shown by log 2 of fold change ratio to mock transfection. Note that the groups of transcripts labeled with 2–8 
are the most sensitive to the off-target effects, suggesting that guide strand nucleotides 2–8 serve as a “seed.” Figure 
from Ui-Tei et al., 2012) 
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II. MATERIALS AND METHODS 
CELL CULTURE 
VCaP and DuCaP cells were cultured in DMEM (Gibco, 41966) containing 10% 
FBS (PAN Biotech, P30-3302) and 1% penicillin/streptomycin (Gibco, 15140). PC3 and 
LNCaP cells were cultured in RPMI1640 (Gibco, 61870) with the same supplements. 
RWPE1 were grown in a medium optimized for this cell line (Invitrogen, Keratinocyte 
Serum Free Medium K-SFM) supplemented with bovine pituitary extract (BPE, 
Invitrogen, K-SFM component), human recombinant epidermal growth factor (EGF) and 
L-glutamine (GIBCO, Kit Catalog Number 17005-075). The cells were then grown in the 
incubator at 37°C with 5% CO2. The RWPE1, PC3, LNCaP and VCaP cell lines were 
purchased from the American Type Culture Collection (ATCC). The VCaP cells were 
also kindly provided by Dr. Matthias Nees from the University of Turku. The DuCaP cell 
line was kindly provided by Prof. Jack Schalken from the Radboud University Nijmegen 
Medical Center, who originally received them from Kenneth J. Pienta, MD, Director of 
Research at The Brady Urological Institute Baltimore where this cell line was created. For 
different passages, the cells were washed twice with PBS (no calcium, no magnesium, 
Gibco, 14190) followed by the addition of trypsin-EDTA (Gibco, 25300) and incubation 
for 3-10 minutes depending on cell line. Subculture was done depending on the density of 
the cells. Usually for VCaP cells, subculture was done once per week, with dilution to 
1/2; DuCaP was once per week, with dilution to 1/10; LNCaP, PC3 and RWPE1 were 
twice per week, with dilution to 1/5. 
CHARCOAL/DEXTRAN STRIPPING OF SERUM 
Charcoal/dextran stripping removes non-polar material such as lipophilic materials 
(virus, certain growth factors, hormones and cytokines) but has little effect on salts, 
glucose, amino acids, etc. Dextran coated charcoal was prepared by stirring 2.5% (w/v) 
Norit-A charcoal and dextran T-70 (0.25% w/v) into PBS and incubating for 18 hours at 
4°C. The dextran-coated charcoal was pelleted by centrifugation at 1,000 g for 5 minutes. 
The supernatant was drained off and replaced with the same volume of Fetal Bovine 
Serum. The mixture was vortexed, to thoroughly mix the charcoal with the serum, and 
then incubated for 12 hours at 4°C. The resulting mixture was passed through a prefilter 
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and 0.45 micron filter before sterilizing through a 0.2 micron filter. The stripped serum 
was aliquoted by 50 ml and stored at -20°C. 
DOUBLE THYMIDINE BLOCK 
 The VCaP cells were plated at 50% confluency in a tissue culture flask. The next 
day, after cells attachment, thymidine was added to a final concentration of 5 mM. Cells 
were incubated in tissue culture incubator for 48 hours (this period corresponds to one 
cell cycle of VCaPs). Next, the culture medium with thymidine was removed, the cells 
were washed once with fresh culture medium, and incubated in fresh DMEM for another 
24 hours to allow cell cycling to restart. After that, thymidine was added for the second 
time to a final concentration of 5 mM. The cells were then incubated for another 48 hours 
in a tissue culture incubator. The cells were released from the block by washing with 
normal culture medium and the addition of fresh DMEM. 
LENS-FREE CELL IMAGING 
CYTONOTE – a Lens-Free Cell Imaging Device (iPRASENSE) is based on 
holographic imaging. Image acquisition using Cytonote doesn’t require any labeling or 
synchronization of cells, and has a large field of view (~30 mm²). This permits the 
monitoring of major morphological properties of cells, including cell adhesion, shape, 
velocity, and also some biological processes, such as cell division and apoptosis (Kesavan 
et al., 2014). For the acquisitions, the cells were plated on culture tissue plates in 
suspension with the testing drugs, and monitored during 3 days using the lens-free 
imaging system. Analysis was performed by Dr. Cedric Allier from CEA Grenoble 
according to the developed and described algorithm (Kesavan et al., 2014). 
SPHEROID FORMATION ASSAY 
To estimate the speed of formation of spheroids time-lapse video microscopy was 
used. Cells were suspended in the standard medium, were subject to treatments (where 
required) and distributed into ultra-low attachment U-bottom plates (Falcon, 353910) at 
concentration of 500 cells/well/100 µl. This resulted in formation of spheroids with 
avarage 400 µm length. For the assay, acquisitions were made every 60 minutes during 4 
days. Typically, 10 spheroids per condition were monitored. For long-term experiments, 
spheroids were grown in the same ultra-low attachment U-bottom plates with a change of 
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culture medim once a week. Prior to the addition of fresh medium, the old culture 
medium were removed using a multichannel pipet. 
SPHEROID SPREADING ASSAY 
Prior to the assay, VCaP spheroids were pre-assembled in ultra-low attachment U-
bottom plates (Falcon, 353910) as described above. Next, the old culture medium was 
removed using multichannel pipet and fresh charcoal-stripped culture medium with or 
without drugs was added into the well. The total volume of the medium along with the 
spheroid were transferred into flat-bottom cell culture plates (Falcon, 353072) using a 
multi-channel pipet. To estimate the speed of spheroids spreading time-lapse video 
microscopy was used. Acquisitions were made every hour during 3 days. The 
development of the images was done using a modified macro script (which was kindly 
created by Dr. Monika Dolega for this purpose). The macro is enclosed in the 
Supplementary Materials. 
TEST FOR SENESCENCE 
Analysis of senescence was performed by measuring of β-galactosidase activity 
according to the protocol described in Nature Protocols (Debacq-Chainiaux et al., 2009). 
The protocol was slightly modified when the test was performed with spheroids. This 
involved the suspension of VCaP cells being distributed in ultra-low attachment U-
bottom plates (Falcon, 353910) in concentrations of 500 cells/well/100 µl and being 
incubated during 10 days. Typically, 30 spheroids per condition were used. Next, the 
spheroids were harvested, pelleted at 600 rpm for 5 min, resuspended in 150 µl of 1.5% 
low-melting agarose (Sigma, A9414) and distributed into Lab Tek chambers (Dominique 
Dutscher, 055082). After polymerization for about 30 minutes, the gels were washed 
twice with PBS, fixed with 2% formaldehyde and 0.2% glutaraldehyde in PBS during 7 
minutes. This was folled by a double wash with PBS, and the addition of a staining 
solution (containing citric acid/Na phosphate buffer, 5 mM K4[Fe(CN)6] 3H2O, 5 mM 
K3[Fe(CN)6], 150 mM sodium chloride, 2 mM magnesium chloride and 1 mg/ml X-gal 
in distilled water). The spheroids were then incubated at 37°C during 5 hours. Then the 
gels were washed multiple times with PBS to remove the background yellow staining of 
agarose. As a final step, the gels were washed with methanol during 1 min and viewed by 




RNA was extracted with an RNeasy Mini Kit (QIAGEN, 74104). 1.5 µg RNA 
was reverse-transcribed in a total volume of 20 µl using a SuperScript® VILO cDNA 
Synthesis Kit (Life Technologies, 11754050) with random primers according to the 
manufacturer’s protocol. Reverse transcription reactions were diluted to 200 µl of 
distilled water and further used in concentrations of 2.5 µl per reaction of quantitative 
PCR (qPCR). 
qPCR was carried out with a Platinum Quantitative PCR SuperMIX-UDG Kit 
(Life Technologies, 11730-017) using a StepOnePlus Real-Time PCR system (Applied 
Biosystems, 4376600). All experiments were run in triplicates, and the results were 
normalized to 18S rRNA expression. Primer sequences are listed in Supplementary Table 
5. 
Standard PCR was done using Herculase II Fusion DNA Polymerase from Agilent 
Technologies (600677). Samples were purified using a MinElute PCR Purification Kit 
from Qiagen (28004) according to the manufacturer’s protocol. Sequencing of PCR 
products was performed on the platform of Beckman Coulter Genomics. 
siRNA TRANSFECTION 
Cells were transfected with siRNA using Lipofectamine® RNAiMAX 
Transfection Reagent (Invitrogen, Ref. 13778) according to the manufacturer’s protocol 
with minor modifications: RNAiMAX was taken 0.75 µl for 1 well of 96-well plate and 
386-well plate. 
Screening of the ubiquitin-proteasome system was performed using ON-
TARGETplus® SMART pool® siRNA Library-Human Ubiquitin Conjugation Subset 1 
from Dharmacon (Supplementary tables 1, 2, 4). Transfection of the SMART pool was 
done at a final concentration of 20 nM of siRNA. Individual siRNAs were added in 
concentrations of 10 nM. 
As controls for transfection AllStars Negative Control siRNA (SI03650318, 
Qiagen) and AllStars Hs Cell Death siRNA Positive cell death phenotype control 
(SI04381048, Qiagen) were used. All controls were used in concentrations equal to the 
concentration of siRNA in the experiment.  The siRNA against the ERG gene was 
prepared by Eurogentec. The sequences of siERG were taken from publication of Tan et 
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al., 2009: sense - 5’-CGACAUCCUUCUCUCACAUAU-3’; antisense - 5’-
AUGUGAGAGAAGGAUGUCGUG -3’ 







Gene Accession GI Number Sequence 
J-003400-05 AR 367 NM_001011645 58535454 GAGCGUGGACUUUCCGGAA 
J-003400-06 AR 367 NM_001011645 58535454 UCAAGGAACUCGAUCGUAU 
J-003400-07 AR 367 NM_001011645 58535454 CGAGAGAGCUGCAUCAGUU 
 
WESTERN BLOT 
All cellular proteins were extracted using RIPA lysis buffer (Sigma, R0278) with 
protease inhibitor cocktail tablets (Complete Mini from Roche Diagnostics, Cat. No. 11 
836 153 001) and supplements: 
Component [C] Application 
RIPA 10 ml base lysis buffer 
Complete Mini pills 1 pill inhibitor of proteases 
OPA (ortho-phenanthroline) 10 mM  inhibitor of metalloproteases (de-neddylation, de-ubiquitylation) 




5 mM inhibitor of phosphatases 
NaF 5 mM inhibitor of phosphatases 
After quantification with a BCA protein assay kit (Pierce, 23225), an equal range 
of concentration (typically 2.5 ng of protein per sample) was run on a NuPAGE Novex 
Bis-Tris Gel (Life Technologies, NP0322BOX, EC60252BOX, NP0323BOX) in MES 
buffer and then transferred onto the nitrocellulose membrane (Amersham™ Protran®, GE 
Healthcare, 10600001). The membranes were blocked in 5% nonfat milk/TBST during 40 
minutes at 37°C, incubated with primary antibodies (a list of antibodies is given in 
Supplementary Table 4) in 5% nonfat milk/TBST during 1 hour at RT or overnight at 
4°C. This step was followed by incubation with secondary HRP-conjugated antibodies.  
Detection was performed with a chemiluminescent reagent depending on the 
concentration of the target protein (Plus-ECL, Perkin Elmer, NEL105001EA; ECL Prime, 




IMMUNOFLUORESCENCE MICROSCOPY OF CELLS 
Cells were grown on plasma-treated glass slides. The culture medium was 
removed and replaced by 4% paraformaldehyde (PFA) for 15 min at RT. Then PFA was 
replaced with 0.2% Tween for 5 min at RT. Treatment with Tween was followed by the 





(PBS++, Sigma, P4417) and blocked with 3 % BSA in PBS++ which had 
been filtered through a 0.2 µm filter for 30 min. Primary antibodies were added in 1.5 % 
BSA (filtered) and left for 2 hours at RT. This was followed by 3 washes with PBS++, 
and then the slides were incubated with secondary antibodies and phalloidin in 1.5 % 
BSA (filtered) for 45 min at RT. This was followed by a 5 min wash in PBS++, then a 5 
min wash in Hoechst, and then again 5 min with PBS++. Then, these glass slides were 
placed on standard microscope slides with mounting solution (DAKO, S302380) and 
dried for 24 hours. Finally, the slides were analyzed by Zeiss Axioimager Z1 Apotome 
from Zeiss. 
IMMUNOFLUORESCENCE MICROSCOPY OF SPHEROIDS 
Prior to the assay, VCaP spheroids were pre-assembled in ultra-low attachment U-
bottom plates (Falcon, 353910) as described above (SPHEROID FORMATION 
ASSAY). Next, the spheroids were harvested, precipitated at 600 rpm for 5 min, and 
resuspended in fresh charcoal-stripped medium with or without treatments. Next, the 
spheroids were poured onto plasma-treated glass slides in 24-well plates (Falcon, 353047) 
and incubated during 5 days to allow attachment and spreading on the slide. The protocol 
of immunostaining here is identical to the above described protocol for the cells, but with 
longer times of incubation (see details below). 
The culture medium was removed and replaced by 4 % paraformaldehyde (PFA) 
for 30 min at RT. Then PFA was replaced by 0.2 % Tween for 8 min at RT. Treatment 
with Tween were followed by the addition of NH4Cl 0.1M for 30 min at RT. Then slides 




(PBS++, Sigma, P4417) for 10 min and blocked 
with 3% BSA in PBS++ filtered through a 0.2µm filter for 2 hours at RT. The primary 
antibodies were added in 1.5% BSA (filtered) and left for overnight at 4°. After 4x wash 
with PBS++ for 15 min, the slides were incubated with secondary antibodies and 
phalloidin in 1.5 % BSA (filtered) for 1.5 hours at RT. This was followed by a 15 min 
wash in PBS++, then a 10 min wash in Hoechst, and then again 15 min with PBS++. 
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Then the slides were placed on the microscope slide with mounting solution (DAKO, 
S302380) and dried for 24 hours. Finally the slides were analyzed by Zeiss Axioimager 
Z1 Apotome from Zeiss. 
ANALYSIS OF CELL CYCLE 
The cell cycle was analyzed by the measurement of total DNA content using flow 
cytometry. Cells were grown in culture medium with or without drug treatment during 5 
days. They were harvested with trypsin as described above, neutralized by culture 
medium and washed once in PBS. Then these cells were fixed with 70% fridge-cold 
ethanol for 30 minutes. Next, BSA was added to a final concentration of 0.5%. Then, the 
cells were spun at 3000 rpm for 7 minutes. The supernatant was discarded, while the cells 
were resuspended in 0.25 % BSA in PBS and spun again at 3000 rpm 7 minutes. The 
supernatant was once more discarded, and replaced by a 50 µg/ml 7-AAD (7-
Aminoactinomycin D) solution in PBS. Then the cells were analyzed by BD™ LSR II 
flow cytometer from BD Biosciences. 
PROLIFERATION ASSAY BY ATP CONTENT 
Level of proliferation/viability of cells was analyzed by measuring ATP content 
using ViaLight™ Plus Cell Proliferation and Cytotoxicity BioAssay Kit from Lonza 
(LT07-121) according to the manufacturer’s protocol. In short, cells were seeded in white 
plates with transparent bottom suitable for luminescence assays (Grenier, 655088). The 
treatments were performed on the next day after cell seeding. At indicated times, the lysis 
reagent was added to the cells directly into culture medium for 10 minutes, followed by 
addition of ATP monitoring reagent for 5 minutes. Luminescence was measured using 
GloMax®-Multi Detection System. 
PROLIFERATION BY EdU INCORPORATION 
The quantity of proliferating cells in the population was determined by 
measurement of DNA synthesis (by EdU incorporation) using Click-iT® EdU Alexa 
Fluor® 647 Flow Cytometry Assay Kit from Invitrogen (C-10419). This involved the 
cells being seeded in black plates with transparent bottoms suitable for fluorescent 
measurements (Fisher Scientific, 781091). The treatments were performed on the day 
after cell seeding. At indicated times, VCaP cells were treated with EdU for 5 hours and 
then fixed and stained according to the manufacturer’s protocol. Finally, some Hoechst 
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reagent was added to the cells followed by incubation for 30 minutes. The labeled cells 
were covered with Glycerol and PBS++ solution (in a ratio 1:1) and stored at 4°C. Image 
acquisitions were performed using CellInsight™ NXT High Content Screening Platform 
from Thermo Scientific. The images were analyzed and quantified by the “Cell Health 
Profiling” program, installed within CellInsight™. The identification of cells (cell 
segmentation) is based on the detection of nuclei by the Hoechst channel. Next, the EdU 
signal was quantified for each nucleus. The results were presented as a percentage of cells 
having nuclear EdU staining.  
APOPTOSIS BY ACTIVATION OF CASPASES 
The increase in the amount of apoptotic cells was estimated using CellEvent™ 
Caspase-3/7 Green Detection Reagent from Invitrogen (C10423). This involved the cells 
being seeded in black plates with transparent bottoms suitable for fluorescent 
measurements (Fisher Scientific, 781091). The treatments were performed on the day 
after cell seeding. Some CellEvent reagent was added during the treatment according to 
the manufacturer’s protocol. At the end of treatment, some Hoechst reagent was added to 
the cells before incubation for 30 minutes. The image acquisitions were performed using 
CellInsight™ NXT High Content Screening Platform from Thermo Scientific. The 
images were analyzed and quantified by “Cell Health Profiling” program, installed within 
CellInsight™. Segmentation is based on the detection of nuclei with the Hoechst channel. 
Using this segmentation, the CellEvent signal was then quantified in each nucleus. The 
apoptotic cells were determined by the increase of the signal from CellEvent reagent (see 
below, SCREEN QUANTIFICATION). 
 
Figure 17. Segmentation of cells during CellEvent-based apoptosis assay on CellInsight. The software detects nuclei 
(Hoechst) (A) and fluorescent CellEvent reagent that accumulated in the nucleus upon cleavage by caspases 3/7 
activity. In case of unclear segmentation, the software excludes some areas from analysis: light gray are included and 
dark gray (shown with white arrows) are excluded. In the case of VCaP cells, which are growing in groups, this 





The percentage of apoptotic cells was calculated as described above (APOPTOSIS 
BY ACTIVATION OF CASPASES). For each gene the effect of four individual siRNAs 
targeting different exons was analyzed. The effect of each siRNA was measured in 4 well 
replicates split into two 384-microwell plates (2 replicates per plate). The fluorescent 
signals (Hoechst and CellEvent) were measured in 9 fields per well-replicate. Based on 
these signals, the “Cell Health Profiling” program performs cell segmentation and obtains 
information about each individual cell, including the intensity of the signal from the 
channel (Hoechst and CellEvent), the area of the nuclei and the total number of cells per 
field. Based on the CellEvent signal intensities from negative siAllStars and positive 
siCellDeath controls, the threshold that distinguishes alive cells from apoptotic was 
established. Based on this threshold, the median value of the percentage of dying cells 
was then calculated. 
 
Figure 18. CellEvent values for cells treated with controls for plate 2 of VCaP screen. The scatter plot on the left shows 
that siCellDeath increased the population of CellEvent-positive apoptotic cells compared to the negative controls 
siAllStars and siERG. The histogram on the right shows the distribution of cells treated with siCellDeath. The 
population of apoptotic cells is clearly identified, allowing to set a CellEvent signal threshold at 100 (the cells having 




For the statistical analysis we used robust Z-score (RZ), which allows the data to 
be less dependent on “outliers”. The Z-score is the distance from the mean of the whole 
plate normalized by its standard deviation. Its robust version, RZ, calculates as follow 
(Birmingham et al., 2009): 
, 
where RZw is a robust Z-score for the well w, Xw is the value for the well (either 
percentage of dying cells or cell number); Md is a median value of the Xw for the whole 
plate, MAD is a median absolute deviation of Xw for the whole plate and k is the constant 
scale factor, which depends on the distribution, and is equal to 1.4826 in case of the 
Gaussian distribution. 
RZ scores were then averaged between 4 repetitions for every siRNA to give a 
merged score (muRZ). To identify hits, we chose a threshold of RZ = 0.82. This 
threshold gives 5% hits (i.e. 5% False Positive) in the hypothetical case where all siRNAs 
are inactive (called null or H0 hypothesis), the distribution of the values is Gaussian, and a 
pro-apoptotic effect of siRNA is the only possible outcome (one sided test). For a 
standard distribution, 95% of the values are below 1.64 but taking into account the 4 




III. RESULTS AND DISCUSSION 
CHAPTER 1. UPS PROFILING IN PROSTATE CANCER 
1.1 INTRODUCTION 
The World Health Organization predicts that tumors may soon become the first 
leading cause of death, leaving behind cardiovascular diseases. At present, more than 
5000 types of cancer are known, which are caused by structural-functional disorders of 
various genes. For the last decades our knowledge of the processes that govern 
carcinogenesis has been rapidly growing. Cancer development is a multistage process – it 
appears as a result of mutation of DNA in a single cell, which has managed to escape 
elimination and has thus subsequently proliferated. The offspring cells then evolve and 
accumulate new genetic alterations, depending on molecular context, lifestyle, treatment 
used, etc. Usually cancer evolution leads to the conservation of the most malignant 
clones, which are capable of avoiding apoptosis, proliferating infinitely, invading 
surrounding tissues, etc. (Hanahan & Weinberg, 2000; Boutros et al., 2015; Sidow & 
Spies, 2015). This phenomenon, known as "oncogene addiction", describes the 
dependency of cancer cells on the altered functioning of oncoproteins. Nevertheless, to 
date, only a few mutations are known to be generally implicated in cancer development, 
including p53, Rb, PTEN, BRCA, etc. At the same time, each cancer patient has a unique 
set of genetic rearrangements influencing the cancer phenotype (Greenman et al., 2007). 
Therefore, it is assumed that some mutations are causal, while the others are acquired 
during carcinogenesis. These latter, somatic mutations, influence the molecular context of 
cancer cells and affect their response to medication. As a result, cancer heterogeneity 
makes each tumor unique and prevents the development of effective anti-tumor drugs. 
Cell constantly faces internal and external stresses, such as mistakes in DNA 
replication and DNA damage, misfolded proteins, toxic byproducts, new signals from the 
environment, etc. To maintain its integrity and homeostasis, the living cell has developed 
various stress-support systems. In a cancer cell, an altered genome redirects normal 
molecular pathways and brings about additional burdens for these systems, which makes 
them the cancer-specific Achilles' heel. This particularity of malignant cells is used in 
cancer treatment: radiotherapy and many chemotherapeutic agents target the increased 
sensitivity of malignant cells to DNA damage, while an inhibitor of the proteasome 
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Bortezomib (or Velcade from Millennium Pharmaceuticals) raises additional proteotoxic 
stress (Luo et al., 2009). Recent data suggest that antioxidants promote cancer 
progression, and vise versa: increasing oxidative stress might suppress the development 
of metastasis in melanoma (Piskounova et al., 2015). Such “non-oncogene addiction”, 
which defines the dependency of tumor on the function of normal genes (Figure 19), 
represents a new attractive strategy for targeted anti-cancer therapy and is expected to be 
specifically toxic for cancer cells (Galluzzi et al., 2013). In some cases, particular agents 
can display genotype-dependent toxicity. For example, it has been shown that inhibition 
of DNA-PKcs is synthetically lethal in cells with defective ATM. In conditions of 
genotoxic stress, suppression of DNA-PKcs leads to failure to repair DNA double-
stranded breaks and to the activation of the apoptotic program (Riabinska et al., 2013). 
Similar results were shown for the TMPRSS2:ERG protein, which affects normal Non-
Homologous End Joining (NHEJ) machinery. Thus, further impairment of DNA repair 
pathway (e.g., inhibition of PARP protein) leads to strong radiosensitization of cells 
harboring this translocation (Chatterjee et al., 2015). 
 
Figure 19. The Hallmarks of Cancer (Luo et al., 2009). In 2000 Hanahan and Weinberg published an article in Cell 
where they describe distinctive features that cancer cells acquire during selection of the most malignant clones (six 
upper symbols). Later, in 2008, Kroemer and Pouyssegur propose an additional trait - avoidance of immune system. In 
2009, Elledge and colleagues describe new features based on increased cellular stresses (metabolic, proteotoxic, 
mitotic, oxidative and DNA damage stress). These hallmarks are interdependent and promote the development of a 




The ubiquitin-proteasome system (UPS) could be viewed as one such stress-
support system. The UPS is a key mediator of molecular turnover in the majority of 
cellular functions, including cell cycle progression, DNA repair and receptor signaling. 
Mutations, genetic rearrangements and rewired molecular pathways result in an 
imbalance of protein levels, causing additional stress for the UPS. It is believed that 
further impairment of the UPS in cancer cells overloads the system, leading to its collapse 
and apoptosis. Indeed, proteasome inhibitors (such as Bortezomib and Carfilzomib) have 
been shown to be highly efficient in hematological malignancies. Unfortunately, because 
targeting the proteasome is a very general approach that influences the degradation of all 
proteins in a cell, these inhibitors often show a lot of negative side-effects. The aim was 
to benefit from the targeting of individual components of the UPS or ubiquitin-like 
modifiers (ULM) pathways, which could make therapy more selective toward tumor 
cells. Indeed, identification of the components of the UPS involved in oncogenesis and 
characterization of their drug susceptibility is of clinical importance as it may lead to the 
discovery of new therapeutic targets. 
The aim of this project was to identify components of UPS/ULM involved in the 
functioning of prostate cancer cells and, in particular, PCa cells harboring the oncogenic 
translocation TMPRSS2:ERG. As a method the loss-of-function siRNA screen of the 
UPS was used. The effects of gene knockdowns were evaluated in five cell lines, 
representing models of non-cancerous cells (RWPE1), ERG-negative cancer cells 
(LNCaP, PC3) and ERG-positive cancer cells (VCaP, DuCaP) (Figure 20). 
 




In the course of this project, a novel systematic approach to the functional 
profiling of the UPS in prostate cancer was applied. This approach, named “cascade 
profiling”, takes as its starting point the cascade organization of the UPS and uses its 
hierarchical mode of function which results in a rather compact and more targeted screen 
compared to genome-wide screens. Ubiquitin (and Ub-like proteins) are activated using 
one of the corresponding E1-activating enzymes. Then this moiety (Ub or ULM) is 
transferred to one of the E2-conjugating enzymes. Next, with the help of E3-ligase, it is 
attached directly to the target protein. At each enzymatic level, the number of individual 
components grows dramatically, which allows for an increase of specificity in a 
combinatorial way (Figure 21, A). Based on this cascade organization of the UPS, we 
were able to reduce the number of genes in the screen without loss of information: 
identification of E1 or E2 as a hit would facilitate identification of the E3s involved. To 
individually knockdown the UPS components siRNA technology was used. 
ON-TARGETplus siRNA SMART-pool approach from Dharmacon was chosen. 
ON-TARGETplus technology reduces the off-target effects mediated by antisense seed-
region interactions (the seed region is defined as nucleotide positions 2–8 from the 5′ end 
of siRNA antisense strand or miRNA loaded on Ago proteins that determine the 
selectivity of inhibition (Jackson et al., 2006)). SMART-pool contains a mix of 4 
individual siRNAs targeting the same gene, which was advantageous for two reasons: 
first it allows the decreasing of the concentration of individual siRNA that is reported to 
reduce off-target effects (Caffrey et al., 2011), while keeping the concentration of the 
total siRNAs targeting the gene high enough to ensure efficient knockdown. Second, it 
allows for the decreasing of the number of samples, which is convenient for primary 
screens that aim to eliminate siRNAs having no effect. In the secondary validation 
screens individual siRNAs from the deconvoluted pools were used (Figure 21, B). Using 
several siRNAs targeting the same gene separately allowed for the confirmation of a 
phenotypic outcome (if several siRNA cause the same effect) or to reveal off-target 
effects (if only one siRNA induces a phenotype, while others have no effect). Pools were 
used at 20 nM total siRNA concentration to minimize off-target effects, while individual 
siRNAs were used at 10 nM concentration. A set of genes were screened using 
Dharmacon “Human siGENOME siRNA Library – Ubiquitin Conjugation Subset 1” 
complemented with siRNAs to target all known E1-E2 genes. The “Ubiquitin 
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Conjugation Subset 1” also contains siRNAs against some members of the E3-RING 
ligases, which were also included in the screen. 
Because the aim was to identify genes which are synthetically lethal with 
TMPRSS2:ERG fusion, the primary screen was done with the ERG-dependent VCaP cell 
line (Figure 21, B). Based on three phenotypic parameters (induction of cell death, 
changes in cell count and ATP level reflecting cell viability/proliferation) 25 potential hits 
were selected out of 107 screened genes. Due to the abundance of the hits from the 
CRL/NEDD8 pathway in the primary screen, three more genes from this pathway were 
added in the secondary screen. The latter identified seven hits, four of which being 
components of CRL/NEDD8 pathway and 2 being potentially ERG-dependent. The 
detailed description of each step is presented below. 
 
 
Figure 21. A. Hierarchical organization of UPS. Ubiquitin (or Ub-like protein) becomes activated by one of the 
corresponding E1-activating enzymes. This moiety is then transferred to one of the E2-conjugating enzymes, and then 
with the help of E3-ligase transferred directly to the target protein. The black square shows the enzymes taken into the 
primary screen. B. Diagram of the screens. The primary screen was done using the VCaP cell line which contains the 
TMPRSS2:ERG mutation. Based on 3 phenotypic parameters (cell death, cell count and cell viability/proliferation) 28 
potential hits were selected out of 107 genes screened. The secondary screen was performed using five cell lines, 4 






1.3 CANCER CELL LINES CHARACTERIZATION 
The cell lines used in the screen (RWPE1, LNCaP, PC3, VCaP and DuCaP) 
represent different stages of cancer development (non-cancerous, cancerous and 
castration-resistant) and different cellular context (+/-/mut AR, +/-ERG) (Table 3). As a 
model for non-cancerous prostatic cells we used the RWPE1 line, established from the 
peripheral zone of a histologically normal adult human prostate, transfected with a single 
copy of the human papilloma virus 18. Among the PCa cell lines we selected two 
TMPRSS2:ERG-positive (VCaP and DuCaP) and two fusion-negative cell lines (PC3 and 
LNCaP). Despite the fact that the LNCaP cells do not possess oncogenic fusion 
TMPRSS:ERG, they harbor another translocation, activating the ETV1 gene from the 
same ETS-family of transcription factors (Tomlins et al., 2007a). The LNCaP, VCaP and 
DuCaP cell lines are AR signaling dependent, while PC3 is AR-independent. The VCaP 
and DuCaP cells have non-mutated AR (Sobel & Sadar, 2005), while the LNCaP cell line 
harbors a mutation in the ligand-binding domain of AR (T877A) in both alleles, which 
allows the receptor to be activated by progesterone, estrogen, adrenal androgens, and 
hydroxyflutamide in addition to androgens (Veldscholte et al., 1992). 
The VCaP and DuCaP cell lines are derived from the same patient, but from 
different metastatic sites: VCaP were established from vertebral metastases and DuCaP – 
from the dura mater sites (Lee et al., 2001). Although these cell lines have the same 
origin, both of them also have distinctive genetic rearrangements (van Bokhoven et al., 
2003a). Because both DuCaP cell line was established from mouse xenografts, DuCaP 
appears to have a contamination with mouse stromal cells, which could reach up to 50% 
in culture. Moreover, complete elimination of stromal cells is difficult in DuCaP cultures, 
because they seem to be required for the growth and adhesion of DuCaP cells (van 
Bokhoven et al., 2003b). Therefore, although we used the DuCaP cell line in our screen, 
the results obtained with this cell line should be considered carefully. 










RWPE1 - + - Non-cancerous immortalized basalcells 
VCaP +++ +++ Vertebral  
LNCaP - +++ 
(T877A) 
Lymph node ETV1-activating fusion. AR is mutated in ligand binding domain 
PC3 - - Vertebrae  
DuCaP + + Dura mater Derived from the same patient as VCaP cell line, but from 




Figure 22. Presence of major prostate cancer markers in four PCa cell lines used in the screen. A. Total cell lysates of 
VCaP, DuCaP, LNCaP and PC3 cells were immunoblotted for major prostate cancer markers. The blots for AR and 
ERG presented in two levels of exposure because of differences in quantity of target protein. ERG (blue arrows) is 
found in VCaP cell lines (2 isoforms) and DuCaP (1 isoform). The red arrow shows a band that possibly corresponds to 
the Fli-1 gene product, since the antibodies we used were shown to cross-react with Fli-1, whose molecular weight is 
about 51 kDa. In LNCaP cells a band of higher molecular weight was observed (green arrow). B. Summary graph with 
quantification of Western Blot data. 
 
 
Figure 23. Difference in ERG and AR expression under hormone-depleted conditions. A. Cells were grown during 5 
days on standard medium (StdM) or charcoal/dextran stripped medium (ChSM). Total cell lysates were immunoblotted 
for AR and ERG. The blots are presented in two types of exposures because of the differences in the concentrations of 




 There are some discrepancies in the description of expression profiles of cell lines 
in the literature. Thus, even for such a well-known cell line as PC3, which is believed to 
be independent on the AR signaling and not expressing AR, there are reports describing 
the presence of AR mRNA and protein (Alimirah et al., 2006). Considering also possible 
stromal contamination of DuCaP cells, precautionary screening was done for major 
prostate cancer markers of the cell lines used. WB was used to detect the presence of AR, 
PSA and ERG proteins in the PCa cell lines (Figure 22). All cell lines, except PC3, 
expressed AR and PSA, but in DuCaP cells the level of these proteins was significantly 
lower. VCaP and DuCaP cells both expressed ERG fusion. In VCaP cells antibodies 
revealed two bands very close in molecular weight, which might represent two the 
isoforms described for VCaP cells: fusion of
 
the first exon of TMPRSS2 gene with the 
forth exon of ERG (T1E4 isoform) with or without the 72 bp fragment of the eleventh 
exon (Wang et al., 2008). DuCaP cells possessed only a high molecular weight isoform at 
low concentrations. 
To recapitulate the conditions of androgen-deprivation therapy a DMEM medium, 
supplemented with the charcoal/dextran stripped FBS (Charcoal-Stripped Medium, 
ChSM), was used. Charcoal/dextran stripping is frequently used for the depletion of 
serum from androgens, but this treatment also decreases the amount of other hormones 
and certain growth factors, such as estradiol, cortisol, corticosterone, the B vitamins, 
triiodothyronine (T3), thyroxine (T4) and prostaglandins (Carter, 1978). The depletion of 
androgens leads to a decrease in the expression of AR-responsive genes, such as PSA and 
TMPRSS2:ERG, which is shown using Western Blot (Figure 23). Interestingly, the 
amount of ERG protein in the DuCaP cell line does not change under hormone-depleted 
conditions (Figure 23). To examine possible differences in the effect of gene knockdown 
in conditions when ERG is depleted or expressed at usual level, this cell line was 





1.4 PRIMARY SCREEN 
The purpose of the primary screen was to identify putative gene-hits important for 
the viability of PCa cells. To estimate the effect of gene knockdown on cell viability  
three parameters were used: induction of apoptosis, proliferation and cell count. Induction 
of apoptosis was measured by activation of caspases (CellEvent Caspase-3/7 Green 
Detection Reagent, Life Technologies). The acquisitions were performed using 
CellInsight™ NXT High Content Screening Platform from Thermo Scientific. The 
images were analyzed and quantified by the “Cell Health Profiling” program, installed 
within the CellInsight™. Proliferation was estimated by the level of ATP (ViaLight™ 
Plus Cell Proliferation and Cytotoxicity BioAssay Kit, Lonza). Cell count was measured 
using images obtained in CellEvent experiments. Using several methods gave 
complementary information while permitting the choice of the most robust method for the 
secondary screen. The primary screen was done on ChSM with VCaP cells; the effects of 
siRNA knockdown were estimated on the fifth day after transfection. The results of the 
primary screen are presented on Figure 24, Figure 25 and Figure 26. Part A of each figure 
represents an ordered distributions of the values (from smallest to the biggest), while part 
B reprensents lists of “positive” and “negative” hits. The thresholds for each readout were 
chosen arbitrarily. 
The dataset “Cell Death” (Figure 24) shows a very good distribution, which 
allows easy detection of hits. The plot has obvious “bends” in the upper and lower part of 
the graph, corresponding to about 20% outliers. The siRNAs found in the middle region 
had no apparent effect on cell viability. The negative control siAllStars is located in the 
center of the assumed “no effect” area, whereas the positive control siCellDeath had the 
highest level of dying cells (93%), which confirms the performance of the screen. The 
second highest value (75% of dying cells) was shown by siUBB, targeting ubiquitin itself. 
Knockdown of ubiquitin by siRNA is known to cause cell death (Oh et al., 2013) and is 
used as a part of siCellDeath from Qiagen (Hahn et al., 2013). 
The results obtained from the measurement of proliferation also show a correct 
distribution. Control siRNAs are at the expected places (Figure 26). The data sets 
"Proliferation" and "Cell Death" show a quite good negative correlation (R= -0.714) 
(Figure 27), reflecting the expected antagonistic relationship between these phenotypes. 
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Both assays (Apoptosis and ViaLight) were most sensitive to the “toxic” siRNAs, which 
inhibit proliferation and induce apoptosis. 
The “cell count” values show a much worse distribution, which complicates 
identification of the hits (Figure 25). Control siRNAs does not show the expected results: 
the effect of siCellDeath is very weak and siAS is shifted to the bottom of the graph. 
Moreover, its correlation with the other two datasets is the lowest. Of note, the parameters 
“Percentage of apoptotic cells” and “Cell Number” were obtained from the same 
experiment and thus supposed to be interdependent. However, the anti-correlation 
between these data sets is weak, with a correlation coefficient r = -0.299 (Figure 28). A 
possible explanation for this poor correlation is that the number of cells is a less 
repeatable parameter in general: it is difficult to put exactly the same amount of cells in 
the well and make them equally distributed within the well – there will always be fields 
with more and less cells. A second reason may be the low proliferation rate of VCaP 
cells: according to ATCC their doubling time is about 53 hours. Proliferation of VcaP 
cells in ChSM is even slower, which does not allow for detecting minor differences in the 
number of cells. Other sources of noise could be the way of cell segmentation during the 
data acquisitions, which is complicated by the properties of VCaP cells. The segmentation 
by the “Cell Health Profiling” program is based on the detection of nuclear staining (by 
Hoechst and CellEvent reagent), which is not often evident with VCaP cells growing in 
tight groups (Error! Reference source not found.). From all these considerations we 





Figure 24. Results of the primary screen with the VCaP cell line; readout - cell death. A – Ordered distributions of the 
data (from the smallest value to the biggest); B – the list of positive and negative hits. In black – negative control 
siAllStars, in red – positive control siCellDeath. 
 
Figure 25. Results of primary screen with VCaP cell line; readout - cell number. A – Ordered distributions of the data 
(from the smallest value to the biggest); B – the list of positive and negative hits. In black – negative control siAllStars, 




Figure 26. Results of primary screen with the VCaP cell line; readout - level of proliferation/ATP level. A – Ordered 
distributions of the data (from the smallest value to the biggest); B – the list of positive and negative hits. In black – 
negative control siAllStars, in red – positive control siCellDeath. 
 





Figure 28. Correlation between data sets "Cell Number" (axis Y) and "Cell Death" (axis X). 
 
Figure 29. Summary of the primary screen. A. Data sets "Cell Death", "Proliferation" and "Cell Number" (blue, red and 
violet lines respectively) are summarized in one graph (without control siRNAs and siUbiquitin). Of interest are both  
potential proto-oncogenes (in the red square), whose suppression reduces viability of PCa cells, and potential onco-
supressors (in the green square), whose knockdown increases proliferation and/or decreases apoptosis rate. B. Genes, 
selected for the secondary screen. In pink – potential proto-oncogenes; in green – potential onco-supressors. Genes are 





During the primary screen two types of hits were identified (Figure 29): putative 
proto-oncogenes (genes, which knockdown decreases proliferation and induces 
apoptosis) and putative tumor suppressors (genes, which knockdown promotes 
proliferation and decreases spontaneous apoptosis). The terms proto-oncogenes and tumor 
suppressors are used to describe the observed short-term effects of knockdown. However, 
the long-term effects of the inhibition of these genes could be opposite: decrease in 
spontaneous apoptosis may be caused by induction of translesion synthesis, inhibition of 
DNA damage response (DDR) proteins, initiation of senescence, etc. These processes can 
lead to cell death through a different mechanism, and thus may not be beneficial to cancer 
cells. The strongest hits from both groups were selected for the secondary screen (Figure 
29, B). 
The 25 strongest hits obtained in the primary screen could be divided in 4 groups 
according to their functions (Figure 30): 
1) E2 Ub-conjugating enzymes (UBE2A, UBE2D2, UBE2G1, UBE2H, UBE2J1, 
UBE2QL1, UBE2S, UBE2U, UBE2W). 
2) E3 Ub-ligases (HERC2, HERC5, RNF25, KIAA0317). 
3) Members of CRL/NEDD8 pathway (CACUL1, CAND1, CUL2, CUL4B, 
DCUN1D3, DCUN1D5, UBA3, UBE2F). The involvement of NEDD8-pathway 
in cancer progression is well-established, though there is much less information 
available on its role in PCa. One specific inhibitor of NEDD8-pathway, 
MLN4924, is currently in phase I of clinical trials. Of note, the screen revealed 
that the different members of NEDD8-pathway caused opposite effects: part of 
them could be referred to as proto-oncogenes, and others as potential onco-
supressors (Figure 29). 
4) Members of N-end rule pathway (UBR1, UBR3, UBR4 and UBR5). The N-end 
rule states that the N-terminal amino acid of a protein determines its half-life 
(chance of being degraded). Specific N-terminal protein residues, called N-
degrons, are recognized by the recognition components N-recognins of UBR E3 
ligases. Although UBR1-5 share the same mechanism of substrate recognition, 
these proteins perform independent functions. 
Due to the enrichment of the hits from the CRL/NEDD8 pathway in the screen, to 
the secondary screen it was decided to add siRNA targeting other genes from this 
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pathway: RBX1 and RBX2 (E3 ligases of the pathway) and SPOP, a substrate receptor of 
CRL3 ligase, which is often mutated in prostate cancer, the event shown to be mutually 
exclusive with TMPRSS2:ERG mutation (Barbieri et al., 2012; Rubin, 2012). The final 
list of the 28 candidate genes selected for further validation is presented in Figure 30. The 
sequences of corresponding siRNAs are given in Supplementary Table 3. 
 
Figure 30. Classification of the hits from the primary screen. A. Classification of genes selected for secondary screen by 
their function. B. Final list the 28 candidate genes selected for further validation. 
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1.5 SECONDARY SCREEN 
1.4.1 Technical notes 
The goal of the secondary screens was preliminary confirmation of the hits. These 
screenings were performed with individual siRNAs from deconvoluted siRNA-pools. The 
complete list of siRNAs chosen for the validation is presented in Supplementary Table 3. 
The cell lines used in this screen were: transformed non-cancerous cells (RWPE1), ERG-
negative cancer cells (LNCaP, PC3) and ERG-positive cells cancer (VCaP, DuCaP). 
Examination of cells with different status (+/-AR, +/- ERG, wt/mut p53, etc.) allowed for 
addressing the dependence of gene knockdown on cellular context. To diminish off-target 
effects, individual siRNAs were used at 10 nM concentration. The time of siRNA 
treatment was optimized for each cell line depending on the proliferation rate and 
sensitivity of the cell line to siRNA. Thus, the effect of gene knockdown was analyzed on 
the third day of siRNA treatment for the LNCaP, PC3 and RWPE1 cell lines, and on the 
fifth day for VCaP and DuCaP cells. 
Because the most robust method to estimate the effect of siRNA on cell viability 
apparent from the primary screen was apoptosis assay for caspases activity (CellEvent 
reagent), this was used as a major parameter in the secondary screening. As a 
complementary method cell count was used. Although this parameter was not very 
reliable for the VCaP cell line, for the other cell lines the expected clear anti-correlation 
with apoptotic rate was observed and the controls were at the expected positions (Figure 
31).  
The same protocol of transfection for all cell lines was used, with 4 well replicates 
per siRNA separated into two plates. A hit was selected when muRZ, the average among 
replicates of the robust Z-score per siRNA was above 0.82 (see the section SCREEN 
QUANTIFICATION). Although this threshold is relatively low, it was considered 
reliable because 5 cell lines were screened and two siRNAs per gene with the same 
phenotype were required to select a gene hit. The scores for each siRNA and each cell 
lines for induction of apoptosis are presented in Supplementary Table 6. Positive scores 





Figure 31. Correlation plots for parameters “Cell Death” and “Cell Number” for all the tested cell lines. Green triangle 
– siCellDeath, blue – negative control siAllStars, red – siERG. VCaP cells show poor anti-correlation and the control 
siAllStars is displaced from expected positions. Nevertheless, the other cell lines show much better correlation and 




Figure 32. EdU pulse in DuCaP cells. Nuclear staining with Hoechst is shown in blue. EdU staining is shown in red. 
After 1 day of incubation there is about 40% proliferating cells in population. After 5 days of incubation the amount of 
proliferating cells (with the same time of EdU-pulse of 7 hours) decreases dramatically. After increasing the time of 
incubation of cells with EdU up to 37 hours we can visualize about 30% of cells incorporating EdU. 
 
Performing the screen, some unexpected effects were observed on control siRNAs 
(Supplementary Table 6, Figure 31). In all tested cell lines, the negative control siAllStars 
did not cause apoptosis, which results in a very low muRZ-scores ranging from -0.03 up 
to 0.16 depending on cell line. The positive control siCellDeath caused massive apoptosis 
in the majority of cell lines resulting in muRZ-scores above 14. However, siCellDeath did 
not cause apoptosis in DuCaP cell line. siCellDeath target two genes: Ub and Polo-like 
kinase 1 (PLK1), which is responsible for progression through the cell cycle. Thus, an 
extremely low level of proliferation and slow metabolism could render cells insensitive to 
siCellDeath. To examine the proliferation level of the DuCaP cell line EdU incorporation 
pulse was performed. Indeed, despite the initial burst of proliferation, the growth rate of 
DuCaP cells decreased dramatically after a few days in culture (Figure 32, left and middle 
panel). Nevertheless, by increasing the time of EdU pulse up to 37 hours, it was possible 
to detect EdU incorporation (Figure 32, right panel). We believe that this extremely low 
proliferation rate was caused by contact inhibition. This could allow DuCaP cells to 
escape from proliferation-dependent apoptosis. 
It was also observed that siRNA against ERG caused apoptosis in all tested cell 
lines except VCaP. Initially, this siRNA was taken as a second negative control, because 
it was shown to decrease proliferation of VCaP cells without induction of apoptosis (Tan 
et al., 2009). Indeed, siERG caused a strong decrease in proliferation without causing 
apoptosis in VCaPs (Figure 24; Figure 26). Unexpectedly, other tested cell lines 
responded to siERG treatment by induction of apoptosis (Supplementary Table 6). At 
present, it is difficult to determine if this effect was specific or off-target. ERG protein 
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expression in prostate tissue is considered to be specific for TMPRSS2:ERG-positive 
samples. Nevertheless, the ERG gene is still present in all cell lines, and might be 
expressed at a very low level. Consistent with this assumption, it has been reported that 
ERG mRNA is expressed in normal prostatic cells and in TMPRSS2:ERG negative PCa 
samples and cell lines, including LNCaP used in the screen (Zammarchi et al., 2013). 
Thus, apoptosis caused by ERG inhibition in this present experiment could be explained 
by critical depletion of the protein resulting in the abortion of some vital function. 
A very good reproducibility was observed of the screen between plate replicates 
with correlation coefficient above 0.9 for all cell lines (Figure 33, A-G). To compare the 
robustness of various cell lines in response to siRNA perturbations global Standard 
Deviation of the dataset (gSD) was used. This parameter reflects the number of hits and 
their strength for each cell line (Figure 33, H). Of note, because the primary screen was 
performed on VCaPs, the pre-selected hits were specific to this cell line. Nonetheless, 
according to gSD, the DuCaP cell line appeared to be the most sensitive to the 
perturbations induced by pre-selected siRNAs. The most robust cell line appeared to be 
PC3. Considering that even siCellDeath did not have a strong effect on PC3 (about 40 
percent of dying cells in the population in comparison to 90-100 percent for other cell 
lines), it might suggest that the time of siRNA treatment (three days) was not optimal for 
this cell line. Increasing the incubation time might increase the sensitivity of PC3 cells to 
siRNA treatment. 
To compare the effect of gene knockdown in conditions when ERG is depleted or 
expressed at normal level, VCaP cells were screened both in ChSM and in StdM. The 
correlation between the data obtained with VCaPs in these two conditions (r = 0.83) was 
higher than the correlation between VCaPs datasets and any other tested cell line (Figure 
34, C). This suggests that the overall response of VCaP cells to siRNA knockdown was 
similar in ChSM and StdM (Figure 34, A). Among the strong hits (muRZ > 2) there were 
four specific to ChSM while the other four were observed only in StdM (Figure 34, B). 
However, because all these perceived hits were the only siRNA having an effect out of 
four siRNAs per gene, this most likely indicates off-target effects. Among weaker hits 
only siRNAs for cullin 2 (CUL2) and CAND1 showed differential behavior in ChSM and 
StdM. Moreover, siRNAs against CUL2 effectively caused cell death in another ERG-
dependent cell line (DuCaP) and had a much weaker (or no) effect on other cell lines. 





Figure 33. A-F. Reproducibility of “the percentage of dying cells per siRNA” parameter in two replicate plates for each 
cell line. G. Reproducibility (correlation coefficient between plates) is very high for all the cell lines (r > 0.9). H. Global 





Figure 34. Comparison of hits for VCaP cell line on StdM and ChSM. A. Scores for each siRNA for the VCaP cell line 
in ChSM and StdM show strong positive correlation (r=0.83), which is close to the correlation coefficients observed 
between replicates for the same cell line. B. Venn diagram, showing overlap between strong hits (muRZ>2). There are 
13 hits that are effective in both StdM and ChSM, and 8 siRNAs that are strong hits either in StdM or ChSM. C. 
Classification of cell lines based on correlation coefficient. VCaP on StdM and on ChSM have the highest correlation 
between each other than with other cell lines. 
 
 
Figure 35. A. Relative level of apoptotic cells in a population of DuCaP cells when treated with control siRNAs: the 
negative control being siAllStars and positive control siCellDeath. B. Correlation plot showing that compared to other 
tested cell lines DuCaP is the most distinct in terms of apoptotic response after siRNA treatment. 
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The cell line DuCaP showed the most distinct behavior. First, siCellDeath did not 
induce apoptosis in this cell line (Figure 35, A). Second, the phenotypical outcome of the 
inhibition of the UPS genes in DuCaPs was the most different compared to other cell 
lines (Figure 35, B). Third, DuCaPs had significantly lower amounts of AR then other 
cell lines, and only one isoform of ERG was present at a significantly lower level 
compared to VCaPs (Figure 22). Moreover, despite DuCaP being considered to be 
androgen-responsive cell line, the amount of ERG protein did not change in ChSM 
compared to StdM (Figure 23). Considering also the reports about stromal contamination, 
it was conclude that the DuCaP cell line is not a reliable model of ERG-dependent PCa 
cells. Thus, VCaP cells were used as the major model of TMPRSS2:ERG-positive PCa, 
although data obtained with DuCaPs could give complementary information. 
1.4.2 Description of hits 
The results of the secondary screening are presented in Supplementary Table 6 (a 
table with muRZ-scores for each individual siRNA and every cell line) and 
Supplementary Table 7 (a table summarizing the screening). Hits selection were based on 
the following parameters: 
1) How many siRNA per gene cause the same phenotype? If two or more siRNA had 
the same phenotype, this gene was considered a hit. 
2) What is the relative strength of the hits?  Are they similar in strength? If one 
siRNA causes a strong effect, while others are rather weak, this most likely signifies an 
off-target effect. 
3) Does inhibition of the gene cause the same phenotype in all cell lines? Having the 
same effect for all tested cell lines would suggest that the function of gene is not 
dependent on cellular context and is of general importance for prostate cells. 
Parameters 1 and 2 allow calculating mixt_muRZ, which represent relative 
probability of the hits for each cell lines. Graphical representations of mixt_muRZ for the 
VCaP cell line are presented in the Figure 36 (A and B). Based on the three parameters 
mentioned above we selected seven hits (Figure 36C). Of these seven, three are E2-Ub-
ligases (UBE2U, UBE2H and UBE2A), while four are the members of CRL/NEDD8 
pathway (CAND1, CUL4B, CUL2 and RBX1). Two hits are potentially ERG-dependent 
(CUL2 and RBX1), because they had an effect in ERG-positive cell lines only (VCaP, or 
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DuCaP, or both). Inhibition of genes had different effects, including apoptosis (for 
UBE2U, CAND1, CUL2, UBE2H) and survival (for UBE2A, CUL4B, RBX1). A 
detailed discussion of these hits is presented below.  
 
Figure 36. General overview of the hits.  
A and B: Mixt_muRZ scores for each gene based on the muRZ scores obtained from 4 siRNAs per gene. Genes beyond 
the blue line have 2 siRNAs being hits, beyond the orange line - 3 siRNAs. When on the line (e.g. UBE2U 
VCaP_StdM), it means just 2 siRNAs, but with high muRZ-score (above 3 here).  
C: Table with summary information about hits (a full summary for each gene can be found in the Supplementary Table 
7). Designations: numeric - number of hit siRNAs causing the same phenotype (apoptosis/increase in cells/etc.). 2 to 3: 
means 2 hits above the threshold, and 1 just below the threshold. 1 (but 07): 1 hit with the 'major' phenotype, but siRNA 
with catalogue number 07 has an opposite effect. In red - hits decreasing viability, in green - increasing viability. 
Column “Overall” describes the “major” phenotype caused by the gene inhibition: death – more apoptosis, survival – 





Figure 37. A. Graphical representation of siRNA action for the UBE2U gene. The graph represents the phenotypical 
changes (proportion of dying cells and changes in cell number) for each of 4 siRNAs and all the 5 cell lines tested 
(VCaP presented in 2 conditions: in ChSM, as all the other cell lines, and in StdM). muRZ is an averaged Robust Z-
score from quadruplicates for each siRNA. The grey dotted lines indicate zero values for both axes. Pink dotted lines 
indicate threshold values: everything above or below these values (outside grey rectangle) is considered to be a hit.  
B: The total cell lysates of VCaP, DuCaP, LNCaP and PC3 cells were immunoblotted with UBE2U antibodies from 2 
manufacturers (Santa Cruz and Sigma). First the membrane was stained with antibodies from Santa Cruz, but since 
there was no signal, antibodies from Sigma were used on the same membrane; hence the loading control (GAPDH) is 
the same. Antibodies from Sigma also did not show any staining at the predicted MW of UBE2U (38 kDa), but it 
reveals bands of much higher MW (with 2 major bands at 95 kDa and 130 kDa).  
C. VCaP cells which had been transfected with siUBE2U pool (total mix of 4 siRNAs) or with negative control siAS 
and immunoblotted against UBE2U (Sigma).  
D. VCaP cells which had been transfected with 3 strongest siRNAs individually (si2U-12, si2U-10 and si2U-11 from 
strongest to the weaker) or with negative control siAS and immunoblotted against UBE2U (Sigma). 
 
UBE2U 
The strongest identified hit was UBE2U. Three of four tested siRNAs caused 
apoptosis in all cell lines with very high muRZ-scores (Supplementary Table 6 and 
Supplementary Table 7; Figure 37). There is almost no information about the function of 
this gene. UBE2U is mentioned only in genome-wide or E2-limited interactome screens 
(Markson et al., 2009; van Wijk et al., 2009; Rolland et al., 2014, etc.). The UBE2U gene 
is only present in mammalian genomes and is mapped to the human Chromosome 1. 
There are about 30 predicted mRNA transcripts in the NCBI database, but only one of 
them has been confirmed so far (NM_152489.1) and it is used in all published reports 
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addressing the function of UBE2U. This isoform has 9 exons and is transcribed into a 226 
a.a. protein (NCBI Reference Sequence: NP_689702.1). Because the protein has a 
characteristic E2-ubiquitin-conjugating fold with a preserved active site Cys, it could be a 
functional E2-Ub-conjugase. However, until now no ubiquitin (or ubiquitin-like) 
conjugation activity have been described in the literature. One of the reports has shown 
that UBE2U has no activity in an in vitro assay for the transfer of Ub from UBE1 or 
UBE6 (Jin et al., 2007). 
The data on UBE2U’s interaction network vary a lot and are not conclusive. Van 
Wijk and colleagues using Y2H system and the E2 + E3 protein library have shown that 
UBE2U has the highest number of interactions with E3s (52 interactions) compared to 
other E2s. They have reported that UBE2U has a unique E3-interactome, and after 
removing UBE2U from the network only 20 of UBE2U’s E3 partners remain connected 
to other E2s, whereas 32 E3s become unconnected (van Wijk et al., 2009). This suggests 
a general role of UBE2U in ubiquitylation. Another team (Markson et al., 2009), also 
using the Y2H system, with E2-bait and genome-wide preys, has shown only 13 
interaction with E3-ligases for this E2-conjugase. The most recent genome-wide study of 
its interactome (Rolland et al., 2014) shows only one E3-partner for UBE2U – TRIM32. 
Interaction partners reported in more than one paper are TRIM32 (Markson et al., 2009; 
Rolland et al., 2014) and RNF144B (Markson et al., 2009; van Wijk et al., 2009). 
TRIM32 and RNF144B are poorly characterized proteins with unrelated 
functions. TRIM32 is a member of the TRIM E3-Ubiquitin ligases family of RING 
proteins with more than 70 members in the human genome. TRIM32 has been shown to 
play an important role in antiviral defense (Zhang et al., 2012; Fu et al., 2015). One study 
showed that, upon induction by pro-inflammatory cytokines, TRIM32 is covalently 
modified by another Ub-like protein FAT10 (Aichem et al., 2012). TRIM32 was shown 
to negatively regulate p53 to promote tumorigenesis (Liu et al., 2014). RNF144B is an 
E3-Ubiquitin ligase with an important role in apoptosis. RNF144B is a transcriptional 
target of p53 and induces p53-dependent but caspase-independent apoptosis by 
ubiquitylation and degradation of p21 (Huang et al., 2006; Ng et al., 2003). RNF144B 
has also been shown to be a direct transcriptional target of ΔNp63 a (transcription factor 
that is critical for the development of stratified epithelia). At the same time RNF144B 
binds and mediates proteasomal degradation of ΔNp63α, generating an auto-regulatory 
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feedback loop. These findings substantiate RNF144B as a potentially critical component 
of epithelial homeostasis (Conforti et al., 2013). 
Considering that the expression of UBE2U mRNA has been shown to be restricted 
to the urogenital tract (to the testis by GTEx Analysis Release V4, Uhlen's Lab and 
Illumina Body Map, and to the prostate by the Cancer Genome Anatomy Project), and 
that there was a strong effect of UBE2U inhibition for all tested prostate cell lines, it was 
of interest to get more information on this protein and on its function in prostatic cells. 
First, the presence of the protein, in the current study’s chosen cell lines, was examined 
(Figure 37, B). Two commercially available antibodies (from Santa Cruz and Sigma) 
were tested, but neither of them showed the presence of a protein of the predicted size (38 
kDa). Finally, antibodies from Sigma, produced against a catalytic domain of UBE2U, 
did show protein staining at higher molecular weight with two major bands at 95 and 130 
kDa. In order to check whether these bands are specific to UBE2U, VCaP cells were 
transfected with siUBE2U-pool (total mix of 4 siRNAs) or with the 3 strongest siRNAs 
separately (si2U-12, si2U-10 and si2U-11 from the strongest to the weakest) (Figure 37, 
C and D). After transfection, the 95-kDa band disappeared compared to the negative 
control siAllStars (siAS), and the strongest si2U-12 also had the strongest effect. 
Nevertheless, there was no success in obtaining a Western Blot of good quality for this 
protein due to the low level of expression and insufficient sensitivity of the method. 
An attempt was made to detect the presence of UBE2U at mRNA level. Four pairs 
of primers were selected targeting different isoforms (pairs 1 and 2 – against described 
transcript NM_152489; pairs 3 and 4 – against predicted isoforms). Amplification was 
weak and not always equal (probably because of the low concentration of target mRNA), 
but using primer pair 3 (Supplementary Table 5) three major isoforms were obtained 
(Figure 38, A). Sequencing has shown that all these isoforms consist of the described 
exons of predicted UBE2U mRNA isoforms (Figure 38, B and C). However, the full 
transcripts were not identical to any described or predicted transcripts, and thus represent 
absolutely new isoforms. Unfortunately, none of the found isoforms contain exons with 
the sequence corresponding to the strongest siRNAs si2U-12, which is present in the 
majority of predicted isoforms from the NCBI database (Figure 39, A). Moreover, the 
proteins transcribed from the isoforms that had been amplified were truncated. The 
predicted protein sequences obtained by translation of identified UBE2U isoforms are 
shown below. Only the largest predicted protein still contains the active site, while the 
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medium and small constructs lack catalytic residues (Figure 39, B) and, therefore, also 
lack enzymatic activity. 
The data from screening suggest an important role of UBE2U in the prostate. 
Unfortunately, at present it is not possible to tell if it is protein or RNA that is crucial for 
the survival of prostatic cells. By PCR the presence of several isoforms of UBE2U were 
demonstrated in the VCaP cell line, but considering the extremely low level of its 
expression and the absence of isoforms with exon bearing the sequence of the most potent 
siRNA, most likely there are many more isoforms present in the genome which could 
have different functions. The presence of a specific band of much higher MW than 
predicted (95 kDa instead of 38 kDa) in all tested prostatic cell lines supports this 
conclusion. To characterize the role of UBE2U in prostatic cell lines it is important to 
determine which isoforms are expressed and are crucial for the survival of these cells, and 




Figure 38. UBE2U mRNA amplification and sequencing. A. Representative electrophoresis of PCR products in agarose 
gel with 3 major isoforms (big, medium and small). B. Alignment of the sequences of obtained isoforms. C. Alignment 





Figure 39. A. Location of siRNAs used in the screening on mRNAs of UBE2U. As a reference the confirmed isoform 
transcript NM_152489 is shown. The most potent si2U-12 does not target any of the amplified isoforms. B. Predicted 
translated proteins from isoforms detected in our research (big, medium and small isoforms) and from reference isoform 
NM_152489. In red the amino acids crucial for formation of active site of E2 enzymes are shown, including the active 
site cysteine (C), star – stop-codon, in grey – non-translated part of the protein. Only the reference isoform translates 
into a full-length protein. The big isoform is shortened, but nevertheless contains amino acids crucial for catalytic 




Knockdown of UBE2H caused apoptosis in TMPRSS-ERG-positive cells VCaP 
and DuCaP, as well as in the non-cancer RWPE1 cell line, but had no effect on either 
PC3 (AR-independent) or LNCaP (ETV1-positive) (Supplementary Table 6 and 
Supplementary Table 7; Figure 40A). The efficacy of tested siUBE2H in the VCaP cell 
line was confirmed at protein level (Figure 40, B). 
UBE2H is an E2-Ubiquitin conjugase overexpressed in many types of cancer, 
including cancer of the prostate, ovaries and breast (The Human Protein Atlas, Expression 
Atlas from EMBL). UBE2H plays an important role in several developmental pathways, 
including the negative regulation of skeletal myogenesis through ubiquitylation and the 
subsequent degradation of focal adhesion kinase (FAK) and insulin receptor substrate 1 
(IRS-1) (Nguyen et al., 2014; Yi et al., 2013) and in the erythroid differentiation of 
hCD34(+) cells (Lausen et al., 2010). UBE2H is also involved in spermatogenesis, where 
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it participates in ubiquitylation of H2A and H2B and thus is essential for chromosome 
remodeling, double strand break (DSB) repair and normal progression through meiosis 
(An et al., 2012). Furthermore, UBE2H participates in degradation of p53 protein (Doyle 
et al., 2010). 
Among tested PCa cell lines, only the VCaPs expressed the UBE2H protein at a 
detectable level (Figure 40, C), which might suggest involvement in the ERG-dependent 
pathways. Nevertheless, considering that UBE2H is often overexpressed in cancers of 
reproductive system (prostate, ovarian and breast cancer) and is involved in cancer 
progression (by DNA remodeling and p53 degradation) it may be an interesting drug-
target. 
UBE2A 
Knockdown of UBE2A decreased apoptosis and increased cell number in the 
VCaP, PC3 and LNCaP cell lines. A weaker prosurvival effect was also observed in 
DuCaP and RWPE1 cells (Supplementary Table 6 and Supplementary Table 7; Figure 
41). Even though not many scores were beyond the threshold, it is clear that all of them 
are shifted to the right lower part of the graph. It should be noted, that due to the 
experimental setup the detection of apoptosis inhibition was more difficult compared to 
apoptosis induction, and thus requires stronger validation. 
 
 
Figure 40. Graphical representation of siRNA action for the UBE2H gene. A. The graph represents the phenotypical 
changes (proportion of dying cells and changes in cell number) for each of 4 siRNAs and all 5 cell lines tested (VCaP 
presented in 2 conditions: in ChSM, like other cell lines, and in StdM). muRZ is an averaged Robust Z-score from 
quadruplicates for each siRNA. Grey dotted lines indicate zero values for both axis. Pink dotted lines indicate threshold 
values: everything above or below these values (outside of grey rectangle) is considered to be a hit. B. The effect of 
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si2H on expression of the protein. VCaP cells were transfected with the 3 strongest siRNAs individually (si2H-5, -7 and 
-8) or with the negative control siAS and immunoblotted against UBE2H. C. Expression of UBE2H in the tested cell 
lines. Only VCaP cells express UBE2H at a detectable level. 
 
 
Figure 41. Graphical representation of siRNA action for the UBE2A gene. A. The graph represents the phenotypical 
changes (proportion of dying cells and changes in cell number) for each of 4 siRNAs and all the 5 cell lines tested 
(VCaP presented in 2 conditions: in ChSM, like the other cell lines, and in StdM). muRZ is an averaged Robust Z-score 
from quadruplicates for each siRNA. Grey dotted lines indicate zero values for both axis. Pink dotted lines indicate 
threshold values: everything above or below these values (outside of grey rectangle) is considered to be a hit. 
 
UBE2A is an E2-Ubiquitin-conjugase homologous to yeast protein Rad6, which is 
a key player in DNA damage response. Monoubiquitylation of the proliferating cell 
nuclear antigen (PCNA) by Rad6 stimulates translesion (error-prone) DNA synthesis, 
while polyubiquitylation of the PCNA with the same enzyme activates the error-free 
repair pathway. Mutations in the catalytic site of Rad6 confer hypersensitivity to a variety 
of DNA damaging agents (Chen et al., 2012b). The human genome encodes two 
homologues of Rad6 protein: UBE2A and UBE2B. They have 70 % of homology and 
often perform complementary, partially redundant functions (Xin et al., 2000). For 
example, under exposure to ionizing radiation (IR), RNF168 attracts both UBE2A and 
UBE2B to the sites of DNA DSB, where they induce ubiquitylation of DNA-bound 
proteins and initiate DNA damage response. Depletion of either UBE2A or UBE2B 
individually does not affect DNA damage response, while the suppression of both 
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proteins at once abrogates DNA-damage-induced Chk1 activation, and affects G2/M cell 
cycle arrest (Liu et al., 2013). Similarly to yeasts, human UBE2A is required for mono- 
and poly-ubiquitylation of the PCNA, the key events of post-replication DNA repair. 
Depletion of UBE2A and 2B impairs homologues recombination (HR) following IR 
treatment and results in increased DNA damage (Liu et al., 2013, Chen et al., 2015).  
UBE2A has also unique functions, distinct from UBE2B, in maintenance of 
cellular homeostasis. Similarly to Rad6, UBE2A may ubiquitylate histone H2B (Chen et 
al., 2012a; Kim et al., 2009a; Masuda et al., 2012). In the monoubiquitylated form H2B 
(H2Bub1) plays key roles in transcription, DDR and stem cell differentiation (Masuda et 
al., 2012; Sadeghi et al., 2014; Shchebet et al., 2012; Barkley et al., 2012; Cole et al., 
2015). In many types of advanced cancers, including breast, colorectal, lung and 
parathyroid cancers, the level of H2Bub1 is downregulated (low to absent), which makes 
H2Bub1 and the enzymes affecting it level a promising therapeutic targets in cancer (Kim 
et al. 2009a; Cole et al., 2015). Indeed, the UBE2A gene was found to be recurrently 
mutated or inactivated in myeloproliferative diseases (de Miranda et al., 2014; Kunapuli 
et al., 2003). 
According to the present study’s results, the inhibition of UBE2A gene decreases 
the level of apoptotic cells and increases cell number. The basal level of apoptosis in the 
screens probably reflects spontaneous death induced by unbalanced proliferation and 
impaired DNA replication. Thus, inhibition of UBE2A protein may lead to the bypassing 
of apoptotic signaling by induction of error-prone DNA synthesis and/or insufficient 
activation of the p53 protein. 
CAND1 
The second strongest hit was CAND1. All 4 tested siRNAs (typically 2 siRNA per 
cell line) caused cell death in all tested cell lines with very high muRZ-scores 
(Supplementary Table 6 and Supplementary Table 7; Figure 42, A). The efficiency of 
tested siRNAs on the inhibition of CAND1 expression was confirmed at the protein level 
(Figure 42, B). The protein was detected in all cell lines at similar levels, with the 
exception of LNCaPs demonstrating significantly lower CAND1 expression (Figure 42, 
C). 
CAND1 (cullin-associated and neddylation-dissociated 1) plays a critical role in 
the function of E3 CRL-ligases and thus in specific protein degradation. It is the only 
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known exchange factor allowing CRL complexes to change substrate specificity (for 
more details see chapter 2.4 NEDD8-pathway of the literature review). The data from the 
literature suggest an important role of CAND1 in cancer development, although the 
precise effect is not clear. Zhai and colleagues (2014) demonstrate downregulation of 
CAND1 protein in tumors compared to normal tissue. Nevertheless, non-biased 
screenings demonstrate both overexpression and downregulation of the protein during 
prostate cancer development (Expression Atlas from EMBL, Korzeniewski et al., 2012). 
The direct effect of CAND1 knockdown on PCa cells was investigated in only one 
study, using LNCaP as a cell model. The authors described androgen-responsive miR-
148a, which controls CAND1 expression (Murata et al., 2007). They showed that miR-
148a inhibits CAND1 expression by binding to the 3′-UTR region of CAND1 mRNA, 
which promotes LNCaPs proliferation. Using siRNA against CAND1, they showed the 
same effect of promoting LNCaP cell proliferation compared to control siRNA. 
Nevertheless, inhibition of CAND1 expression and stimulation of proliferation could be 
independent events: miRNAs were shown to regulate hundreds of genes through partial 
complementarity in the seed region (Laganà et al., 2014). Moreover, the authors have 
tested the effect of a single siRNA against CAND1 with a single cell line. The off-target 
effects of siRNA are well known, and currently it is advised to use at least four siRNAs 
against different exons of the gene to confirm the phenotypical outcome. On the other 
hand, the mechanism of CAND1 regulation by miR-148a may be LNCaP-specific, as, 
according to the present study’s data, CAND1 is strongly down-regulated in LNCaPs 
comparing to other cell lines (Figure 42, C). 
In the present study, siRNAs targeting four different regions of CAND1 mRNA in 
five prostatic cell lines were used. Induced apoptosis in all four siRNAs was observed in 
all tested cell lines, including LNCaP. Interestingly, for the VCaP cell line the effect of 
siCAND1 is weaker in standard medium than in charcoal-dextran stripped medium 
(Supplementary Table 6 and Supplementary Table 7), this could suggest an AR-




Figure 42. Graphical representation of siRNA action for the CAND1 gene. A. The graph represents the phenotypical 
changes (proportion of dying cells and changes in cell number) for each of 4 siRNAs and all the 5 cell lines tested 
(VCaP presented in 2 conditions: in ChSM, as all the other cell lines, and in StdM). muRZ is an averaged Robust Z-
score from quadruplicates for each siRNA. Grey dotted lines indicate zero values for both axis. Pink dotted lines 
indicate threshold values: everything above or below these values (outside of the grey rectangle) is considered to be a 
hit. B. Effect of siCAND on the expression of the protein. VCaP cells were transfected with 3 strongest siRNAs 
individually (siCAND1-9, -10 and -12) or with negative control siAS and immunoblotted against CAND1. C. 
Expression of CAND1 protein in the tested cell lines. 
 
 
Figure 43. Graphical representation of siRNA action for CUL4B gene. A. The graph represents the phenotypical 
changes (proportion of dying cells and changes in cell number) for each of 4 siRNAs and all the 5 cell lines tested 
(VCaP presented in 2 conditions: in ChSM, like the other cell lines, and in StdM). muRZ is an averaged Robust Z-score 
from quadruplicates for each siRNA. Grey dotted lines indicate zero values for both axis. Pink dotted line indicates 





The knockdown of cullin 4B (CUL4B) decreased apoptosis and increased cell 
number in all tested cell lines except LNCaPs (Supplementary Table 6 and 
Supplementary Table 7; Figure 43). 
CUL4B is a scaffold protein for E3-ubiquitin CRLs (Cullin-RING-Ligases) (more 
details about the structure and function of CRLs are given in the literature review, 
paragraph 3.4.2 NEDD8 TARGETS). Cullin 4-Ring E3 ligases (CRL4), assembled with 
CUL4B, DDB1 substrate adaptor and RBX1 as the core components, participate in a 
broad variety of physiologically and developmentally controlled processes such as cell 
cycle progression, replication, and DNA damage response. In mammals, there are two 
Cullin 4 members, CUL4A and CUL4B. CUL4A and CUL4B have many common 
substrates and are believed to be redundant for some functions (Sharifi et al., 2014). 
CRL4 has emerged as a “master coordinator of cell cycle progression and genome 
stability” (Abbas & Dutta, 2011). CRL4 regulates cell cycle progression through the 
degradation of several factors upon entry into S phase, including replication licensing 
factor Cdt1, Cyclin E (responsible for G1 to S phase transition), cyclin-dependent kinase 
inhibitor p21 and transcriptional suppressor Set8. During DNA synthesis under normal 
conditions, CRL4 is required for translesion synthesis (TLS) via a mechanism that is 
dependent on PCNA monoubiquitylation by UBE2A (Havens & Walter, 2011). 
CRL4 also plays a key role in DNA-damage response by the activation of the error-free 
isoform of DNA-polymerase δ (Polδ) and the degradation of Cdt1, p21, and Set8 (Havens 
& Walter, 2011; Zhang et al., 2013). Depletion of CRL4 subunits induces replication 
stress and DNA damage, leading to cell cycle arrest in G2. This phenotype has been 
shown to depend, at least in part, on the DNA re-replication caused by failure to degrade 
replication origin licensing proteins (Sertic et al., 2013; Zou et al., 2009). 
Although cullins 4A and 4B are thought to be functionally redundant, CUL4A 
does not substitute 4B in all functions. In response to DNA damage CRL4B was shown to 
ubiquitylate and degrade the HUWE1 protein (Yi et al., 2015), which is responsible for 
induction of apoptosis upon DNA damage. Unlike any other cullins, CUL4B contains a 
nuclear localization signal (NLS) and has been shown to colocalize with DNA-damage 
markers inside the nucleus (Guerrero-Santoro et al., 2008). Recent studies have 
established the role of CRL4s, especially of CRL4B, as important epigenetic regulators; 
CUL4B facilitates H3K9 tri-methylation and DNA methylation, two key epigenetic 
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modifications involved in gene silencing (Nakagawa & Xiong, 2011; Yang et al., 2015). 
Depletion of CUL4B resulted in loss of these markers, leading to de-repression of a 
number of genes, including the tumor suppressor IGFBP3 (Yang et al., 2015a; Hu et al., 
2012). 
In accordance with the experimental data, many recent works present CUL4B as 
an oncogene. Inhibition of CUL4B decreases proliferation and induces apoptosis in 
human osteosarcoma, glioma, cervical carcinoma and hepatocarcinoma cells (Chen et al., 
2014; Yuan et al., 2015b; Dong et al., 2015; Yang et al., 2015). Moreover, in colon 
cancer CUL4B overexpression correlates with tumor invasion and metastases (Jiang et 
al., 2013). On the other hand, CUL4B has been shown to be strongly down-regulated or 
to have inactivating mutations in many cancer types (The Human Protein Atlas; de 
Miranda et al., 2014), which is not consistent with the oncoprotein role. 
Collectively, all these data suggest that CUL4B plays an important role in 
chromatin remodeling and DNA-damage response. The present study’s results, showing 
that a knockdown of CUL4B has a survival effect, could be explained by the induction of 
error-prone DNA synthesis and/or cell cycle arrest, which could decrease the level of 
spontaneous apoptosis, but may further lead to increased genetic instability, induction of 
senescence and apoptosis. These effects could be tracked with markers of senescence 
(beta-galactosidase activity, p21, Cdt1) and increased DNA-damage. 
RBX1 
Knockdown of the Ring-Box 1 (RBX1) gene decreased apoptosis and increased 
cell number in the ERG-positive cell line VCaP, and decreased proliferation in LNCaP, 
PC3 and RWPE1 (Supplementary Table 6 and Supplementary Table 7; Figure 44). The 
effect of RBX1 knockdown on another ERG-positive cell line (DuCaP) is not clear. 
However, considering the particularity of DuCaP cells (Figure 32, Figure 35), the effect 
of RBX1 inhibition may still be ERG-dependent. 
RBX1 (also known as ROC1) is a RING E3-ligase, which is a part of the CRL 
complex (more details about the structure and function of CRLs are given in the literature 
review, paragraph 3.4.2 NEDD8 TARGETS). Both RBX1 and RBX2 are able to bind all 
the cullins. Nevertheless, under physiological conditions, RBX2 is selectively associated 
with CUL5, while RBX1 binds to the other members of the family (Wei & Sun, 2010; 
Kamura et al., 2004). Compared to RBX2, which is stress inducible, RBX1 is 
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constitutively expressed. Within the CRL complex RBX1 performs three important roles: 
1) with the help of DCUN1D proteins, it transfers NEDD8 from E2 to cullin to activate a 
CRL; 2) it acts as a scaffold for the E2-conjugating enzyme; 3) it facilitates the transfer of 
Ub moiety from E2 to the substrate. RBX1 protein is expressed ubiquitously, but the level 
of RBX1 expression in malignant tissues seems to be dependent on cell type. For 
example, in ovarian, prostate and testes cancer RBX1 protein is often downregulated 
(Human Protein Atlas; Martinez et al., 2014), but it is often overexpressed in head and 
neck carcinoma, hepatocellular carcinomas, melanomas and gastric cancers (Human 
Protein Atlas; Yang et al., 2013; Nai &, Marques, 2011; Chen et al., 2015b). 
Through promoting timely degradation of many key regulatory proteins as a part 
of E3 CRL ligases, RBX1 controls numerous cellular processes including DNA repair 
and cell cycle progression. There are many reported targets for RBX1, including Cdt1, 
IκBa, IKKβ, c-Jun, HIF-1α, histones H3 and H4, cyclin D1 and many others, including 
oncogenes and tumor suppressors. Thus, the effect of RBX1 gene inhibition relies on the 
stabilization of target proteins, and the resulting phenotypical outcome would vary 
depending on the cellular context. Thus, accumulation of Cdt1 and ORC1 proteins causes 
re-replication, genome instability and senescence, while stabilization of RhoB, p21 and 
p27 (CUL1) induces G2/M cell cycle arrest and apoptosis (Xu et al., 2015). These toxic 
effects have been shown for many cancer cell lines including glioblastoma, bladder and 
liver cancer, and non-small cell lung carcinoma (Jia et al., 2009; Yang et al., 2013; Wang 
et al., 2013). On the other hand, accumulation of Nrf2, which helps cells to maintain a 
favorable redox balance, or HIF1α, a master-gene in hypoxia, are beneficial for cancer 
progression (Park et al., 2010; Martinez et al., 2014; Martinez et al., 2015). 
RBX1 neddylates, and thus activates, the majority of CRL complexes; 
respectively, RBX1 gene knockdown inhibits the CRL/NEDD8 pathway. The anti-cancer 
drug, MLN4924, has an effect similar to RBX1 inhibition: it prevents attachment of 
NEDD8 to the cullins (Lin et al., 2010). Indeed, in the present study, the effects of RBX1 
inhibition resemble the effect of low-dose (<100 nM) MLN4924 treatment (CHAPTER 
2), where VCaP cells undergo G0/G1 cell cycle arrest, thus decreasing spontaneous 
apoptosis, while other cell lines respond with a decrease of proliferation and induction of 
apoptosis. Thus, this study’s data suggest that inhibition of cullin neddylation in PCa cell 
lines (by RBX1 gene knockdown and NAE inactivation by MLN4924) causes differential 




Figure 44. Graphical representation of siRNA action for RBX1 gene. A. The graph represents the phenotypical changes 
(proportion of dying cells and changes in cell number) for each of 4 the siRNAs and all 5 cell lines tested (VCaP 
presented in 2 conditions: in ChSM, like the other cell lines, and in StdM). muRZ is an averaged Robust Z-score from 
quadruplicates for each siRNA. Grey dotted lines indicate zero values for both axis. Pink dotted lines indicate threshold 
values: everything above or below these values (outside of the grey rectangle) is considered to be a hit. 
 
Figure 45. Graphical representation of siRNA action for CUL2 gene. A. The graph represents the phenotypical changes 
(proportion of dying cells and changes in cell number) for each of 4 siRNAs and all 5 cell lines tested (VCaP presented 
in 2 conditions: in ChSM, like the other cell lines, and in StdM). muRZ is an averaged Robust Z-score from 
quadruplicates for each siRNA. Grey dotted lines indicate zero values for both axis. Pink dotted lines indicate threshold 




Inhibition of CUL2 gene by siRNA induces apoptosis in the ERG-positive cell 
lines VCaP and DuCaP (Supplementary Table 6 and Supplementary Table 7; Figure 45). 
Therefore, it seems that this hit is possibly ERG-dependent. 
Cullin 2 (CUL2) is a scaffold protein of the CRL2 complex (more details about 
the structure and function of CRLs are given in the literature review, paragraph 3.4.2 
NEDD8 TARGETS). The effect of CUL2 inhibition is caused by the stabilization and 
accumulation of target proteins of the CRL2 E3-ligases. The majority of CRL2 substrates 
are oncogenes: HIF1α (Maeda et al., 2008; Okumura et al., 2012), NF-κB (Maine et al., 
2007), RNA polymerase II subunit hsRPB7 (Brower et al., 2002), PKCλ (Okuda et al., 
2001), topoisomerase IIα (Yun et al., 2009), β2AR (Xie et al., 2009). Nevertheless, some 
reports suggest that CUL2 function may favor cancer development. Upregulation of 
CUL2 was found in aggressive PCa and was linked to a poor prostate cancer outcome 
(Shipitsin et al., 2014). In esophageal cancer, CUL2 upregulation was shown to be a 
predictive factor for resistance to neoadjuvant chemotherapy; and vice versa – 
downregulation of CUL2 mRNA correlated with a favorable prognosis (Metzger et al., 
2010). According to the Human protein Atlas, CUL2 is overexpressed in some types of 
cancer, including glioma, pancreatic and prostate cancer. On the other hand, 
downregulation of CUL2 was associated with a bad prognosis in oral squamous cell 
carcinoma (Diniz et al., 2015). 
Altogether these data show the important role of CUL2 in carcinogenesis. The 
data of the present study suggest a potential ERG-dependence of the outcome of CUL2 
knockdown in PCa cell lines, which requires further validation. 
 1.6 DISCUSSION 
1.5.1 Screening parameters 
The outcome of the inhibition of a gene depends on the cellular context and may 
vary strongly depending on the cell line. The use of multiple cell lines allows for the 
identification of hits which are generally important for the functioning of cells of a given 
cellular type (prostate), as well as hits specific to cell lines bearing certain a pheno-/geno-
type, such as castration-resistance, specific mutations, etc. When comparing the effects of 
siRNAs in different cell lines the unique characteristics of each cell line should be taken 
into account, such as the level of proliferation, basal rate of apoptosis, transfection 
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efficiency, robustness in response to perturbations and many others. For these reasons, for 
each cell line it was important to make a primary optimization of the screening conditions 
by using control siRNAs. This helped to have similar and, thus, comparable responses to 
siRNA treatment. To adjust the efficiency of transfection, three-day siRNA treatments 
were used for fast proliferating cell lines (PC3, LNCaP and RWPE1) and five-day 
treatments for the slow proliferating ones (VCaP and DuCaP). Nevertheless, the treatment 
time was still not optimal for the PC3 cells and possibly should be increased to four or 
five days. To compare the results in different cell lines the same parameters was used (i.e. 
apoptosis and cell number), as well as the same layout of the plates, and statistical 
analysis. The particularity of DuCaP cells did not allow using this cell line as a proper 
model for an ERG-dependent PCa. The data obtained with DuCaPs was taken into 
account, but the results should be interpreted carefully. 
 An important part of the optimization process is the choice of siRNA 
concentration. In the screening low concentration of siRNA were used (20 nM in the 
primary screen and 10 nM in the secondary), despite that many reported screens use much 
higher (up to 100 nM) concentrations (Reynolds et al., 2004). Therefore, a complete 
knockdown of a gene might not have always been achieved, and there may have been 
more false-negative results. On the other hand, lower concentrations of siRNA decrease 
the amount of false-positive results and off-target effects. Usually, for optimized siRNAs, 
a concentration of a few nM (typically 1-2.5 nM) is sufficient to suppress the expression 
of a target protein. To achieve efficient knockdown it is better to use slightly higher 
concentration, but this may affect expression of many other, potentially hundreds, of 
genes (Caffrey et al., 2011; Laganà et al., 2014; Urbinati et al., 2015). Therefore, the 
choice was made to use lower concentration of siRNA for the present study, while paying 
attention to weak effects by decreasing the muRZ threshold. 
Performing a relatively small siRNA screening (107 genes in the primary screen) 
has several advantages compared to genome-wide approach. It decreases cost, time and 
effort, while increasing control over the conditions, allowing a more detailed analysis 
with multiple cell lines to be carried out. Nevertheless, even in these conditions, it was 
difficult to analyze all the available information. The “Cell Health Profiling” software 
allows estimating many parameters: the total number of cells in the field, the percentage 
of apoptotic cells, the area of the nucleus, the total Hoechst in the nuclei that reflect DNA 
content, etc. However, after primary screening, the level of apoptosis was chosen as the 
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most reliable parameter, thus omitting some data. A lot of information is also found in 
cell line-specific effects. In the screen attention was focused on the genes important for 
the survival of all the prostate cancer cell lines and on the ERG-specific effects. 
Nevertheless, siRNAs for DCUN1D5, CACUL1 and UBE2S also had an impact on the 
viability of PCa cells, but it was more dependent on cellular context and thus requires 
further validation. 
Among the parameters used in the analysis (induction of apoptosis, cell count and 
measurement of proliferation/ATP level), cell count proved to be the least reliable. The 
number of cells always slightly varies between wells. Moreover, with slow-proliferating 
cells (such as VCaPs) it was difficult to obtain a significant change in the number of cells 
in five-day experiments. A measurement of the level of apoptosis was the most reliable 
parameter. The “Cell Health Profiling” software is suitable for high-throughput screens in 
384-well plates, which allows for a sufficient number of replicates to be made, and, with 
acquisition of 9 fields per well, the analysis of about 2 million cells per cell lines. It 
provides a reliable data distribution and allows for the detecting of weak effects. The 
parameter “apoptosis” was found to be highly reproducible between replicates and 
different experiments, even when distinct experimental design were used (e.g., during 
primary and secondary screens). A measurement of proliferation by the level of ATP can 
also be used, but optimization is needed, because this parameter is sensitive to the seeding 
density. Also this readout has a lower dynamic range thus allowing mainly the strongest 
effects to be seen only. 
Finally, although both measurement of apoptosis and proliferation are easy-to-
follow phenotypical parameters, they are too general which complicates the validation of 
the hits and the elucidation of the mechanism of their function. Cell growth and death 
could be affected by many factors, including the deregulation of the proteins governing 
cell cycle progression, DNA repair and replication, cytoskeleton assembly, metabolism 
and many others. It would be better to find more “targeted” parameters to follow, which 
would allow for the identification of the affected pathway and thus facilitate hit 
validation. Examples of such parameters are degradation of a specific protein, or 
activation/inhibition of specific pathways, where the role of the UPS has been suggested. 
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1.5.2 Hits and primary validation 
 The objective of the primary screening was to identify the UPS components 
crucial to the viability of prostate cancer cells and, in particular, PCa cells harboring the 
oncogenic translocation TMPRSS2:ERG. Seven genes were identified, of which two are 
potentially ERG-specific. 
 The most prominent hit is UBE2U. This uncharacterized protein, with an 
urogenital pattern of expression and a robust apoptotic effect of its knockdown in 
prostatic cells, could potentially be a perfect drug target for prostate cancer. Attempts in 
cloning and characterization of this protein suggest the existence of multiple mRNA 
splicing isoforms, with at least some of them truncated. This might suggest that these 
mRNA could have some specific functions. For example, UBE3A was shown to have 
multiple mRNA isoforms coding enzymatically inactive proteins. These mRNAs were 
shown to regulate miRNA governing neuronal development (Valluy et al., 2015). To 
better understand the function of UBE2U, and its role in the prostate and PCa, it is 
important to characterize the existing isoforms and identify those involved in PCa cell 
viability. 
The genes UBE2H, UBE2A, CUL4B have the established roles in chromatin 
remodeling and DNA-damage response. The data from the literature suggest their general 
role in cancer development, and therefore, these genes may not be PCa-specific. For these 
hits basic validation has been done using multiple siRNA targeting the same gene as well 
as confirmation of the efficiency of these siRNA by Western Blot. 
Four (CAND1, CUL4B, RBX1 and CUL2) of the seven identified hits belong to 
the CRL/NEDD8-pathway. Moreover, two of them (RBX1 and CUL2) are potentially 
ERG-specific. In order to elucidate the role of the CRL/NEDD8 pathway in prostate 
cancer MLN4924 was used, which is a potent inhibitor of neddylation, recently 






CHAPTER 2. DISTINCT OUTCOMES OF CRL/NEDD8 
PATHWAY INHIBITION IN CANCER CELLS 
2.1 INTRODUCTION 
The major goal of cancer therapy is to specifically suppress malignant neoplasm 
without detriment to normal cells. Recently, the ubiquitin-proteasome system (UPS) 
appeared as one of the principal cancer targets. Indeed, the inhibition of the major UPS 
component, the proteasome, has proven to be efficient against many types of cancer. Two 
proteasome inhibitors, Bortezomib and Carfilzomib, have been approved by FDA for the 
treatment of hematologic malignancies, while other related compounds, Ixazomib and 
Oprozomib, are in clinical trials. Among major difficulties in cancer treatment are 
extreme plasticity, evolvability, and heterogeneity of the disease. Thus, although 
Bortezomib (+/- Dexamethasone) has shown efficacy against multiple myeloma and, 
more recently, against mantle cell lymphoma, the treatment often leads to a relapsed, 
refractory disease. In some cases, this problem may be addressed by combining 
proteasome inhibitors with additional drugs such as Panobinostat and 
Thalidomide/Lenalidomide, which target other tumor-specific liabilities 
(http://www.themmrf.org/multiple-myeloma-knowledge-center/myeloma-drugs-
guide/velcade/velcade-clinical-studies/). It is also noteworthy that in standard regimens, 
Bortezomib fails against solid tumors, while a dose increase results in peripheral 
neuropathy. Given that the proteasome plays an important role in normal cells, the 
observed neurotoxicity raises the question of the selectivity of proteasome inhibitors in 
cancer treatment. 
Apart from the proteasome, other potential anti-cancer targets from the UPS 
comprise cullin-RING E3 ligases (CRLs). Deregulation of CRLs has been observed in 
many cancers and is linked to tumorigenesis (Lee J & Zhou, 2010; Chairatvit & 
Ngamkitidechaku, 2007; Li et al., 2014; Meehan et al., 2002). Notably, the inhibition of 
CRLs can stabilize a number of tumor suppressors without affecting global cellular 
catabolism, and, therefore, it seems to be a more specific anti-cancer approach compared 
to proteasome inhibition (Soucy et al., 2009). CRLs are multi-protein complexes 
assembled (in mammals) on seven cullin scaffolds (cullins 1, 2, 3, 4a, 4b, 5, 7). Pro-
degradative Ub-ligase activity of CRLs requires modification of the cullin subunit with a 
small Ub-like protein – NEDD8. Similar to ubiquitylation, the neddylation involves an 
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ordered transfer of NEDD8 by specific E1-activating enzymes (NAE/Uba3 heterodimer), 
E2-conjugating enzymes (UBE2F or UBE2M) and E3 ligases (RBX1 and RBX2 for 
CRLs, and others). Some of these enzymes are druggable and, therefore, provide a 
powerful way to block CRL function. Thus, a recently developed NAE inhibitor, 
MLN4924, efficiently abrogates cullin neddylation and suppresses the growth of various 
types of cancer cells in vitro and in vivo (Soucy et al., 2009). MLN4924 is currently being 
evaluated in clinical trials for the treatment of both hematologic malignancies and solid 
tumors (https://clinicaltrials.gov).  
Despite the growing evidence for non-cullin NEDD8 regulation (Hjerpe et al., 
2012; Enchev et al., 2014), all proposed mechanisms of MLN4924 function/action 
implicate inhibition of CRLs. Depending on the cell type these include: (1) induction of 
DNA re-replication through the stabilization of chromatin licensing factor Cdt1 (2) cell 
cycle arrest through the upregulation of cell cycle regulators such as p21, p27, and Wee1; 
(3) inhibition of the NF-κB pathway in NF-κB-dependent cancer cells; (4) suppression of 
tumor angiogenesis as a result of cell cycle arrest and accumulation of RhoA GTPase 
(Enchev et al., 2014; Yao et al., 2014) , etc.  Surprisingly, only two outputs for these 
multitude of mechanisms have been documented, which recapitulate the therapeutic effect 
of MLN4924: cancer cell senescence and apoptosis. However, considering a complex 
network of CRL regulation in the cell, one would expect a much wider range of cellular 
responses to CRL inhibition. It seems possible that, by tracking only death outcomes, 
some cellular phenotypes could be overlooked. Indeed, despite the unique target (NAE, 
IC50 ~5 nM), the toxicity of MLN4924 (EC50) in various cell lines can vary by three 
orders of magnitude, suggesting that suppression of CRL does not necessary lead to cell 





 by MLN4924 can also induce autophagy that protects cancer 
cells from apoptosis (Zhao et al., 2012). Complementing MLN4924 treatment with an 
autophagy inhibitor markedly enhanced the drug efficacy. Therefore, analysis of all 
possible outcomes of MLN4924 action is of clinical importance for the evaluation of 
CRL/NEDD8 pathway as a therapeutic target and for optimization of treatment regimens. 
Here the consequences of CRL/NEDD8 pathway inhibition in prostate cancer 
cells are investigated. Notably, this study shows that: (1) distinct cell lines have 
significantly different sensitivity to MLN4924; (2) knockdown of CRL components may 
have opposite effects on cell proliferation and survival; (3) a different degree of 
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CRL/NEDD8 pathway inhibition can result in a completely different cell fate. 
Specifically we found that in VCaP cancer cells, 95% suppression of NEDD8 conjugation 
activates androgen receptor (AR), resulting in reversible cell quiescence and protection 
from proliferation-dependent cell death. Also demonstrated is the fact that knocking 
down/suppressing supplementary targets such as CAND1 and AR can potentiate the toxic 
effect of MLN4924 on prostate cancer cells.  All together, these results demonstrate 
plasticity of cancer cells and suggest ways for the optimal utilization of NAE inhibitors in 
prostate cancer treatment.  
2.2 DIFFERENT SENSITIVITY OF PROSTATE CANCER CELL LINES TO 
MLN4924 
Previous work has shown that MLN efficiently induced cell death in the LNCaP 
prostate cancer cell line (EC50=50 nM) (Soucy et al., 2009). To investigate whether 
MLN4924 is generally potent against other types of prostate cancer we compared its 
effect on LNCaP cells (AR+, androgen-dependent, p53-wt) with PC3 (AR-, androgen-
independent, p53-null) cells, and DuCaP and VCaP cells (both of these AR+, androgen-
sensitive, and contain the TMPRSS2:ERG mutation, p53-R248W). First we used 
ViaLight™ Plus Cell Proliferation chemiluminescent assay to measure cellular ATP 
level. Consistent with previous observations (Soucy et al., 2009), MLN4924 induced a 
marked decrease in total cellular ATP in LNCaP cells, suggesting efficient growth and 
metabolism inhibition in this cell line (Figure 46, A).  Treatment of LNCaP cells with 500 
nM MLN4924 for 3 days resulted in 95% cell mortality confirmed by phase-contrast 
microscopy (Figure 46, A, right panel). Though less sensitive, PC3 cells also showed a 
significant decline in ATP level (>60%) and cytotoxicity with 500 nM MLN4924. On the 
contrary, DuCaP and VCaP cells were largely resistant to up to 1 µM of MLN4924, 
showing little effect on ATP level and on the number of cells after 3 days of treatment 
(Figure 46, A). Most surprisingly, at the concentrations below 1 µM, MLN4924 induced 
an apparent increase of total ATP in DuCaP cells. Both VCaP and DuCaP cell lines were 
derived from the same patient and contain an amplified AR gene as well as 
TMPRSS2:ERG chromosomal translocation. This mutation, which is present in 50-70% 
of prostate cancers, fuses the TMPRSS2 promoter to the ERG gene resulting in androgen-
dependent expression of the truncated ERG protein (Tomlins et al., 2005). ERG is a 
transcription factor that tightly interacts with AR in reprogramming the fate of prostate 
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cancer cells (Yu et al., 2010).  It seems, therefore, possible that this particular genetic 
context renders VCaP and DuCaP cells less dependent on the CRL/NEDD8 pathway. 
Inhibition of the CRL/NEDD8 pathway was shown to induce senescence and 
apoptosis in cancer cells (Enchev et al., 2014). To investigate whether the MLN4924-
inflicted death of prostate cancer cells was due to the induction of apoptosis, we 
examined the activation of pro-apoptotic caspases 3&7 (Figure 46, B). Cells were 
incubated with CellEvent™ Caspase-3/7 fluorogenic substrate (CE) and analyzed by 
automated fluorescence microscopy. MLN4924 induced massive apoptosis in LNCaP 
cells, while PC3 cells were much less affected. Consistent with a MLN4924-resistant 
phenotype, at 3 days of treatment, VCaP and DuCaP cells showed negligible caspase 3/7 
activity, even with 1 µM of MLN4924 (Figure 46, B, right panel). 
 
Figure 46. The effect of MLN4924 treatment on proliferation (A) and apoptosis (B) in PCa cell lines grown in ChSM. 
The images represent phase-contrast (A, right panel) or fluorescent acquisitions (B, right panel) of PCa cells treated 
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with vehicle (DMSO) or 500 nM MLN4924. On the fluorescent images the nuclei are shown in blue, while the caspase 
CellEvent substrate is in green. 
 
Taken together, these results revealed significant difference in the sensitivity of 
prostate cancer cells toward NAE inhibition. This may reflect genetic and functional 
heterogeneity of these cells apparent from their different phenotypes, androgen 
dependences and proliferation indexes. Thus, VCaP and DuCaP cells have two to three 
times longer doubling time compared with LNCaP and PC3 cells (60-120h vs 30-35h). 
Because the toxic effect of MLN4924 on cancer cells was shown to be proliferation-
dependent (Lin et al., 2010), this may be one of the reasons for their resistance to the 
drug. However, though a longer treatment of VCaP cells with MLN4924 increased the 
cytotoxicity, it was still much less pronounced then with LNCaP cells (see below, and 
Supplementary Figure 1). Furthermore, despite the different proliferation rates, a quite 
similar MLN4924-inhibition profile was observed in cells cultured on standard 
(Supplementary Figure 3) and androgen-deprived (Figure 46) medium, suggesting that 
cell cycle progression is not the only factor determining MLN4924 toxicity. The distinct 
sensitivity of prostate cancer cell lines toward NAE inhibition might also reflect their 
different p53 status, though, contrary to our results, MLN4924 has been shown to be 
generally more toxic to the cells with a mutant p53 (Lin et al., 2010). 
2.3 MLN4924 EFFICIENTLY INHIBITS NEDD8 PATHWAY IN VCaP CELLS 
Poor drug bioavailability and multidrug resistance are common causes of cancer 
cell resistance to a variety of drugs (Kuppens et al., 2005; Holohan et al., 2013). To 
investigate whether the resistance of TMPRSS2:ERG-positive prostate cancer cells 
toward MLN4924 treatment results from inefficient NAE inhibition, we examined the 
effect of this drug on protein neddylation in VCaP cells. Expressing major prostate 
epithelial markers, this cell line is a widely used cellular model for androgen-sensitive 
TMPRSS2:ERG-positive prostate tumors (van Bokhoven et al., 2003a). We found that 
the increasing concentration of MLN4924 induced a progressive decline in the amount of 
NEDD8 conjugates (Figure 47, A). Because no significant changes were observed with 
Ub and SUMO1 conjugates, the inhibition appeared to be NAE-specific (Supplementary 
Figure 5).  Surprisingly, the efficacy and profile of the inhibition of the neddylation were 
quite similar to those previously reported for highly MLN4924-sensitive cell lines (Soucy 
et al., 2009; Brownell et al., 2010): with an abrupt decline in NAE- and Ube2M-NEDD8 
conjugates at 10-25 nM of the drug (bands 4 and 6) and slightly shifted toward higher 
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~100 nM MLN4924 concentrations, a decrease in neddylated cullins (bands 2/3). 
Notably, the suppression of total NEDD8 conjugates attained ~ 90% at 50 nM MLN4924 
and was almost complete at 100 nM (Figure 47, B). These findings were corroborated by 
immunofluorescence microscopy, where negligible anti-NEDD8 staining was observed 
already at 50 nM MLN4924 (Figure 47, C). 
The results presented on Figure 46 and Figure 47 lead to the unexpected 
conclusion that the inhibition of the majority of cellular neddylation is not toxic for 
TMPRSS2:ERG-positive prostate cancer cells. Although surprising, the possible 
explanations for this finding could be that: (1) toxic effects are present but are not 
detected; (2) residual (~5%) neddylation is still sufficient to perform vital cellular 
functions; (3) the cells somehow adapt to low neddylation; (4) vital cellular functions do 
not depend on NEDD8 pathway in these cells. 
 
Figure 47. The effect of MLN4924 on neddylation in the VCaP cell line. A. Western Blot shows a dose-dependent 
decrease in neddylated proteins. Quantification of the WB (B) shows IC50 for total neddylation is about 10 nM, while 
IC50 for CRL is equal to 25 nM. At 50 nM residual neddylation is 10 % compared to control, while 500 nM causes 
complete blocking of neddylation. Immunostaining against NEDD8 (C) showed that neddylation is negligible for both 




2.4 DIFFERENTIAL EFFECT OF NEDD8 PATHWAY INHIBITION ON CELL 
CYCLE PROGRESSION AND VIABILITY 
Because VCaP are slow cycling cells (their doubling time is more than 53 hours 
according to ATCC), more prolonged incubation with MLN4924 might be required to see 
the cytotoxic effect of NAE inhibition. Indeed, extending the MLN4924 treatment to 5 
days increased the percentage of apoptotic cells, albeit only for the drug concentrations 
above 500 nM (Supplementary Figure 1). Curiously, for lower drug doses we observed 
small, but repeatable decrease in caspase 3/7 activity compared to the control, thereby 
inferring a decreased rate of spontaneous apoptosis (Supplementary Figure 1). 
 
Figure 48. The effect of NEDD8 pathway inhibition using different concentration of MLN4924 on cell cycling and 
viability. A. Analysis of the cell cycle by flow cytometry using 7-AAD staining after 5 days of treatment on VCaP cells 
with MLN4924. B. Effect of MLN4924 on the NF-κB pathway (phospho-p65 and phospho-IκB) and phospho-β-
catenin. C. Effect of MLN4924 on the markers of NF-κB pathway (Cdt1), senescence (p21) and DNA-damage 
(γH2AX). D. Effect on DNA synthesis after 3, 24 or 120 hours after treatment with MLN4924. E. Immunostaining for 





The cytotoxic effect of MLN4924 has been linked to the accumulation of a 
number of CRL substrates, e. g. Cdt1, p21, Wee1 (Lin et al., 2010; Jia et al., 2011; Wei et 
al., 2012). This can provoke DNA re-replication and/or cell cycle arrest. Notably, in some 
cell lines the growth arrest by MLN4924 does not necessary cause apoptosis (Jia et al., 
2011). We, therefore, used flow cytometry to examine how NAE inhibition affects cell 
cycle in VCaP cells (Figure 48, A). 
Consistent with the reduced rate of spontaneous death (Supplementary Figure 1), 
the treatment of cells with 50 nM MLN4924 decreased the percentage of sub-G1/G0 
(dead) cells compared to control (Figure 48, A, bottom histogram). Unexpectedly, the 
cells accumulated in the G1/G0 phase, indicating a cell cycle arrest. Because VCaP cells 
express mutant p53-R248W, they are unable to induce G1 arrest (Sobel & Sadar, 2005; 
Willis et al., 2004) and therefore other mechanisms seem to be involved.  Higher doses of 
MLN4924 increased the fraction of sub-G1/G0 dead cells, the cells in G2/M (500 nM of 
drug) and S (5 µM of drug) phases as well as a percentage of cells with high (>4N) DNA 
content. These data are in agreement with the proposed mechanism of MLN4924 action, 
which includes stabilization of replication licensing factor Cdt1 factor, of which 
accumulation leads to DNA re-replication, cell cycle arrest at G2/M, and apoptosis. 
Corroborating this conclusion, Western Blot analysis revealed an elevated level of 
cellular Cdt1 at higher MLN4924 concentrations (Figure 48, B). 
To detect possible DNA re-replication, we measured cellular DNA synthesis 
following different times of NAE inhibition. The Click-iT EdU incorporation assay was 
used. Here, again, distinct responses to low and high doses of MLN4924 were observed 
both in androgen-deprived (Figure 48, D) and in standard medium (Supplementary Figure 
2).  Specifically, the treatment with 50 nM MLN4924 induced progressive inhibition of 
EdU incorporation from 90% of the control value at 24h to 65% at 120h. Meanwhile at 
500 nM and 5 µM the effect of the drug was biphasic: at 24 hours the EdU signal rose to 
200-250% of the control value, followed by complete cessation of DNA synthesis at 
120h. This initial increase in EdU incorporation coincided with Cdt1 accumulation and 
might indicate DNA re-replication and/or repair processes induced by DNA damage. On 
the other hand, the DNA synthesis arrest probably reflects a shutdown of cell functions as 
the result of an inability to repair the inflicted damage. 
To ascertain that MLN4924 can induce DNA damage we examined the status of 
Ser-140 phosphorylated histone H2AX (γH2AX), a marker of DNA double strand breaks. 
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Western Blot analysis revealed a massive accumulation of γH2AX in the cells treated 
with 5 µM MLN4924, while only a small increase in γH2AX signal was observed with 
250-500 nM concentrations (Figure 48, B). This small increase in total γH2AX could 
indicate an onset of DNA damage provoked by intermediate MLN4924 doses. Indeed, an 
analysis of the cells treated with 500 nM MLN4924 by immunofluorescence microscopy 
revealed a marked increase in population of cells having multiple γH2AX foci, the 
presumed sites of DNA damage (Figure 48, E). Notably, at 50 nM, MLN4924 slightly 
reduced the incidence of γH2AX foci compared to the control, inferring that the G0/G1 
cell cycle arrest and reduced rate of DNA synthesis imposed by this dose prevents 
spontaneous DNA breaks.  
A similar dose-response to MLN4924 in γH2AX formation and caspase 3/7 
activation pointed to DNA damage as a primary trigger of apoptosis. On the other hand, 
what caused a G0/G1 cell cycle arrest at MLN4924 concentrations below 100 nM was 
less clear. We observed a significant increase in cyclin-dependent kinase inhibitor p21, 
the substrates of multiple CRLs (Abbas & Dutta, 2011; Yu et al., 1998), already at 25 nM 
MLN4924 (Figure 48, C). This, by itself, may contribute to cell cycle arrest at G0/G1. 
Furthermore, at the same concentration, MLN4924 induced a marked buildup of 
phosphorylated IκB (p-IκB) protein; an inhibitor of NF-κB and a substrate of CRL1βTrcp 
(Figure 48, C). NF-κB, a key transcription factor in prostate carcinogenesis, is 
constitutively active in advanced tumors and in ETS-positive cancer cells (Lambert et al., 
1997; Wang et al., 2011; Rayet & Gélinas, 1999). Because an inhibition of NF-κB 
signaling in VCaP cells was shown to suppress cell growth (Wang et al., 2011), this may 
be the mechanism/cause of G0/G1 cell cycle arrest by MLN4924. Consistent with this, 
the stabilization of IκB by MLN4924 was accompanied by an accumulation of 
cytoplasmic, but not nuclear, phospho-p65, an active subunit of NF-κB (Supplementary 
Figure 7). Finally, we observed that MLN4924 also stabilized phosphorylated β-catenin 
(p-b-Cat) (Figure 48, C). Phospho-β-Cat is a component of β-Cat/Wnt signaling, one of 
the major ERG-driven transformation pathways in TMPRSS2:ERG-positive prostate 
cancer cells (Gupta et al., 2010). 
Collectively, our data suggest that, depending on the dose, MLN4924 can instigate 
two apparently distinct cell responses: (1) at concentration below 100 nM (~95% 
inhibition of cellular neddylation), the drug affects NF-κB and β-Cat/Wnt pathways,  
arrests cells in the G1/G0 phase and inhibits DNA synthesis, thus preventing spontaneous 
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DNA damage and apoptosis; (2) at concentration above 500 nM (complete neddylation 
inhibition) MLN4924 causes DNA damage, cell cycle arrest in G2/M and S phases, and 
apoptosis. 
2.5 KNOCKDOWN OF CRL COMPONENTS CAN HAVE OPPOSITE EFFECT 
ON CELL PROLIFERATION AND SURVIVAL 
Although surprising, the discontinuous effect of “almost complete” to “complete” 
NAE inhibition on cell fate was not totally unexpected. Cullins are major neddylation 
substrates. Various CRLs regulate thousands of diverse cellular factors that have distinct 
impacts on cell function (Lee J & Zhou, 2010).  It is possible, therefore, that the inhibition 
of some CRLs by MLN4924 would promote cell death, while the inhibition of others 
would favor pro-survival processes. In this case the final outcome could be discontinuous 
depending on the role, weight, and degree of (susceptibility to) the inhibition of each 
component within the CRL network. To test this hypothesis we analyzed the effect of 
inhibition of CRL components on the viability of VCaP cells (data obtained during our 
primary screening) (Figure 49, A). 
 
Figure 49. A. The effect of inhibition of CRL components on viability of VCaP cells. B. Inhibition of CAND1 protein 
using sub-optimal concentration of siRNA potentiates the toxic effect of MLN4924. 
 
We found that, while knockdown of CUL1 and, particularly, CUL2 inhibited cell 
growth and induced apoptosis, knockdown of CUL7 and CUL4B had an apparent 
beneficial effect by increasing cell number or reducing the fraction of apoptotic cells. 
Some other components of CRL/NEDD8 pathway were also found on the opposite ends 
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of the distribution: CAND1, UBE2F, CACUL1 (pro-apoptotic siRNAs) and 
DCUN1D4/DCN4, DCUN1D5/DCN5 (growth promoting siRNAs). These results suggest 
that the inhibition of NEDD8-dependent activation of CRLs may have opposite outcomes 
depending on the balance within the CRL network. 
Notably, CAND1, one of the key regulators of the CRL network balance, was the 
most prominent hit identified by this screening. CAND1 acts as a protein exchange factor 
catalyzing dynamic redistribution of substrate-receptors between CRLs. Knocking down 
CAND1 induced a significant apoptotic death suggesting it is a limiting component of the 
CRL network in VCaP cells (Figure 49, A). We reasoned, therefore, that, if the 
cytotoxicity of MLN4924 was mainly due to compromised CRL function, the inhibition 
of CAND1 would further potentiate the toxic effect. To examine this possibility we 
suppressed CAND1 with suboptimal concentration of siRNA (1 nM). Under these 
conditions, the extinction of CAND1 protein was not complete and only a limited cell 
mortality was observed (Figure 49, B). Yet, this amount of siCAND1 significantly 
increased the apoptosis induced by 500 nM MLN4924, pointing to the epistatic 
relationship between CAND1 and NAE in prostate cells (Figure 49, B). 
Taking together these data (1) provide some explanation for the differential effect 
of MLN4924 on VCaP cells; (2) support the role of CRLs as a major effector of NAE 
inhibition; (3) suggest CAND1 as another potential therapeutic target for prostate cancer. 
2.6 MLN4924 INDUCES REVERSIBLE GROWTH ARREST IN 3D 
PROSTATOSPHERE MODEL 
The results shown above suggest that the apparent resistance of TMPRSS2:ERG-
positive cancer cells toward MLN4924-induced apoptosis may come from cell cycle 
arrest at the G0/G1 phase. Considering a potential clinical application of MLN4924, the 
principal question is whether this arrest is irreversible (senescence) or reversible 
(quiescence). The latter may lead to tumor re-growth in the case of sub-optimal 
MLN4924 treatment. To address this question we investigated the outcome of NAE 
inhibition in tumor-relevant 3D prostatosphere model. VCaP spheroids were pre-formed 
in 96-well round bottom ultra-low attachment plates, subjected to long-term MLN4924 
treatment, and analyzed by optical microscopy (Figure 50, A, B). Exponential spheroid 
growth was observed in control condition (Figure 50, A, B). Treatment of the spheroids 
with 50 nM MLN4924 blocked their growth for about 6 weeks without visible impact on 
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spheroid integrity (Figure 50, A, B). By contrast, applied at a 500 nM concentration, 
MLN4924 caused complete dissolution/dispersion of the prostatospheres within 2-3 
weeks of treatment (Figure 50, A, B). These results corroborate our findings in 2D 
culture, where significant cell apoptosis was detected only at MLN4924 concentrations 
above 500 nM (Figure 46, B).   
Confirming apoptotic cell death, the staining with CellEvent™ reagent revealed 
strong activation of Caspases-3/7 upon the treatment of the prostatospheres with 500 nM 
MLN4924 (Figure 50, C). Curiously, some caspase activity was also seen in the center of 
the spheroids grown under control conditions. This basal apoptosis may be caused by 
intensive cell proliferation that leads to a local exhaustion of nutrients within the core of a 
rapidly growing spheroid (Hamilton, 1998). On the other hand, consistent with growth 
arrest, only rare apoptotic events were detected in prostatospheres treated with 50 nM 
MLN4924 (Figure 50, C). 
It has been shown that MLN4924 can trigger senescence in some cell types (Jia et 
al., 2011). To test whether MLN4924 treatment causes irreversible growth arrest in VCaP 
spheroids, we measured the activity of senescence-associated beta-galactosidase (SA-β-
GAL) by using colorimetric X-GAL substrate. While the prostatospheres treated with 500 
nM MLN4924 showed intensive X-GAL staining, negligible SA-β-GAL activity was 
detected in control and 50 nM MLN4924 conditions (Figure 50, C). This result implies 
that the cell growth arrest imposed by sub-total NAE inhibition in VCaP cells is not 
senescence and, therefore, may be reversible. In agreement with this conclusion, 
transferring the spheroids arrested for 40 days (with 50 nM MLN4924) into a drug-free 
medium resulted in spheroid re-growth similar to normal pace (Figure 50, A, B). 
Summing up, the results suggest that 90-95% inhibition of cellular neddylation by 
MLN4924 induces quiescence in TMPRSS2:ERG-positive VCaP cells that may protect 





Figure 50. A. Differential effect of CRL/NEDD8 pathway inhibition on the viability of VCaP spheroids. A, B. 
MLN4924 caused reversible (at 50 nM) or irreversible (at 500 nM) inhibition of spheroids proliferation. C.  MLN4924 
induced accumulation of senescence (β-galactosidase) and apoptosis (caspases 3,7) markers only at 500 nM 
concentration 
 
2.7 INHIBITION OF NAE ACTIVATES ANDROGEN RECEPTOR 
For many types of cells the G0/G1 cell cycle arrest and exit into a quiescent state 
is an essential step in terminal differentiation. In normal prostate epithelium and low-
grade primary cancer this process is driven by the androgen receptor (AR). Accumulation 
of various mutations during carcinogenesis results in AR reprogramming in favor of cell 
dedifferentiation and proliferation that often accompanies the resurgence of castration-
resistant (androgen-refractory) prostate cancer (Yeh et al., 2009). In TMPRSS2:ERG-
positive cancers, ERG oncogene plays a critical role in suppressing the AR activity 
leading to poorly differentiated, invasive tumor phenotypes (Yu et al., 2010). 
Because the inhibition of cellular neddylation triggered quiescence in VCaP cells, 
we asked whether it involves a reactivation of the AR differentiation program. First, we 
analyzed the effect of MLN4924 on the protein level of AR, ERG and PSA, as AR-




Figure 51. Effect of CRL/NEDD8 pathway inhibition on the AR transcription program in VCaP cells. A. Western Blot 
demonstrates the level of AR and AR-responsive proteins (PSA and ERG). B. Test ELISA showed that 50 nM 
concentration stimulates secretion of soluble PSA in 3D (spheroids) and 2D (cells) models. C. Examination of RNA 
level by qPCR showed that a 50 nM concentration of MLN4924 stimulated expression of AR-responsive genes PSA 
(KLK3), prostein (SLC45A3) and ERG. Treatment of VCaP cells with 500 nM MLN4924 caused a decrease in PSA 
and prostein expression, while expression of ERG was still strong. Another AR-responsive gene FKBP51 seemed to not 
be sensitive to MLN4924 treatment. 
 
 
Treatment of the cells with up to 100 nM MLN4924 did not change the level of 
AR, while at higher doses the drug caused a slight decline in AR protein probably 
reflecting an onset of cytotoxicity. By contrast, the level of ERG protein rose 
progressively reaching the maximum at 100-500 nM of MLN4924 (Figure 51, A). This 
increase in ERG could result from the stimulation of AR-dependent transcription, or, 
alternatively, from the stabilization of the protein. The abrupt disappearance of ERG in 
cells treated with 5 µM MLN4924 (Figure 51, A) and our qPCR data (see below) strongly 
suggest transcriptional regulation. Most strikingly, when cells were treated with 50-100 
nM of MLN4924, the level of PSA protein rose approximately fourfold, but dropped 
again when higher doses of the drug where used. A similar biphasic dose-response was 
observed for two others prostate differentiation markers, SLC45A3/prostein and FKBP51, 
whose expression is controlled by AR (Supplementary Figure 6). Notably, despite the 
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accumulation of ERG, the level of presumed ERG targets, FZD4 and LEF1, remained 
unchanged suggesting that the MLN4924 effect was AR-specific (Figure 61). 
To confirm that the changes in differentiation markers observed by Western Blot 
were due to differential gene expression, we measured the level of the corresponding 
transcripts. The cells were treated with 0, 50 and 500 nM of MLN4924 and the expression 
of four AR target genes, TMPRSS2:ERG, KLK3 (PSA), SLC45A3 (prostein) and 
FKBP51, and then analyzed by quantitative RT-PCR (qPCR). We found that the 
inhibition of NAE with 50 nM of MLN4924 stimulates the expression of all tested AR 
target genes except FKBP51. In accordance with previous observations (Figure 51, A; 
Supplementary Figure 6), 500 nM MLN4924 inhibits transcription of PSA and SLC45A3, 
while transcription of ERG continues to increase (Figure 51, C). 
Finally, we examined whether the spheroid growth arrest caused by 50 nM of 
MLN4924 (Figure 5) is accompanied by one of the prostatic differentiation features, the 
secretion of PSA. The spheroids were treated with 0 or 50 nM of MLN4924 for 5 days 
and the amount of PSA in the medium was measured by the standard ELISA kit. About a 
twofold increase in secreted PSA compared to the control value was observed (Figure 51, 
B). 
Taking together these results demonstrate that at <100 nM-doses MLN4924 
stimulates AR-dependent transcription leading to the expression of prostate 
differentiation markers. Thus, the activation of the differentiation program may be one of 
the reasons for cell quiescence caused by subtotal NAE inhibition. 
2.8 OPPOSITE ROLES OF AR & ERG IN VCaP CELL RESPONSE TO NAE 
INHIBITION  
It has been shown that in TMPRSS2:ERG-positive prostate cancer cells ERG 
binds to AR and the majority of AR target genes, disrupting androgen signaling. Our 
finding, that at <100 nM doses MLN4924 activates AR and the AR-dependent 
differentiation program, may imply that subtotal inhibition of neddylation somehow 
relieves AR from ERG suppression. This may switch the cellular program from a 
potentially detrimental ERG-dependent pro-proliferating regime to a pro-differentiated 
AR-dependent quiescent state, thus protecting cells from ERG- and re-replication-






Figure 52. A. Knockdown of ERG using siRNA protects VCaP cells against MLN4924-induced cytotoxicity, while 
knockdown of AR sensitizes them. In accordance with these data, stimulation of the AR-program by DHT (C) has a 
protective effect upon MLN4924 treatment. B. Western Blot confirmed that using siRNA efficiently suppresses target 
proteins (AR and ERG) and alters the expression of markers corresponding to the AR program (PSA) or the ERG 
program (c-Myc). 
 
This scenario suggests that in TMPRSS2:ERG-positive prostate cancer cells the 
cytotoxic effect of MLN4924 is suppressed by AR and potentiated by ERG. To test this 
hypothesis we examined the effect of AR- and ERG-knockdowns on MLN4924-induced 
apoptosis (Figure 52, A). We used specific siRNAs that potently downregulated the level 
of target proteins in VCaP cells (Figure 52, B). Knockdown of ERG strongly suppress the 
levels of ERG and c-Myc protein, the expression of which in VCaP cells was shown to be 
a part of the ERG-dependent transformation program (Sun et al., 2008). This was 
accompanied by a visible increase in the amount of PSA protein consistent with the 
previously reported AR de-repression and activation (Yu et al., 2010). Strikingly, siERG 
also strongly suppressed the apoptosis induced by MLN4924. It may be, at least in part, 
due to the activation/reprograming of AR by ERG knockdown. Indeed, stimulation of AR 
by DHT also had an anti-apoptotic effect, though much less pronounced compared to 
siERG (Figure 52, C). On the other hand, AR knockdown significantly increased the 
MLN4924 cytotoxicity within the whole range of drug concentrations (Figure 52, A). 
These data support an antagonistic role of AR and ERG in response to MLN4924, 
though the mechanism of how CRL inhibition de-represses AR transcription is not clear. 
One possible link may be the NF-κB pathway, which is positively regulated by ETS 
transcription factors, and ERG in particular (Lambert et al., 1997; Wang et al., 2011; 
Rayet & Gélinas, 1999). Several previous reports demonstrated mutual transcriptional 
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repression between AR and NF-κB (Palvimo et al., 1996; Nelius et al., 2007; Han et al., 
2014). We observed that the inhibition of NF-κB signaling occurred at low doses of 
MLN4924 and correlated with AR activation (Figure 48; Figure 51). It seems, therefore, 
possible that NF-κB plays the role of transcriptional switch between ERG-dependent 
proliferation and AR-dependent cell growth arrest. 
Another important question is how the activation of AR is linked to G0/G1 cell 
cycle arrest and quiescence induced by MLN4924. Although we observed that AR 
stimulation by MLN4924 correlated with a buildup of cyclin-dependent kinase inhibitors 
p21Cip1 (Figure 48), this resulted, most probably, from direct inhibition of the 
degradation of these proteins by MLN4924 rather than from AR transcriptional activity. 
Indeed, at higher doses, MLN4924 produced an even more significant accumulation of 
p21Cip1 without inducing G0/G1 cell cycle arrest (Figure 48). This observation suggests 
that the induction of a differentiation-like quiescence state was not, or not only, due to the 
stabilization of p21Cip1. Recent reports from John T. Isaacs’s laboratory documented that 
AR suppresses cell proliferation via AR/b-Cat/TCF-4 complex inhibition of c-MYC 
transcription (Antony et al., 2014). This mechanism could also explain our data showing 
that the knockdown of ERG, which stimulated AR and abolished c-Myc expression 
(Figure 52, B), protected cells from MLN4924-induced proliferation-dependent apoptosis 
(Figure 52, B). To determine whether NAE inhibition by MLN4924 affects c-Myc 
expression we performed a Western Blot. Indeed, five days of treatment with low doses 
of MLN4924 (10-50 nM) caused a significant decrease in c-Myc protein level, and an 
accumulation at higher doses (> 100 nM) (Supplementary Figure 4). This correlated with 
the profile of activation of the transcriptional program of AR (Figure 51; Supplementary 
Figure 6). 
Taken together, these data demonstrate that the subtotal inhibition of the 
CRL/NAE pathway by MLN4924 triggers cell reprograming by turning off NF-κB 
signaling, stimulating AR, and suppressing c-Myc. As a result, the cells acquire a pro-





2.8.1 Causes of differential phenotypic outcome. 
We observed differential sensitivity of PCa cells toward MLN4924 depending on 
ERG and proliferation status, where TMPRSS2:ERG-positive slow-proliferating cell lines 
(VCaP and DuCaP) were the most resistant. Moreover, in the VCaP cell line the 
inhibition of the CRL/NEDD8 pathway has a discontinuous effect with two major 
outcomes: quiescence and apoptosis/senescence. 
Using the siRNA approach we have demonstrated that the knockdown of the 
principal CRL components, i.e. cullins and neddylation regulators, can have different 
outcomes. It should be noted that the organization of the CRL system is much more 
complex and comprises a combinatorial hierarchical assembly of adaptor proteins and 
substrate receptors. Thus, multiple CRL complexes can be assembled on the same cullin 
scaffold and play distinct and even opposite roles in cell fate. We did not address this 
complexity in our small siRNA screening. Nevertheless, our data demonstrate that, even 
on the primary level, knockdown of the basic CRL/NEDD8 components may have 
different outcomes. Therefore, the discontinuous cellular response to MLN4924 may, in 
principle, be explained by differential susceptibility of various CRLs to neddylation 
inhibition. Specifically, our results suggest that CRL-suppressors of pro-quiescent 
pathways are more sensitive to MLN4924 (inhibited at < 100 nM doses), whereas CRL-
regulators of pro-apoptotic/senescence pathways are less susceptible to MLN4924 
inhibition (> 250 nM). The latter suggests robust apoptosis suppression by CRL even at 
low level of neddylation, and may reflect the irreversible “last solution” role of this 
outcome. 
Notably, our results imply a principal role of CAND1 protein for CRL functioning 
under suboptimal neddylation conditions. CAND1 is an exchange factor that catalyzes 
redistribution of CRL cofactors (Duda et al., 2011). CAND1 binds non-neddylated cullin 
complexes which are produced by COP9 deneddylase. This binding stimulates the 
dynamics of the CRL adaptor proteins’ exchange and redistribution of CRL components 
for performing diverse cellular functions (Pierce et al., 2013). Therefore, CAND1 may 
become particularly important when the dynamics of the CRL network is perturbed by 
MLN4924. There is also evidence that CAND1 can function as a chaperon by protecting 
non-neddylated cullins from the degradation by proteasome. Notably, this CAND1 
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function becomes apparent when the neddylation of cullins is suppressed (Kim et al., 
2010). Therefore, the knockdown of CAND1 may also potentiate the inhibitory effect of 
MLN4924 by stimulating the degradation of cullins. 
The role of CAND1 in carcinogenesis is largely unexplored. In pulmonary cancer, 
negative correlation between neddylated cullins and CAND1 has been observed, 
supporting the conclusion that CAND1 function is particularly important when 
neddylation is compromised (Salon et al., 2007). The data on the implications of CAND1 
in prostate cancer are controversial. It has been reported that in LNCaP prostate cancer 
cells the expression of CAND1 is negatively regulated by androgen-stimulated Lin RNA. 
On the other hand, analysis of the limited cohort of PC specimens revealed an aberrant 
CAND1 status in cancer tissue with both over- and under-expression levels compared to 
normal prostate. Notably, interrogation of the Oncomine database revealed general up-
regulation of CAND1 in prostate cancer with CAND1 found in the top 2% of upregulated 
genes in intraepithelial neoplasia and in the top 3-10% in prostate adenocarcinoma. 
These data suggest that inhibition of the CAND1-cullin interaction may represent 
a new approach in the treatment of cancer pathology.  
2.8.2 Direct effectors of CRL inhibition  
MLN4924 was reported to be highly selective and to have only one target – E1 
enzyme for NEDD8, NAE. Nevertheless, different doses of MLN4924 caused 
accumulation of different proteins. At low doses (25-100 nM) we observed accumulation 
of phospho-IκB, p21 and phospho-β-catenin, while higher doses (250 nM and higher) 
lead to an accumulation of Cdt1. This might suggest that different doses of MLN4924 
could lead to the inhibition of different CRL complexes, which would lead to an 
accumulation of different targets and, thus, would lead to different phenotypes. 
IκB, β-catenin and p21 are degraded by CUL1-based CRLs. An accumulation of 
p21 can induce G0/G1 cell cycle arrest. Moreover, MLN4924 induced an accumulation of 
the NF-κB inhibitory subunit phospho-IκB and blocked the translocation of the phospho-
p65 subunit of NF-κB into the nucleus (Supplementary Figure 7). As discussed 
previously, the inhibition of NF-κB signaling in ERG-positive VCaP cells was shown to 
suppress cell growth (Wang et al., 2011) and might be another cause of G0/G1 cell cycle 
arrest by MLN4924. A similar mechanism of MLN4924 action has been described with 
NF-κB-dependent activated B cell-like diffuse large B cell lymphoma (ABC) DLBCL 
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(Milhollen et al., 2010). These cells show constitutive IκB kinase (IKK) activity, and 
rapid IκB degradation that distinguish them from other subtypes of DLBCL cells. 
Treatment of ABC-DLBCL cells with MLN4924 results in IκB stabilization, inhibition of 
NF-κB signaling, G1 cycle arrest and apoptosis.  Accumulating data suggest that 
activation of the NF-κB pathway also plays a central role in prostate carcinogenesis and, 
particularly, in the acquisition of castration resistance. NF-κB signaling promotes survival 
of prostate cancer cells at low androgen level and switches the transcriptional program to 
an invasive, metastatic phenotype (Lindholm et al., 2000; Wang et al., 2011). There is 
also a significant correlation between the constitutively active NF-κB pathway and the 
upregulation of ETS transcription factors suggesting a causal link. Indeed, ERG and other 
ETS proteins increase the expression of a number of NF-κB-associated genes and 
promote NF-κB-transcriptional activity while cytokines can stimulate ETS expression via 
NF-κB (Wang et al., 2011). This provides a positive feedback loop leading to constitutive 
activation of ETS and NF-κB through the sustained inflammatory circuit. A recent study 
demonstrated that the NF-κB-dependent production of lymphotoxin by B lymphocytes 
from tumor inflammatory infiltrates is essential for the growth of cancer cell progenitors 
(Ammirante et al., 2010). Therefore, the ability of MLN4924 to inhibit NF-κB both in 
prostate and B cells may be particularly efficient in suppression of castration resistance. 
Generally, however, the inhibition of NF-κB in prostate cancer cells is not sufficient to 
induce apoptosis (Evans et al., 2015). Moreover our data suggest that G1 cell cycle arrest 
induced by MLN4924 in TMPRSS2:ERG-positive VCaP cells is reversible. 
Higher doses of MLN4924 (>250 nM) causes accumulation of the replication 
licensing factor Cdt1 protein, which is recognized to be a substrate of CRL1 and CRL4. 
Inability to degrade Cdt1 induces re-replication, and further DNA damage (followed by 
an increase of H2AX-positive foci), cell cycle arrest in the G2/M phase, which is finally 
manifested by senescence and apoptosis. The mechanism of apoptosis is not clear. VCaP 
cells have a R248W mutation in the p53 gene which abolishes the ability of p53 to initiate 
apoptosis (Sobel & Sadar, 2005; Song et al., 2007). The putative effectors are p21 and c-
Myc. 
2.8.3 General outcomes: transcriptional reprogramming  
In our study, the inhibition of the classical NF-κB pathway (< 100 nM MLN4924) 
correlates with an activation of the AR transcriptional program. AR activation results in 
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the expression of prostate differentiation markers (PSA, prostein, FKBP51); moreover, 
using 2D and 3D prostatosphere models, we showed an increased secretion of PSA. We 
also observed increased ERG expression, but the ERG-expression program seemed to be 
intact (judging by LEF1 and FZD protein levels). Altogether, these data suggest an 
activation of the differentiation program that might be a potential cause of observed 
cellular quiescence (G1 cell cycle arrest without apoptosis and senescence). The finding 
that the knockdown of AR sensitizes cells to low doses of MLN4924, while the activation 
of AR by DHT has a protective effect, supports this conclusion. Some possible 
mechanisms of AR activation: 
1. Direct regulation of AR transcriptional activity by neddylation. Some 
evidence suggest that the intact NEDD8-pathway is essential for transcriptional activation 
of steroid receptors, but they have never show direct neddylation of these proteins (Fan et 
al., 2002; Fan et al., 2003). The direct neddylation of AR was reported in grant 
application (Don Chen, 2009), but the final results are still not published. Moreover, we 
did not detect neddylation of AR in VCaP cells (data not shown). 
2. Activation of the AR-dependent program by accumulated phospho-β-
catenin. Several studies suggest a complex interaction between AR and the Wnt/β-cat 
pathway. It has been shown that β-cat interacts with AR and potentiates AR signaling in 
prostate cells (Pawlowski et al., 2002; Truica et al., 2000), while AR represses the β-cat-
induced transcriptional program (Chesire & Isaacs, 2002; Song et al., 2003). Thus, in 
VCaP cells an accumulation of β-cat without activation of the Wnt-dependent program 
could lead to the re-activation of AR transcription program. 
3. Mutually exclusive activity of AR with NF-κB. Thus, the inhibition of NF-
κB would de-represses AR activity. Previous reports on NF-κB-AR interaction were 
contradictory. Several reports demonstrated mutual transcriptional repression between 
AR and NF-κB (Palvimo et al., 1996; Nelius et al., 2007; Han et al., 2014), while others 
suggest the opposite correlation (Zhang et al., 2009; Chen & Sawyers, 2002). Our data 
supports mutual inhibition of AR and NF-κB. First, in VCaP cells, MLN4924 caused 
dose-dependent inhibition of NF-κB inhibition (stabilization of IκB) negatively correlated 
with AR activation (expression of differentiation markers). Second, the transcriptional 
program of ERG, the major driver of NF-κB activation in TMPRSS2:ERG-positive cells, 
was not stimulated despite a higher ERG protein level. Considering that in 
TMPRSS2:ERG-positive cells AR was shown to be suppressed due to NF-κB activation, 
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we conclude that AR re-activation may occur, at least partially, through NF-κB inhibition, 
though other CRL-NEDD8-dependent mechanisms may exist. 
High doses of MLN4924 (250-500 nM) shut down transcription of AR targets 
except ERG. Of note, at 5 µM MLN4924 we observed a spectacular disappearance of 
ERG and PSA proteins but at this dose MLN4924 may cause a general, non-specific 
toxicity. Strikingly, MLN4924-induced apoptosis was almost completely ERG-
dependent. Pro-proliferation-inducing activity of ERG (and other ETS proteins) in 
prostate cancer cells was shown to generate a relatively high level of spontaneous DNA 
damage (Swanson et al., 2011). Also, aberrant transcriptional activity of AR in cancer 
cells can also produce a significant rate of DNA damage (Shen MM & Abate-Shen C, 
2010). Although the detailed mechanisms of inflicted DNA damage are not clear, this 
seems to be a general hallmark of carcinogenesis which aims for the suppression of DDR 
in favor of proliferation. Furthermore, with a compromised DDR, the high rate of 
replication-associated DNA lesions may lead to genomic instability, providing some 
evolutional advantage to cancer cells. More specifically, in ETS-positive cancers, ERG 
has been shown to directly suppress the expression of master checkpoint kinase Chk1 
releasing the blocking of error-prone DNA replication. This leads to an ERG-dependent 
accumulation of spontaneous DNA damage in VCaP cells; this effect we also observed in 
our experiments. At the same time, ERG and other ETS factors cooperate with PARP1 
and upregulate the NF-κB pathway, insuring cancer cell survival even at high level of 
DNA damage.  We found that, in contrast to other AR-targets, high doses of MLN4924 
(500 nM) significantly induced ERG both on transcription and protein synthesis levels. 
Thus, ERG-driven cell cycling in combination with re-replication imposed by Cdt1 may 
favor further accumulation of DNA damage, G2/M cell cycle arrest, and apoptosis. 
Notably, the protective effect of G1-arrest at this MLN4924 concentration is overwritten 
by the suppression of AR activity. 
2.8.4 Cancer cell plasticity: implication for cancer treatment 
Thie discontinuous response to the inhibition of the CRL/NEDD8 pathway is an 
example of cancer cell plasticity. TMPRSS2:ERG mutation, found in more than 50% of 
prostate cancers, seems to be a master-gene, switching the transcriptional program from 
differentiation to proliferation. ERG has been shown to activate NF-κB (Wang et al., 
2011), leading to increased proliferation in prostate tumors; induce the Wnt/β-cat 
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pathway (Wang et al., 2011; Birdsey et al., 2015), leading to increased migration; induce 
c-Myc (Sun et al., 2008), stimulating metabolism; suppress AR-signaling (Yu et al., 
2010), which could lead to an amplification of AR and the induction of an androgen-
independent phenotype (Figure 53).  
On the other hand, switching the transcriptional program from pro-proliferating 
(ERG:NF-κB:c-Myc:Wnt/β-cat branch) to quiescent/differentiated (AR/β-cat) could help 
PCa cells to adapt to diverse internal and external stimuli. Thus, cancer progression, 
proliferation, invasion, and functioning under androgen deprivation would select cells 
with an active ERG:NF-κB:c-Myc:Wnt/β-cat pathway, whereas, adverse environmental 
conditions, negative pressure on proliferation and functioning under higher androgen 
level would favor the activation of the AR-dependent differentiated pathway. Thus, 
quiescence observed under low doses of MLN4924 (< 100 nM) could be considered as an 
adaptive mechanism to avoid apoptosis. Damage induced by higher doses of MLN4924 
(> 500 nM) is too strong and cannot be overcome. 
 
Figure 53. Known interactions between ERG, AR, NF-κB and β-catenin signaling. 
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CHAPTER 3. INHIBITION OF CRL/NEDD8 PATHWAY BY 
MLN4924 CHANGES VCaP MORPHOLOGY  
3.1 INTRODUCTION AND PRELIMINARY OBSERVATIONS 
Nowadays, genome-wide siRNA screening is a standard technique allowing the 
identification of protein functions. Cancer-related screening most often aims to identify 
new drug targets and thus look for proteins required for the survival of cancer cells. Often 
only a limited number of parameters, such as apoptosis, proliferation or DNA damage is 
analyzed. At the same time, some genes may be involved in diverse important biological 
processes, which are not vital and, therefore, not analyzed and, thus, omitted from the 
screenings. Therefore, paying attention to other phenotypes, distinct from cell death and 
proliferation, would help to obtain important information on cancer biology.  
In our screening, we aimed to identify components of the UPS crucial for the 
viability of PCa cells. Among seven identified hits, four belong to the CRL/NEDD8-
pathway; moreover, two of them are putatively ERG-dependent. In the screening and, 
further, using MLN4924 we showed that the inhibition of CRL/NEDD8 pathway in PCa 
has a complex outcome on viability and depends on cellular context. During the screening 
we noticed that MLN4924 also alters the morphology of VCaP cells, suggesting 
additional functions of the CRL/NEDD8-pathway. Thus, under normal conditions VCaP 
cells are rounded and weakly adherent, but increasing the density results in cells growing 
in colonies without visible borders between them (Figure 54, A). VCaP cells are nearly 
immobile, and do not move from the occupied positions after primary attachment to the 
substrate. Rarely, VCaP cells move to join bigger groups of cells that seem to favor their 
growth (Figure 54, B; supplementary video 1). This observation was corroborated by a 
wound-healing assay: VCaPs don’t “heal wounds” after the scratch (Figure 54, C). 
Inhibition of the CRL/NEDD8 pathway caused a dose-dependent change in the 
morphology of VCaP cells (Figure 55, A). After 5 days of treatment with MLN4924, cells 
grown in 50 nM MLN4924 acquired a fibroblast-like morphology. An increase of 
MLN4924 concentration up to 500 nM caused an aggregation of the cells into clusters 
(Figure 55, A). To further investigate this morphological change we performed 
immunostaining with phalloidin (Figure 55, B). The obtained images demonstrated a 
fibroblast-like morphology of cells treated with 50 nM MLN4924, and tight groups at 500 
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nM. Moreover, we observed the appearance of stress-fibers and a clearly visible leading 
edge in the cells cultured in 500 nM MLN4924. 
 
Figure 54. A. VCaP cells grown at low and high density. B. Exchange of cells between colonies (extract from 
supplementary video 1). Red arrows show the dividing cell. Two resulting cells have different fate – one of them joins 
the nearest colony, the other leaves the field of view. C. Wound healing assay on VCaP. After primary attachment 




Figure 55. Dose-dependent effect of CRL/NEDD8 pathway inhibition on the VCaP cell line. Phase-contrast (A) and 
immunofluorescence (B) microscopy; images were obtained 5 days after treatment. Nuclei are shown in red, actin is 
shown in green. An addition of 50 nM MLN4924 leads to a strong increase of the number of fibroblast-like type of 




Altogether these observations suggest that neddylation might have additional 
functions in VCaP cells that might be important in cancer. We conducted a series of 
experiments to get more insights into the mechanism of this morphological change. 
3.2 MORPHOLOGY CHANGE CORRELATES WITH INCREASED ADHESION 
OF VCaP CELLS 
The fibroblast-like morphology and the appearance of stress-fibers are the 
signatures of many cellular processes, including cell adhesion and migration (Parsons et 
al., 2010; Vallenius et al., 2013). First, we examined the involvement of neddylation in 
cell adhesion. To follow cell-to-surface adhesion we used a CYTONOTE - Lens-Free 
Cell Imaging Device. CYTONOTE has a large field-of-view (29.4 mm²) providing the 
possibility to follow several thousand cells at once. Analysis of the acquired images using 
a special algorithm allows for the retrieval of information about morphological properties 
of cells, such as cell adhesion, shape, size, velocity, etc. (Kesavan et al., 2014). The 
resulting scatterplots show the number of cells having a certain type of morphology 
(Figure 56). To perform lensless imaging we placed cell suspension with increasing 
concentrations of MLN4924 in cell culture treated plates. The acquisitions were 
performed every 20 minutes during 4 days. Low concentrations of MLN4924 (50 nM) 
lead to a dramatic increase in the number of adherent cells (60%) compared to the control 
(35%). There were also mostly elongated cells (high aspect ratio) with a relatively small 
cell surface. Higher concentrations of MLN4924 (500 nM) also increased the proportion 
of adherent cells (about 45%), but does not induce the “elongated” morphology. Instead, 
we observed an increase of the average cell surface, which probably reflects the formation 
of cell clusters. These results indicate that the inhibition of CRL/NEDD8 pathway 
increases adhesion of VCaP cells to the substrate. 
To examine the effect of MLN4924 on cell-to-cell adhesion we performed a 
spheroid formation assay. To promote spheroids formation, we placed some cell 
suspension in low attachment U-bottom plates (~500 cells/well) in the presence of 
increasing concentrations of MLN4924. The spheroids assembly was monitored by 
videomicroscopy and the diameter of the spheroids was measured. Both tested 
concentration of MLN4924 (50 and 500 nM) decreased the characteristic time of 
spheroids formation by about 10 hours compared to the control (Figure 57). Thus, we 
conclude that MLN4924 increases the cell-to-cell adhesion of VCaP cells also. 
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In the Chapter 2 of Results and Discussion we showed that the inhibition of the 
NEDD8-pathway by MLN4924 leads to the re-activation of the AR program 
accompanied by an increase in ERG protein level. Both AR and ERG could stimulate 
migration and invasion of PCa cells (Wang et al., 2014; Wu et al., 2013; Tomlins et al., 
2008; Zarif et al., 2015; Kim et al., 2015). We examined, therefore, whether the effects of 
MLN4924 on cell adhesion depends on ERG or AR. To this end the spheroid formation 
assay was performed after a 24-hour pre-treatment of cells with siRNA targeting ERG 
and AR (Figure 58). Both siRNAs abolished the stimulation of spheroids formation 
induced by MLN4924 at low concentration 50 nM, but not at higher concentration of the 
drug (500 nM). 
Together, these data suggest that the inhibition of neddylation in VCaPs renders 
cells more adherent to the surrounding substrates. Stimulation of cell-to-cell interactions 
by MLN4924 is dependent on the intact AR and ERG transcriptional program at least at 
drug concentrations below 100 nM. On the other hand, the effect of higher doses of 
MLN4924 may also be affected by the onset of cytotoxicity. 
3.3 STIMULATION OF SPHEROID SPREADING 
A fibroblast-like phenotype and stress-fibers are both markers of migrating and 
invasive cells. Thus, we wanted to examine the effect of MLN4924 on cell 
invasion/migration properties. Different methods permit analysis of cell migration 
potential: 
1) Measurement of average cell velocity. Our data obtained using lensless 
technology show that MLN4924 treatment did not change the speed of individual cells at 
all tested concentrations (Figure 56). 
2) Cell spreading assays (Transwell migration assay, Platypus Migration Assay, 
Wound healing assay). No significant migration of VCaP cells was detected using these 
methods. Optimization of assay conditions, i.e. increase in seeding density, addition of 





Figure 56. Characterization of changes in cellular morphology using lensless technology. Adhesion scatterplots reflect 2 different population of cells – with high and low adhesion to the 
substrate. Addition of 50 nM MLN4924 leads to a dramatic increase in the amount of cells with high adhesiveness (from 30 to 60 %). At 500 nM MLN4924 the proportion of weakly 
adhesive cells decreases significantly comparied to the control. The Aspect Ratio scatterplot shows populations of cells having different morphology (from rounded to elongated). The 
addition of MLN4924 50 nM causes an increase in elongated population of cells. An increase in concentration to 500 nM abolishes this effect.  Surface scatterplots show the size of the 
cells in the population. An addition of 500 nM MLN4924 causes an increase in the average size of the cells, which reflects the formation of clusters. The velocity scatterplots show the 




Figure 57. Spheroids formation assay. Cells were suspended in culture medium containing different concentrations of 
MLN4924 (0 nM with DMSO as a vehicle, 50 nM and 500 nM) and incubated in U-bottom ultra-low attachment plates 
to allow the formation of spheroids to occur. Cells were followed by videomicroscopy and the largest diameter of the 






Figure 58. Spheroids formation assay. Suspensions of VCaP cells were distributed in U-bottom well plates together 
with one of the siRNAs (siAllStars negative control, siERG or siAR) for 24 hours. MLN4924 was added on the next 
day at indicated concentration (0 nM with DMSO as a vehicle, 50 nM, 500 nM). Cells were followed by 
videomicroscopy. The time point 30 hours after the addition of MLN4924 was shown. The tested siRNA targeting AR 
and ERG both abolished the effect of MLN4924 on spheroid formation at the low concentration of 50 nM, but did not 




Figure 59. Spheroids Spreading Assay. A. Spreading on different coatings (no treatment, poly-L-lysine or Matrigel®) 
shows that MLN4924 increases the ability of spheroids to spread on a plane. B. An increase in the concentration of 
MLN4924 up to 500 nM potentiates spheroids spreading. C. MLN4924 stimulated spheroid spreading is not affected by 
MMP inhibitor Batimastat or PLAU inhibitor UK122. 
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3) Spheroid-based tests for spreading and invasion. Spheroids are organ-like 
cellular aggregates characterized by primitive hierarchy of cell-to-cell interactions and 
formation of an extra-cellular matrix (ECM). Compared to a 2D culture, spheroids better 
recapitulate the real situation in tumors. To study the effect of MLN4924 we performed a 
Spheroids Spreading Assay, which measures the disassembly of spheroids on a plane and 
its transformation into a 2D-layer (Xu et al., 2003; Burleson et al., 2006; Indovina et al., 
2008). We tested different plate coatings: cell-culture untreated plates, plates coated with 
poly-L-lysine or with Matrigel®, which recapitulate the composition of the extra-cellular 
matrix (Figure 59, A). With all types of coating, 50 nM MLN4924 increased the 
spreading of VCaP spheroids. We performed all subsequent experiments in poly-L-
lysine-coated plates, since it was the most efficient substrate inducing spheroid spreading. 
Using increasing concentrations of the drug, we observed that at any tested concentration, 
MLN4924 stimulates spreading of VCaP spheroids (Figure 59, A, Supplementary videos 
2-4). Notably, the accelerated spreading was not a result of proliferation within the 
spheroids (we show in Chapter II that MLN4924 decreases the proliferation compared to 
the control). 
We have shown that the inhibition of the NEDD8-pathway by MLN4924 leads to 
an increase in the amount of ERG protein (Figure 51, A). ERG was reported to increase 
the invasion potential of prostate cancer cells (Wang et al., 2014; Wu et al., 2013; Tian et 
al., 2014; Leshem et al., 2011; Tomlins et al., 2008). Moreover, ERG has been shown to 
enhance the expression of matrix metalloproteases (MMP3, MMP9, ADAM19) and 
serine-type endopeptidase PLAU (Plasminogen Activator, Urokinase) (Tomlins et al., 
2008; Tian et al., 2014). Tomlins and his colleagues have demonstrated that the increase 
in invasion potential by ERG protein depended mainly on the activity of PLAU and could 
be abolished using PLAU inhibitors (Tomlins et al., 2008). We hypothesized that the 
activation of ERG could lead to the induction of MMPs and PLAU, thus facilitating 
disaggregation of ECM and accelerating the spreading of the spheroids. We examined the 
effect of pan-MMP inhibitor (Batimastat) and PLAU inhibitor (UK122) on spheroid 
spreading. Data presented in Figure 59C show that none of the tested inhibitors could 
reduce spheroids disaggregation and spreading. Therefore, we conclude that stimulation 
of spheroid spreading by MLN4924 does not depend on the increased activity of MMPs 
or PLAU. This is in accordance with our previous findings that, despite that the relative 
amount of ERG protein increases after the addition of MLN4924, the ERG-driven 
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transcription program seems to not be activated (as judged by the levels of Lef1 and 
FZD4 proteins). 
We also investigated changes in the invasive potential of VCaP cells caused by the 
inhibition of the CRL/NEDD8 pathway. We decided to use VCaP spheroids pre-formed 
in low-attachment U-bottom plates. Pre-formed spheroids can grow in a 3D matrix, but 
do not invade into the Matrigel (Figure 60, A) and other tested 3D matrixes (Cultrex® 
and PuraMatrix®). Furthermore, MLN4924 (50 or 500 nM) did not stimulate the invasion 
of VCaP spheroids into Matrigel (Figure 60, B). Nevertheless, these results might also be 
explained by the particular properties of VCaP cells. It has been shown that individual 
VCaP cells do not form 3D-structures in Matrigel (Härmä et al., 2010). In this matrix 
VCaP cells remain single and might undergo terminal differentiation or senescence. 
VCaP growth was not, however, restricted in collagen type I gels (Härmä et al., 2010). 
Thus, it is possible that Matrigel is not a suitable matrix for invasion assays with VCaP 
spheroids. 
The obtained results suggest that MLN4924 does not stimulate the migration of 
individual cells. However, MLN4924 does stimulate the disassembly and spreading of 
spheroids on the plane, which is not dependent on the activation of MMP or PLAU. The 




Figure 60. A. Growth of the pre-formed spheroids in Matrigel. Spheroids increase their volume for about 50% every 
two days. During the time of the observation (6 days) spheroids did not invade into the Matrigel ECM. B. Growth of the 
pre-formed spheroids in Matrigel in presence of MLN4924. During the time of the observation (4 days) none of the 
conditions induced invasion into the Matrigel. 
 
Figure 61. Expression of EMT markers. Localization of total β-catenin remains plasma membrane/cytoplasmic in 
presence of MLN4924 (A). The amount of LEF-1 and FZD-4 proteins does not change in the presence of MLN4924, 
suggesting no activation of the Wnt-pathway (B). The level of other principal EMT markers (E-cadherin, β-catenin, 




3.4 MLN4924 DOES NOT INDUCE EMT 
Change of cellular phenotype from epithelial to fibroblast-like is widely described 
for cancer cells by the term of Epithelial-to-Mesenchymal Transition (EMT), which is a 
hallmark of cancer invasion and metastasis. EMT has some well-established markers, 
including a loss of E-cadherin and some cytokeratins, a decrease in GSK3β expression, 
and a translocation of β-catenin into the nucleus upon the activation of Wnt-pathway 
(Thiery et al., 2002). Moreover, ERG was shown to induce EMT (Wang et al., 2014; Wu 
et al., 2013; Tian et al., 2014; Leshem et al., 2011; Tomlins et al., 2008) by the activation 
of FZD4/Lef1/Wnt-signaling (Gupta et al., 2010; Wu et al., 2013) and the up-regulation 
of the EMT transcription factors ZEB1 and ZEB2 leading to the suppression of E-
cadherin expression (Leshem et al., 2011). In order to examine the possible induction of 
the EMT program on CRL/NEDD8 pathway inhibition we analyzed the expression of 
major EMT markers. The data presented in Figure 61 show that the expression of these 
markers is not affected by MLN4924. We showed the accumulation of phospho-β-catenin 
(Figure 48, C). However, using antibodies against total β-catenin, we did not detect its 
translocation to the nucleus, suggesting an inactive Wnt-pathway. These data suggest that 
mechanisms other than EMT are responsible for the change of the cellular phenotype 
induced by MLN4924. 
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3.5 EFFECT ON CELL JUNCTION PROTEINS 
The increased cell adhesion might reflect changes in the composition of 
membrane proteins. There are five major classes of protein complexes involved in cell 
adhesion (Figure 62): tight junction, adherens junction, desmosomes, gap junction and 
focal adhesions (Kawauchi, 2012). We, therefore, analyzed the effect of inhibition of the 
CRL/NEDD8 pathway on some of these proteins. 
 
Figure 62. This table summarizes the major types of cellular contacts. The picture demonstrate the molecular structures 
of cell-cell and cell-ECM junctions. (a) Epithelial cells contain both cell-cell junctions (Tight junctions, Adherens 
junctions, Desmosomes and Gap junctions) and cell-ECM junctions (Focal adhesions and Hemidesmosomes). While 
fibroblasts are also able to form cadherin-based cell-cell junctions, the majority of adhesion in fibroblasts is still 
integrin-based focal adhesions. Red bars: actin filaments, Purple lines: intermediate filaments, Orange dots in the lower 
panel: focal adhesions, Purple dots in the lower panel: focal complex (immature focal adhesion); (b–e) Molecular 




3.5.1 Tight junction 
The tight junction (TJ) is found in the apical region around the cell's 
circumference. Compared to other adhesion complexes, TJs form the closest contact 
between the adjacent cells. This brings the cells together to make a barrier with 
controllable transport of the substances around it. Another important function of TJs is the 
maintenance of the apical-basolateral polarity of epithelial cells. The transmembrane 
component of TJs is represented by occludin, claudin and JAM proteins. The intracellular 
scaffold consist of ZO1/2/3 proteins, coupled to actin filaments. 
To estimate the effect of CRL/NEDD8 pathway inhibition on TJs proteins, we 
analyzed the expression of ZO-1 and occludin. We incubated VCaP cells and spheroids 
with increasing concentrations of MLN4924 and analyzed them using 
immunofluorescence microscopy (Figure 63, A-E). We did not observe significant change 
in the expression of the ZO-1 protein (Figure 63, D-E). However, the protein level of 
occludin increased dramatically after 5 days of incubation with 500 nM MLN4924 
(Figure 63, A-B). In parallel, Western Blot demonstrated a dose dependent accumulation 
of occludin, starting at 25 nM MLN4924 and reaching a maximum (tenfold compared to 
the control) at 500 nM (Figure 63, F). According to the current data, the increased level of 
occludin might explain both the increased cell-to-cell adhesion and spheroid spreading 
(Du et al., 2010; Fletcher et al., 2012). Specifically, occludin was shown to participate in 
collective migration (Safferling et al., 2013; Karagiannis et al., 2014), modeled by the 
spheroid spreading assay. 
Immunofluorescence microscopy revealed that occludin accumulates not only on 
the plasma membrane, but also in the granules within the cytoplasm (Figure 63, C). 
Occludin has been shown to be internalized through endocytosis and degraded in the 
lysosomes (Fletcher et al., 2014) in a ubiquitin-dependent manner (Murakami et al., 
2009). We suggest that MLN4924 impedes the degradation of occludin in the lysosomes. 
This would lead to the accumulation of occludin in the late endosomes or lysosomes (seen 




Figure 63. MLN4924-induced changes in tight junction proteins. Immunostaining of cells and spheroids for occludin 
(A, B, C) and ZO-1 (D, E). Western Blot (F) shows a dose-dependent increase in occludin in presence of MLN4924. 
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However, the CRL/NEDD8 pathway has not been reported to regulate occludin 
degradation (Traweger et al., 2002; Raikwar et al., 2010). Thus, to define the mechanism 
of the MLN4924-dependent accumulation of occluding, further investigation is needed. 
This may reveal the cause of this accumulation (due to an increased transcription or an 
attenuated degradation) and the mechanism (reinforced recycling, inability to degrade, 
etc.), as well as which role in these is processes played by the NEDD8-pathway. 
3.5.2 Adherens junction 
Adherens junctions (AJs) maintain the physical association between the cells, 
regulate cell shape and translate actomyosin-generated forces throughout the tissue. AJs 
are present in many types of tissue, where they have different localization. In epithelium, 
adherens junction form a belt in a juxtaluminal zone of the cells below the tight junction, 
while in fibroblast cells, AJs are spotty and discontinuous (Meng & Takeichi, 2009). 
Classical cadherins are the major transmembrane proteins of the AJs. Epithelial cells 
typically express E-cadherin, whereas mesenchymal cells express various cadherins, 
including N-cadherin, R-cadherin and cadherin-11. The intracellular scaffold consists of 
the catenin family of proteins and vinculin, attached to the actin filaments (Hartsock & 
Nelson, 2008). 
To analyze the possible influence of the CRL/NEDD8 pathway inhibition on the 
proteins forming AJs we examined the expression of β-catenin, E-cadherin and N-
cadherin using immunofluorescence microscopy and Western Blot. We found that the 
amount and localization (cytoplasmic) of total β-catenin did not change (Figure 61, C; 
Figure 64, A). Treatment of VCaP cells with MLN4924 did not affect the total level of 
cellular E-cadherin (Figure 61, C; Figure 64, B), but it did induce its cleavage (Figure 64, 
E). Because the antibody we used recognizes the intracellular C-terminal part of E-
cadherin, the cleaved 38 kDa-fragment corresponds to the intracellular plus 
transmembrane domain of E-cadherin (David & Rajasekaran, 2012). This type of E-
cadherin cleavage has been shown to be performed by multiple extracellular proteases, 
including MMPs, A-disintegrin-and-metalloproteinases (ADAMs), plasmin, and 
kallikrein 7. This cleavage has been shown to weaken cellular contacts and promote cell 
migration (Solanas et al., 2011; David & Rajasekaran, 2012; Grieve & Rabouille, 2014). 
Nevertheless, the effect of MLN4924 on cell phenotype was not abolished by MMPs or 
uPA inhibitors (Figure 59, C). This might suggest that either accelerated spheroid 
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spreading was not dependent on the cleavage of E-cadherin, or that other enzymes are 
involved in E-cadherin cleavage upon inhibition of the CRL/NEDD8-pathway. 
Interestingly, we also observed that MLN4924 treatment causes translocation of 
N-cadherin from the plasma membrane to the peri-nuclear area (at 50 nM), and then to 
the nucleus (at 500 nM) (Figure 64, C, D). One major function of N-cadherin is the 
establishment of the AJ, which is a dynamic structure. N-cadherin is delivered to the 
plasma membrane, and then either internalized, degraded in the lysosomes, or recycled 
(Kowalczyk & Nanes, 2012). Thus, the observed effects of N-cadherin re-localization 
might be explained by impaired trafficking of N-cadherin inside the cell. A similar effect 
was reported for the insecticide DDT (1,1,1-trichloro-2,2-bis(p-chlorophenyl)ethane), 
which disrupts cellular contacts by causing re-localization of N-cadherin, ZO-1 and gap 
junction proteins from the membrane into the vacuoles (Fiorini et al., 2008). On the other 
hand, there are also several reports on the specific role of N-cadherin within the nucleus. 
N-cadherin was found in the nuclei of honey bee gonads (Florecki & Hartfelder, 2012) as 
well as the neuronal crest cell, where it serves as a transcription factor and antagonizes 
the Wnt/β-catenin program (Shoval et al., 2007). Moreover, there are some reports 
showing a correlation between cytoplasmic/nuclear localization of N-cadherin and poor 
cancer prognosis (Luo et al., 2012; Pawar et al., 2013). These data might suggest a 
specific role of the CRL/NEDD8 pathway inhibition in the regulation of N-cadherin 
localization. 
3.5.3 Focal adhesion 
Focal adhesions (FAs) are responsible for the establishment of the contact with 
ECM, mechanosensing and signaling. FAs play a crucial role in migration: new FAs are 
assembled at the leading edge of migrating cells. In resting cells, FAs serve as fixation 
points and help maintain cell shape. Extracellular component of FAs consist of α/β 
integrin heterodimer, which binds to the extracellular matrix. The intracellular element of 
FAs are comprised of multiple proteins. The core proteins are focal adhesion kinase 
(FAK), tallin, vinculin and paxillin. The macromolecular complex of FA is anchored on 
the actin cytoskeleton. To analyze the effect of CRL/NEDD8 pathway inhibition on the 






Figure 64. MLN4924-induced changes in adherens junction proteins. Immunostaining of cells and spheroids for β-





Figure 65. MLN4924-induced changes in focal adhesions proteins. Immunostaining of VCaP cells for FAK (A) shows a 
delocalization of FAK. Western Blot shows an accumulation of both total FAK and phospho-paxillin (B). The 
translocation of FAK to the nucleus correlates with a decrease of p53 protein level (C). 
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We found that while the amount of total paxillin did not visibly change, the level 
of phosphorylated paxillin increased significantly (Figure 65, B). Paxillin has been shown 
to be degraded by the UPS (Didier et al., 2003; Iioka et al., 2007), and at least in some 
cases this degradation is regulated by phosphorylation (Abou Zeid et al., 2006). However, 
the role of CRL/NEDD8 pathway in this process has never been shown. 
In parallel we observed that MLN4924 increased the level of FAK in an adose-
dependent manner. Moreover, immunofluorescence microscopy showed a translocation of 
FAK from the membrane to the perinuclear space and to the nuclei (Figure 65). FAK has 
multiple functions in FAs. It serves as a scaffold protein for the assembly of FA 
complexes, while, as a kinase, it translates signals from ECM into the cell by the 
activation of multiple pathways, including MAPK, PI3-K/Akt and Rho GTPases. FAK is 
often overexpressed in cancer, where it exerts pro-proliferative and anti-apoptotic effects 
(Kamarajan & Kapila, 2007; Tai et al., 2015). Nuclear localization was first shown for 
SUMOylated FAK (Golubovskaya et al., 2005; Stewart et al., 2002), but the biological 
role of this translocation was not described. Recently, several articles reported novel, 
kinase- and SUMOylation-independent mechanism for nuclear FAK. Thus, nuclear FAK 
was shown to exert anti-inflammatory role (Lim et al., 2012) and to be a scaffold for 
MDM2-mediated degradation of p53 (Golubovskaya et al., 2008; Lim et al., 2008). 
Indeed, treatment of VCaP cells with 50-100 nM MLN4924 induced weak (2-fold), but a 
reproducible decrease in the amount of p53 protein in VCaP cells (Figure 65, C). Of note, 
VCaP cells bear a mutation in p53 R248W that abolishes the tumor-suppression activities 
of p53 (Sobel & Sadar, 2005; Song et al., 2007). Nevertheless, we don’t have solid 
evidence that FAK re-location to the nucleus and decrease in p53 quantity are 
interdependent events. Moreover, at 500 nM, MLN4924 induced an increase in p53 
protein, though the nuclear localization of FAK was even more pronounced. 
3.6 DISCUSSION 
This part of thesis documents that the inhibition of the CRL/NEDD8 pathway by 
MLN4924 induced morphological changes in VCaP cells, manifested by an increased 
cell-substrate and cell-to-cell adhesion and accelerated spreading of VCaP spheroids. 
Although we did not find induction of EMT markers, we demonstrated multiple dose-
dependent changes in the expression and localization of proteins forming cellular 
contacts. These included: extracellular E-cadherin cleavage; accumulation of occludin on 
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the plasma membrane and into the intracellular granules; translocation of N-cadherin to 
the nuclei/perinuclear area; and accumulation of FAK and its translocation to nuclei/peri-
nuclear area. Of course, each of these events may have an independent cause and function 
as discussed above. However, taken together these effects suggest that the inhibition of 
the CRL/NEDD8 pathway does result in some general alterations in the trafficking and 
degradation of membrane proteins. MLN4924 might affect trafficking through inhibition 
of CRLs or directly through inhibition of the neddylation of membrane receptors. 
Ubiquitylation of membrane proteins is a well-acknowledged sorting signal for 
both lysosomal and proteasome-dependent degradation (Piper & Katzmann, 2007). 
However, only limited data are available on the participation of CRLs in this type of 
ubiquitylation; in mammals CRL ligases regulate trafficking of growth hormone receptor 
(van Kerkhof et al., 2011), influenza A virus and epidermal growth factor receptor 
(Huotari et al., 2012). 
A growing body of knowledge demonstrates the important role of the 
CRL/NEDD8 pathway in the regulation of protein sorting. Recently, Cullin 3 has 
appeared as an important factor in protein trafficking. Cullin 3-based RING-ligases 
(CRL3) has been shown to control the formation of cytoskeleton tubules, allowing 
trafficking of vesicles from the Golgi to the plasma membrane (Yuan et al., 2014). 
Moreover, ubiquitylation of SEC31 by CRL3 regulates the size of the vesicles formed in 
the endoplasmic reticulum, which allows for the sorting of the molecules by size, which, 
in turn, is important for the transport of macromolecules such as collagen (Jin et al., 
2012). Thus, the inhibition of CRL3 functions could lead to the incorrect trafficking and 
attenuated degradation of plasma receptors. Moreover, direct neddylation regulates 
trafficking and/or degradation of transmembrane proteins TGF-β type II receptor (TβRII) 
(Zuo et al., 2013), chemokine receptor CXCR5 (Renaudin et al., 2014) and EGFR (Oved 
et al., 2006). Together these data suggest a general role of the CRL/NEDD8 pathway in 
the regulation of sorting and degradation of membrane proteins. 
Further investigation is needed to elucidate the role of the NEDD8-pathway in the 
trafficking of membrane-bound proteins. We are planning to perform a proteomics of the 
plasma membrane and intracellular proteins in VCaP cells. This would make it possible to 
establish how general the effects of NEDD8-pathway inhibition on vesicle trafficking are, 





In this work we describe a systematic approach for the screening of the UPS, based 
on its cascade organization. We evaluated the effect of knockdowns of individual UPS 
components on the viability of PCa cell lines with a major focus on TMPRSS:ERG-
positive cells, as a model for the prevalent phenotype of prostate cancer. Seven genes are 
identified as being involved in the functioning of tested PCa cell lines (UBE2U, CAND1, 
UBE2H, UBE2A, CUL4B, CUL2, RBX1), while two of them are putatively 
TMPRSS2:ERG-dependent (CUL2, RBX1). Importantly, the majority of identified hits 
belong to the CRL/NEDD8 pathway. The identified UPS components are crucial for PCa 
cell functioning and their investigation could provide some keys for a better 
understanding of cancer biology. We selected the most prominent hits, the CRL/NEDD8 
pathway and the UBE2U enzyme, for further validation. 
UBE2U was the strongest hit identified in siRNA screening. During 
characterization of the enzyme, we found that, in VCaP cells, UBE2U is present in 
multiple isoforms. Some of these isoforms are predicted to be enzymatically inactive. 
Moreover, in contrast to existing data, we demonstrate the presence of an UBE2U 
isoform of significantly higher molecular weight (95 kDa compared to 38 kDa). Thus, we 
first provide evidence for UBE2U involvement in prostate carcinogenesis. Although 
further investigation is required, our study is the first step the characterization of UBE2U 
as a potential drug-target. 
Enrichment of the components of the CRL/NEDD8 pathway (CAND1, CUL4B, 
CUL2, RBX1) in the hits suggested a general importance of neddylation in PCa biology. 
Moreover, the potential ERG-dependency of CUL2 and RBX1 hits could indicate a 
specific role of neddylation in TMPRSS2:ERG-positive cells. Indeed, our investigation 
using the neddylation-specific inhibitor, MLN4924, has demonstrated that inhibition of 
the CRL/NEDD8 pathway in prostate cancer cells has a complex outcome that strongly 
depends on the cellular context. MLN4924 induced apoptosis in all tested cell lines, 
though TMPRSS2:ERG positive cell lines were significantly more resistant. We 
demonstrate that the resistance of VCaP cells toward NAE inhibition is the result of cell 
plasticity ensured by a sophisticated interaction network ERG:NF-κB:c-Myc:Wnt/β-
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cat:AR. It has been shown that in TMPRSS2:ERG-positive PCa cells AR is suppressed 
by ERG (Yu et al., 2010). We found that in conditions of incomplete (90-95%) inhibition 
of neddylation, VCaP cells undergo transcriptional reprogramming leading to cell 
quiescence and inhibition of proliferation-dependent apoptosis. This was achieved by re-
activation of the AR transcriptional program and induction of a differentiation-like state. 
These results suggest that targeting AR could potentiate the efficacy of MLN4924-based 
therapy in TMPRSS2:ERG-positive PCa cells. Indeed, knockdown of AR significantly 
increased apoptotic response to MLN4924. By contrast, knockdown of ERG completely 
abolished MLN4924-induced cytotoxicity. Higher doses of MLN4924 caused complete 
inhibition of CRLs and induced an accumulation of replication licensing factor Cdt1, 
leading to re-replication, DNA-damage and subsequent senescence and/or apoptosis.  
Our siRNA screens have shown that the knockdown of different cullins in VCaP 
cells had opposite effects. We thus hypothesized, that the complex outcome of MLN4924 
treatment that we observed in VCaP cells can be explained, at least partially, by the 
different sensitivity of cullins toward MLN4924. Indeed, using Western Blot we have 
shown that the accumulation of CRL substrates had two characteristic onsets: 25 nM (b-
catenin, IKK and p21, being the substrates of CRL1) and 250 nM (Cdt1, being the 
substrate of CRL4). We thus conclude that the effect of MLN4924 might depend on the 
subset of CRLs inhibited at a given dose of the drug. 
Our siRNA screening revealed the crucial role of CAND1 in PCa cells. Moreover, 
we have also shown that when neddylation is compromised, CAND1 exchange factor 
plays a critical role to ensure CRLs functioning. Indeed, knockdown of CAND1 increased 
the susceptibility of VCaP cells to MLN4924 treatment. These data suggest that CAND1 
is a potential drug target. 
Our conclusion is that the CRL/NEDD8 pathway regulates the cancer 
transcriptional network and determines cancer cells plasticity. This knowledge makes it 
possible to find better treatments for TMPRSS2:ERG-positive cancers using potential 
complementary drugs that target AR and CAND1. 
Multiple studies of MLN4924 have shown that it efficiently induces senescence 
and/or apoptosis in many cancer cell lines, including PCa. Furthermore, MLN4924 is 
currently being evaluated in clinical trials for the treatment of hematological malignancies 
and solid tumors. Nevertheless, our data suggest that the effect of MLN4924 on prostate 
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cancer cell lines harbouring TMPRSS2:ERG translocation is mixed. Low-dose treatment 
with MLN4924 induces protective reversible quiescence in cancer cells. Taking into 
account a frequent problem of drug bioavailability, it raises concern about possible 
undertreatment in MLN4924 therapy. Of note, higher doses of MLN4924 were reported 
to produce side-effects and are generally toxic. In conclusion, our data question the 
suitability of MLN4924 for treatment of TMPRSS2:ERG-positive prostate cancers. 
Apart from the above described effects on the viability, we have observed that 
MLN4924 changed membrane properties of VCaP cells and rendered them more adherent 
in cell-substrate and cell-to-cell interactions. While we did not find changes in the 
expression of several EMT markers, we demonstrated dose-dependent changes in the 
expression and re-localization of several membrane-associated proteins, including 
occludin, N-cadherin and FAK. We thus conclude that the CRL/NEDD8 pathway might 
be involved in the sorting/trafficking of membrane proteins. This part of the work 
requires further investigation, as understanding of the underlying mechanisms might 
uncover new a role of the CRL/NEDD8 pathway having general importance for cell 
biology. Our data reveal a potentially globally new role of the CRL/NEDD8 pathway in 
the regulation of intracellular trafficking, composition of plasma membrane and cell 
adhesion. 
Final conclusions: 
1) We have performed a comprehensive screening of the E1-E2 UPS components 
to identify the genes essential for PCa viability. 
2) Our work has revealed new potential drug targets for PCa treatment (UBE2U, 
CAND1) 
3) We have demonstrated the role of the CRL/NEDD8 pathway in the regulation 
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Supplementary Figure 2. Effect on DNA synthesis 3, 24 or 120 hours after treatment with MLN4924 in Standard 






Supplementary Figure 3. The effect of MLN4924 treatment on proliferation (A) and apoptosis (B) of PCa cell lines 









Supplementary Figure 5. Effect of MLN4924 on ubiquitylation and SUMOylation. Cells were treated with increased 






Supplementary Figure 6. Western Blot, demonstrating expression of AR-responsive genes prostein, FKBP51 and PSA 
at different concentrations of MLN4924. All the tested genes show biphasic behavior: protein level increases at low 






Supplementary Figure 7. Immunofluorescence microscopy for phospho-p65 component of NF-κB. Images demonstrate 
accumulation of phospho-p65. However, it remains cytoplasmic and does not enter the nuclei. 
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Supplementary Table 1. Dharmacon ON-TARGETplus® SMART pool® siRNA Library-Human Ubiquitin 











































































































































































































































































































































































7332 NM_003347 38157977 GUAAGAAUGCUGAAGAGUU 













































































































































































































































































































































































4734 NM_006154 38257154 GAACUAGAGCUUCUUAUGU 













































































































































































































































































































































































64400 NM_022476 61743931 GUGCACUGCUCGUUUGUUU 













































































































































































































































































































































































9870 NM_014821 42734314 GCGCAAGGCUGGGCGUUAU 





















































































































































































































































































































GENE ID Gene Accession GI Number Sequence 
SAE1 L-006402-01 J-006402-09 10055 NM_005500 4885584 GCACAGUAUGACCGGCAGA 
SAE1 L-006402-01 J-006402-10 10055 NM_005500 4885584 GGGUCUGUUGGCCGAAAUA 
SAE1 L-006402-01 J-006402-11 10055 NM_005500 4885584 UGAAGUCAUUGGCCCGAUA 
SAE1 L-006402-01 J-006402-12 10055 NM_005500 4885584 GUUCUUGAGUUUUCGUUUA 
UBA2 L-005248-01 J-005248-09 10054 NM_005499 50592990 GUGCAAAGAGGUCACGUAU 
UBA2 L-005248-01 J-005248-10 10054 NM_005499 50592990 GGACAAACUAUGGCGGAAA 
UBA2 L-005248-01 J-005248-11 10054 NM_005499 50592990 CAUAACCAGUCAUGAGAUA 
UBA2 L-005248-01 J-005248-12 10054 NM_005499 50592990 GCUAGAACUGUUAGACACA 
NAE1 L-006401-00 J-006401-05 8883 NM_001018160 66363687 GAUGAUCGCUGCAUAAAUA 
NAE1 L-006401-00 J-006401-06 8883 NM_001018160 66363687 GCACAGUGGUAUAGUGAAA 
NAE1 L-006401-00 J-006401-07 8883 NM_001018160 66363687 GAUUUUAGCUCGUGCCUUA 
NAE1 L-006401-00 J-006401-08 8883 NM_001018160 66363687 GUUACGGGCUGUUGAUAGA 
ATG7 L-020112-00 J-020112-05 10533 NM_006395 5453667 CCAACACACUCGAGUCUUU 
ATG7 L-020112-00 J-020112-06 10533 NM_006395 5453667 GAUCUAAAUCUCAAACUGA 
ATG7 L-020112-00 J-020112-07 10533 NM_006395 5453667 GCCCACAGAUGGAGUAGCA 
ATG7 L-020112-00 J-020112-08 10533 NM_006395 5453667 GCCAGAGGAUUCAACAUGA 
UFC1 L-020623-01 J-020623-09 51506 NM_016406 7705480 CCUUUGAUAGGCUACGAUA 
UFC1 L-020623-01 J-020623-10 51506 NM_016406 7705480 AAAUAUGCCUGACGGAUCA 
UFC1 L-020623-01 J-020623-11 51506 NM_016406 7705480 AAUAUGAGUUUGACAUCGA 
UFC1 L-020623-01 J-020623-12 51506 NM_016406 7705480 AGUUGUGGGUGCAGCGACU 
ATG10 L-019426-01 J-019426-09 83734 NM_031482 33589825 CGUCUCAGGAUGAACGAAA 
ATG10 L-019426-01 J-019426-10 83734 NM_031482 33589825 AGGAAUUGCGGCACGAAGA 
ATG10 L-019426-01 J-019426-11 83734 NM_031482 33589825 GGAGGAGGCUUUCGAGCUA 
ATG10 L-019426-01 J-019426-12 83734 NM_031482 33589825 CCAACGUUAUUGUGCAGAA 
ATG3 L-015375-00 J-015375-05 64422 NM_022488 34147490 GAGAGUGGAUUGUUGGAAA 
ATG3 L-015375-00 J-015375-06 64422 NM_022488 34147490 GCGGAUGGGUAGAUACAUA 
ATG3 L-015375-00 J-015375-07 64422 NM_022488 34147490 GAGCAACGGCAGCCUUUAA 
ATG3 L-015375-00 J-015375-08 64422 NM_022488 34147490 ACAAGACACUUCACAAUGU 
RNF25 L-007047-00 J-007047-05 64320 NM_022453 34878786 GGUCAAAUCAGCAAAGGUU 
RNF25 L-007047-00 J-007047-06 64320 NM_022453 34878786 AGGCUGAGCGAAACCGAUA 
RNF25 L-007047-00 J-007047-07 64320 NM_022453 34878786 UGAGUCAGCUGUAGAUGUC 
RNF25 L-007047-00 J-007047-08 64320 NM_022453 34878786 GACCAGGAUUCACAGUAUG 
RWDD1 L-020946-02 J-020946-18 51389 NM_015952 55953122 GGCUAUGCUCAGAGGGUUA 
RWDD1 L-020946-02 J-020946-19 51389 NM_015952 55953122 UGAAGAUGAUCCAGACUAU 
RWDD1 L-020946-02 J-020946-20 51389 NM_015952 55953122 GCAGAACUCUUGGAAAUUA 
RWDD1 L-020946-02 J-020946-21 51389 NM_015952 55953122 UCUAGUGACAGCUGUGCAA 
UBR4 L-014021-01 J-014021-09 23352 NM_020765 82659108 GGGAACACCCUGACGUAAA 
UBR4 L-014021-01 J-014021-10 23352 NM_020765 82659108 UCAUGAAGCCUGUUCGAAA 
UBR4 L-014021-01 J-014021-11 23352 NM_020765 82659108 CUACGAAGCUGCCGACAAA 
UBR4 L-014021-01 J-014021-12 23352 NM_020765 82659108 UGAACAAAUUUGCCGAUAA 
UBR3 L-016653-00 J-016653-05 130507 NM_172070 40255162 AGAAAAGUCUUACGAAGUA 
UBR3 L-016653-00 J-016653-06 130507 NM_172070 40255162 AGGCAAACCUCUCUACAUU 
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UBR3 L-016653-00 J-016653-07 130507 NM_172070 40255162 GAGAAAGCUCACCCAGUUA 
UBR3 L-016653-00 J-016653-08 130507 NM_172070 40255162 AGAUCGACCUACUGGAUUA 
UBR2 L-006954-00 J-006954-05 23304 NM_015255 27597060 CAACAGAGAUUACGCUUAC 
UBR2 L-006954-00 J-006954-06 23304 NM_015255 27597060 GCGUAGGUCUGUUCGAUAU 
UBR2 L-006954-00 J-006954-07 23304 NM_015255 27597060 GCUUAGUGAUUCCAAAUUA 
UBR2 L-006954-00 J-006954-08 23304 NM_015255 27597060 UCAGAGAUCAACUGUAUUA 
UBR1 L-010691-00 J-010691-06 197131 NM_174916 83656781 GGAAAUCAGCGCGGAGUUA 
UBR1 L-010691-00 J-010691-07 197131 NM_174916 83656781 GUACAAUCGUGUGGACAUA 
UBR1 L-010691-00 J-010691-08 197131 NM_174916 83656781 GCGAAGAAAUGGACUGUCU 
UBR1 L-010691-00 J-010691-09 197131 NM_174916 83656781 GAUCAGCAAACCCACAAUA 
UBR7 L-016489-01 J-016489-09 55148 NM_175748 28411949 AUGAUGGAUUGGUGCGGAA 
UBR7 L-016489-01 J-016489-10 55148 NM_175748 28411949 GAAAGGAUGAUGUCCGGGA 
UBR7 L-016489-01 J-016489-11 55148 NM_175748 28411949 UGGCGUAGCAAGUUGUGUA 
UBR7 L-016489-01 J-016489-12 55148 NM_175748 28411949 UGAAUAGAGUCCAGCAAGU 
USP2 L-006069-00 J-006069-11 9099 NM_171997 28565284 ACACCAACCAUGCUGUUUA 
USP2 L-006069-00 J-006069-12 9099 NM_171997 28565284 GCGCUUUGUUGGCUAUAAU 
USP2 L-006069-00 J-006069-13 9099 NM_171997 28565284 GUGUACAGAUUGUGGUUAC 
USP2 L-006069-00 J-006069-14 9099 NM_171997 28565284 GACCUAAGUCCAACCCUGA 
USP9X L-006099-00 J-006099-06 8239 NM_021906 74315357 AGAAAUCGCUGGUAUAAAU 
USP9X L-006099-00 J-006099-07 8239 NM_021906 74315357 ACACGAUGCUUUAGAAUUU 
USP9X L-006099-00 J-006099-08 8239 NM_021906 74315357 GUACGACGAUGUAUUCUCA 
USP9X L-006099-00 J-006099-09 8239 NM_021906 74315357 GAAAUAACUUCCUACCGAA 
VCP L-008727-00 J-008727-09 7415 NM_007126 7669552 GCAUGUGGGUGCUGACUUA 
VCP L-008727-00 J-008727-10 7415 NM_007126 7669552 CAAAUUGGCUGGUGAGUCU 
VCP L-008727-00 J-008727-11 7415 NM_007126 7669552 CCUGAUUGCUCGAGCUGUA 
VCP L-008727-00 J-008727-12 7415 NM_007126 7669552 GUAAUCUCUUCGAGGUAUA 
SENP1 L-006357-00 J-006357-05 29843 NM_014554 45505133 GCAUUUCGCCUGACCAUUA 
SENP1 L-006357-00 J-006357-06 29843 NM_014554 45505133 GGAAGUGACUGUGGGAUGU 
SENP1 L-006357-00 J-006357-07 29843 NM_014554 45505133 CAAGAAGUGCAGCUUAUAA 
SENP1 L-006357-00 J-006357-08 29843 NM_014554 45505133 GCAGUGAAACGUUGGACAA 
UBB L-013382-00 J-013382-05 7314 NM_018955 22538474 GCUGUUAAUUCUUCAGUCA 
UBB L-013382-00 J-013382-06 7314 NM_018955 22538474 GUAUGCAGAUCUUCGUGAA 
UBB L-013382-00 J-013382-07 7314 NM_018955 22538474 UCGAAAAUGUGAAGGCCAA 
UBB L-013382-00 J-013382-08 7314 NM_018955 22538474 CACCUGGUCCUGCGUCUGA 
SUMO1 L-016005-00 J-016005-07 7341 NM_001005781 54792064 GUGCAUAUAUGAUACAGUU 
SUMO1 L-016005-00 J-016005-08 7341 NM_001005781 54792064 GCACUGAAAGUUACUGAAG 
SUMO1 L-016005-00 J-016005-09 7341 NM_001005781 54792064 CAUAAAUACUGGAAAUUGC 

















GENE ID Gene 
Accession 
GI Number Sequence 
AREL1 J-007184-09 J-007184-09 AREL1 9870 NM_014821 42734314 GGGAAUGGUUUGAGCUAAU 
AREL1 J-007184-06 J-007184-06 AREL1 9870 NM_014821 42734314 GCGCAAGGCUGGGCGUUAU 
AREL1 J-007184-07 J-007184-07 AREL1 9870 NM_014821 42734314 CGAAGAAGGUGUACUGCUA 
AREL1 J-007184-08 J-007184-08 AREL1 9870 NM_014821 42734314 GCAUUUACUUUGAGGCUUA 
CACUL1 J-016305-11 J-016305-11 CACUL1 143384 NM_153810 54262140 GGGUACAGAUAGUGAAUGU 
CACUL1 J-016305-12 J-016305-12 CACUL1 143384 NM_153810 54262140 GCAUUAGAAAGUCUUGUUA 
CACUL1 J-016305-09 J-016305-09 CACUL1 143384 NM_153810 54262140 AGGCGAUGAUGGACGACCA 
CACUL1 J-016305-10 J-016305-10 CACUL1 143384 NM_153810 54262140 GGAUAUUGGGAGCAAGUAA 
CAND1 J-015562-12 J-015562-12 CAND1 55832 NM_018448 21361793 CAUAACAAGCCAUCAUUAA 
CAND1 J-015562-10 J-015562-10 CAND1 55832 NM_018448 21361793 CGUGCAACAUGUACAACUA 
CAND1 J-015562-11 J-015562-11 CAND1 55832 NM_018448 21361793 CAACAAGAACCUACAUACA 
CAND1 J-015562-09 J-015562-09 CAND1 55832 NM_018448 21361793 GACUUUAGGUUUAUGGCUA 
CUL2 J-007277-06 J-007277-06 CUL2 8453 NM_003591 19482173 CAUCCAAGUUCAUAUACUA 
CUL2 J-007277-05 J-007277-05 CUL2 8453 NM_003591 19482173 GGAAGUGCAUGGUAAAUUU 
CUL2 J-007277-08 J-007277-08 CUL2 8453 NM_003591 19482173 UGGUUUACCUCAUAUGAUU 
CUL2 J-007277-07 J-007277-07 CUL2 8453 NM_003591 19482173 GCAGAAAGACACACCACAA 
CUL4B J-017965-06 J-017965-06 CUL4B 8450 NM_003588 28372492 CAGAAGUCAUUAAUUGCUA 
CUL4B J-017965-08 J-017965-08 CUL4B 8450 NM_003588 28372492 GCUAUUGGCCGACAUAUGU 
CUL4B J-017965-05 J-017965-05 CUL4B 8450 NM_003588 28372492 UAAAUAACCUCCUUGAUGA 
CUL4B J-017965-07 J-017965-07 CUL4B 8450 NM_003588 28372492 CGGAAAGAGUGCAUCUGUA 
DCUN1D3 J-018390-05 J-018390-05 DCUN1D3 123879 NM_173475 27735046 AAGGAUCUCUACCGGUUUA 
DCUN1D3 J-018390-06 J-018390-06 DCUN1D3 123879 NM_173475 27735046 ACGGUUCCCUAGCCUCUUA 
DCUN1D3 J-018390-07 J-018390-07 DCUN1D3 123879 NM_173475 27735046 CCAGAACAAUCCUCCGGUA 
DCUN1D3 J-018390-08 J-018390-08 DCUN1D3 123879 NM_173475 27735046 GUAAGAAUCCCUCAUCGAC 
DCUN1D5 J-014842-09 J-014842-09 DCUN1D5 84259 NM_032299 34147410 CAAUCAAAGUAUCGUGUUA 
DCUN1D5 J-014842-10 J-014842-10 DCUN1D5 84259 NM_032299 34147410 GUUGAAUGAUAUUUCGUCA 
DCUN1D5 J-014842-12 J-014842-12 DCUN1D5 84259 NM_032299 34147410 UGAUGGGCAUUGAGCCACA 
DCUN1D5 J-014842-11 J-014842-11 DCUN1D5 84259 NM_032299 34147410 CCGUCAGACAUCAUAGCAA 
HERC2 J-007180-12 J-007180-12 HERC2 8924 NM_004667 67190865 GCAGAUGUGUGCUAAGAUG 
HERC2 J-007180-10 J-007180-10 HERC2 8924 NM_004667 67190865 CGAUGAAGGUUUGGUAUUU 
HERC2 J-007180-09 J-007180-09 HERC2 8924 NM_004667 67190865 GCACAGAGUAUCACAGGUA 
HERC2 J-007180-11 J-007180-11 HERC2 8924 NM_004667 67190865 GAUAAUACGACACAGCUAA 
HERC5 J-005174-06 J-005174-06 HERC5 51191 NM_016323 7705930 GGAAGUAGCAUAACUGUCA 
HERC5 J-005174-07 J-005174-07 HERC5 51191 NM_016323 7705930 GAACCAGGAUAUAACAGUU 
HERC5 J-005174-08 J-005174-08 HERC5 51191 NM_016323 7705930 UAAGAGCACUGACAUGUUU 
HERC5 J-005174-09 J-005174-09 HERC5 51191 NM_016323 7705930 GACUUUCCCUGUUCAAUUG 
RBX1 J-004087-07 J-004087-07 RBX1 9978 NM_014248 22091459 GAAGCGCUUUGAAGUGAAA 
RBX1 J-004087-08 J-004087-08 RBX1 9978 NM_014248 22091459 GGGAUAUUGUGGUUGAUAA 
RBX1 J-004087-09 J-004087-09 RBX1 9978 NM_014248 22091459 GGAACCACAUUAUGGAUCU 
RBX1 J-004087-10 J-004087-10 RBX1 9978 NM_014248 22091459 CAUAGAAUGUCAAGCUAAC 
RNF25 J-007047-05 J-007047-05 RNF25 64320 NM_022453 34878786 GGUCAAAUCAGCAAAGGUU 
RNF25 J-007047-06 J-007047-06 RNF25 64320 NM_022453 34878786 AGGCUGAGCGAAACCGAUA 
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RNF25 J-007047-07 J-007047-07 RNF25 64320 NM_022453 34878786 UGAGUCAGCUGUAGAUGUC 
RNF25 J-007047-08 J-007047-08 RNF25 64320 NM_022453 34878786 GACCAGGAUUCACAGUAUG 
SAG J-011105-08 J-011105-08 SAG 6295 NM_000541 10880124 GCAAGAGAGCCUGCUUAAA 
SAG J-011105-06 J-011105-06 SAG 6295 NM_000541 10880124 GUUCUCUACUCGAGUGAUU 
SAG J-011105-07 J-011105-07 SAG 6295 NM_000541 10880124 GAACCGAACCAUGUUAUCU 
SAG J-011105-05 J-011105-05 SAG 6295 NM_000541 10880124 AAAGUUAUCAGGAUGCAAA 
SPOP J-017919-10 J-017919-10 SPOP 8405 NM_001007228 56117829 CAACUAUCAUGCUUCGGAU 
SPOP J-017919-09 J-017919-09 SPOP 8405 NM_001007228 56117829 GGUAAAGGUUCCUGAGUGC 
SPOP J-017919-08 J-017919-08 SPOP 8405 NM_001007228 56117829 GAGAGUCAACGGGCAUAUA 
SPOP J-017919-11 J-017919-11 SPOP 8405 NM_001007228 56117829 AAAUGGUGUUUGCGAGUAA 
UBA3 J-005249-08 J-005249-08 UBA3 9039 NM_198197 38045945 CAAUCUAAAUAGGCAGUUU 
UBA3 J-005249-05 J-005249-05 UBA3 9039 NM_198197 38045945 CAAUAGUGCUUCUCUGCAA 
UBA3 J-005249-07 J-005249-07 UBA3 9039 NM_198197 38045945 GAUAAAUGGCAUGCUGAUA 
UBA3 J-005249-06 J-005249-06 UBA3 9039 NM_198197 38045945 UACAGGAGGUUUUGGAUUA 
UBE2A J-009424-07 J-009424-07 UBE2A 7319 NM_181762 32967275 GGACAUACUUCAGAACCGU 
UBE2A J-009424-05 J-009424-05 UBE2A 7319 NM_181762 32967275 CUAUGCAGAUGGUAGUAUA 
UBE2A J-009424-08 J-009424-08 UBE2A 7319 NM_181762 32967275 GAACAAACGGGAAUAUGAA 
UBE2A J-009424-06 J-009424-06 UBE2A 7319 NM_181762 32967275 GCGUGUUUCUGCAAUAGUA 
UBE2D2 J-010383-09 J-010383-09 UBE2D2 7322 NM_003339 33188457 UCCAGGAACUUGAUUGUUA 
UBE2D2 J-010383-06 J-010383-06 UBE2D2 7322 NM_003339 33188457 UCUGUUCUCUGUUGUGUGA 
UBE2D2 J-010383-08 J-010383-08 UBE2D2 7322 NM_003339 33188457 GUAUGUGGUUUCUCAGUUA 
UBE2D2 J-010383-07 J-010383-07 UBE2D2 7322 NM_003339 33188457 CAAAUGACAGUCCCUAUCA 
UBE2F J-009081-09 J-009081-09 UBE2F 140739 NM_080678 18087856 CAAGUAAACUGAAGCGUGA 
UBE2F J-009081-11 J-009081-11 UBE2F 140739 NM_080678 18087856 CAAUAAGAUACCCGCUACA 
UBE2F J-009081-10 J-009081-10 UBE2F 140739 NM_080678 18087856 AUGACUACAUCAAACGUUA 
UBE2F J-009081-12 J-009081-12 UBE2F 140739 NM_080678 18087856 CUGAAGUUCCCGAUGCGUA 
UBE2G1 J-010154-08 J-010154-08 UBE2G1 7326 NM_182682 75992938 GUAUAGAUCCCGUCACUAA 
UBE2G1 J-010154-09 J-010154-09 UBE2G1 7326 NM_182682 75992938 UAUAGAAACUCGUAAGUGU 
UBE2G1 J-010154-07 J-010154-07 UBE2G1 7326 NM_182682 75992938 GCUAGUAACUUCACUUAUU 
UBE2G1 J-010154-06 J-010154-06 UBE2G1 7326 NM_182682 75992938 GAUGGGAAGUCCUUAUUAU 
UBE2H J-009134-05 J-009134-05 UBE2H 7328 NM_182697 33356153 GAGUGGACCUACCUGAUAA 
UBE2H J-009134-08 J-009134-08 UBE2H 7328 NM_182697 33356153 UCAAGCUCAUCGAGAGUAA 
UBE2H J-009134-06 J-009134-06 UBE2H 7328 NM_182697 33356153 GAUAUGGAGUUGUAGUAGA 
UBE2H J-009134-07 J-009134-07 UBE2H 7328 NM_182697 33356153 GGCGGAGUAUGGAAAGUUA 
UBE2J1 J-007266-08 J-007266-08 UBE2J1 51465 NM_016021 37577121 GCCAUAGGUUCUCUAGAUU 
UBE2J1 J-007266-06 J-007266-06 UBE2J1 51465 NM_016021 37577121 GAGUAUAAGGACAGCAUUA 
UBE2J1 J-007266-07 J-007266-07 UBE2J1 51465 NM_016021 37577121 GAUGUCCUGUUGCCUUUAA 
UBE2J1 J-007266-05 J-007266-05 UBE2J1 51465 NM_016021 37577121 GCUCUUAUAUUCCGACGAA 
UBE2QL1 J-024273-12 J-024273-12 UBE2QL1 134111 XM_940609 88987241 GACUAAAGAUUGUCAACGA 
UBE2QL1 J-024273-09 J-024273-09 UBE2QL1 134111 XM_940609 88987241 GCAAAUGCCGUUCGGAUUA 
UBE2QL1 J-024273-10 J-024273-10 UBE2QL1 134111 XM_940609 88987241 CCACUUAGAUAUCGACUCA 
UBE2QL1 J-024273-11 J-024273-11 UBE2QL1 134111 XM_940609 88987241 GAGUCAUAAUAGUCGUGAA 
UBE2S J-009707-06 J-009707-06 UBE2S 27338 NM_014501 7657045 GGAGGUCUGUUCCGCAUGA 
UBE2S J-009707-07 J-009707-07 UBE2S 27338 NM_014501 7657045 GCAUCAAGGUCUUUCCCAA 
UBE2S J-009707-05 J-009707-05 UBE2S 27338 NM_014501 7657045 ACAAGGAGGUGACGACACU 
UBE2S J-009707-08 J-009707-08 UBE2S 27338 NM_014501 7657045 CCAAGAAGCAUGCUGGCGA 
UBE2U J-008998-11 J-008998-11 UBE2U 148581 NM_152489 22749026 GCUUUCUAAUCCAGUGCUA 
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UBE2U J-008998-09 J-008998-09 UBE2U 148581 NM_152489 22749026 CCUAAAGACCCACGUAAAU 
UBE2U J-008998-10 J-008998-10 UBE2U 148581 NM_152489 22749026 GGGUAUCACUGCUAAGCCU 
UBE2U J-008998-12 J-008998-12 UBE2U 148581 NM_152489 22749026 ACAGAAUACUACAGAACUC 
UBE2W J-009643-08 J-009643-08 UBE2W 55284 NM_001001482 47933382 ACAUAGGCCUACAGAAUUA 
UBE2W J-009643-07 J-009643-07 UBE2W 55284 NM_001001482 47933382 GGAAAUGAGUAGUGAUAUG 
UBE2W J-009643-10 J-009643-10 UBE2W 55284 NM_001001482 47933382 GAGGAGGUACUGUGUGUUA 
UBE2W J-009643-09 J-009643-09 UBE2W 55284 NM_001001482 47933382 GUAAUGCAUUGUUGAAAGA 
UBR1 J-010691-06 J-010691-06 UBR1 197131 NM_174916 83656781 GGAAAUCAGCGCGGAGUUA 
UBR1 J-010691-09 J-010691-09 UBR1 197131 NM_174916 83656781 GAUCAGCAAACCCACAAUA 
UBR1 J-010691-07 J-010691-07 UBR1 197131 NM_174916 83656781 GUACAAUCGUGUGGACAUA 
UBR1 J-010691-08 J-010691-08 UBR1 197131 NM_174916 83656781 GCGAAGAAAUGGACUGUCU 
UBR3 J-016653-08 J-016653-08 UBR3 130507 NM_172070 40255162 AGAUCGACCUACUGGAUUA 
UBR3 J-016653-07 J-016653-07 UBR3 130507 NM_172070 40255162 GAGAAAGCUCACCCAGUUA 
UBR3 J-016653-06 J-016653-06 UBR3 130507 NM_172070 40255162 AGGCAAACCUCUCUACAUU 
UBR3 J-016653-05 J-016653-05 UBR3 130507 NM_172070 40255162 AGAAAAGUCUUACGAAGUA 
UBR4 J-014021-12 J-014021-12 UBR4 23352 NM_020765 82659108 UGAACAAAUUUGCCGAUAA 
UBR4 J-014021-09 J-014021-09 UBR4 23352 NM_020765 82659108 GGGAACACCCUGACGUAAA 
UBR4 J-014021-11 J-014021-11 UBR4 23352 NM_020765 82659108 CUACGAAGCUGCCGACAAA 
UBR4 J-014021-10 J-014021-10 UBR4 23352 NM_020765 82659108 UCAUGAAGCCUGUUCGAAA 
UBR5 J-007189-09 J-007189-09 UBR5 51366 NM_015902 41352716 GGUCGAAGAUGUGCUACUA 
UBR5 J-007189-06 J-007189-06 UBR5 51366 NM_015902 41352716 GCACUUAUAUACUGGAUUA 
UBR5 J-007189-07 J-007189-07 UBR5 51366 NM_015902 41352716 GAUUGUAGGUUACUUAGAA 





Supplementary Table 4. List of antibodies. 
 
Protein Manufacturer Reference Application 
Androgen Receptor ThermoScientific MA5-13426 WB 
β-catenin (Ser33/37/Thr41-phospho) Cell Signaling 9561 WB 
β-catenin (total) Transduc lab 610468 WB/IF 
c-Myc Santa Cruz (1.N.2): sc-70469 WB 
CACUL1 (C10orf46) ABGENT AP4997b-ev WB 
CAND1 Abnova H00055832 WB 
Cdt1 Abcam ab70829 WB 
Cytokeratin 18 Dako M 7010 WB 
E-Cadherin BD Transduc lab 610181 WB/IF 
ERG Abcam [EPR3864] (ab92513) WB 
ERG Santa Cruz (C-17): X sc-354 X IP 
FAK Transduc lab F15020 WB/IF 
FKBP51 Santa Cruz (H100) : sc-13983 WB 
Frizzled-4 Santa Cruz (C-18): sc-66450 WB 
GAPDH Santa Cruz sc-25778 WB 
GSK3-beta Cell Signaling 9315 WB 
γH2AX (Ser139) Millipore 16-202A WB/IF 
phospho-IκB (Ser32) Cell Signaling 2859 WB 
Integrin beta 1 Abcam ab30394 WB/IF 
LEF1 Millipore 17-604 WB 
N-Cadherin BD Transduc lab 610921 WB/IF 
NEDD8 Abcam ab81264 WB/IF 
phospho-NF-κB (Ser536) Cell Signalling 3033 WB/IF 
Occludin In Vitrogen 33-1500 WB/IF 
P21 Santa Cruz (C-19): sc-397 WB 
P27 Cell Signalling 3686 WB 
P53 Santa Cruz  (FL-393 G): sc-6243-G WB 
Paxillin Transduc lab 13520 WB 
Prostein Santa Cruz  (A-5) : sc-393069 WB 
PSA DAKO  A0562 WB 
SUMO-1 Santa Cruz (FL-101): sc-9060 WB 
UBE2A GeneTex GTX114186 WB 
UBE2H Santa Cruz (18-Z): sc-100620 WB 
UBE2S ABGENT AP20071b-ev WB 
UBE2U Sigma HPA021660 WB/IF 
UBE2U Santa Cruz sc-104725 WB 
Ubiquitin Santa Cruz (P4D1): sc-8017 WB 





Supplementary Table 5. List of primers. 
 
































Supplementary Table 6. Scores muRZ for Apoptosis and Cell Number, obtained during secondary screens. In red –
scores above the threshold muRZ > 0,82, decreasing viability (increasing apoptosis or decreasing cell number). In gold 
- strongest scores RZ>1,5, decreasing viability (increasing apoptosis or decreasing cell number). In green –scores above 
the threshold muRZ > 0,82, increasing viability (decreasing apoptosis or increasing cell number). 
 


































































AREL1-06 -1.39 0.14 -0.19 -0.86 0.10 -0.29 0.73 0.91 0.22 0.38 -0.21 0.09 
AREL1-07 -0.03 2.54 2.50 2.01 0.67 7.70 0.31 -0.04 -0.44 -0.90 -0.71 -1.60 
AREL1-08 0.46 0.02 0.09 -0.91 -0.30 0.07 0.61 0.10 -0.04 1.07 0.30 1.73 
AREL1-09 -0.61 -0.22 0.01 -0.15 -0.65 0.33 -0.15 -0.05 0.31 0.25 0.38 -0.16 
CACUL1-09 0.78 0.77 5.41 0.02 1.19 35.80 -0.13 0.40 -0.11 -1.27 -0.70 -2.29 
CACUL1-10 11.47 19.01 4.65 -0.67 4.08 1.62 1.73 -0.72 -1.27 -0.35 1.03 -0.72 
CACUL1-11 0.80 0.24 0.89 1.02 -0.10 0.08 0.08 1.37 0.01 0.08 0.72 0.90 
CACUL1-12 -0.54 -0.26 -0.36 -1.08 0.09 -1.11 0.47 0.24 0.35 0.67 -0.43 0.51 
CAND1-09 2.29 0.13 0.09 -0.12 2.67 0.96 0.87 -0.40 1.21 0.14 -0.31 1.28 
CAND1-10 2.23 4.22 6.97 2.04 21.77 21.55 0.34 1.01 -1.19 -1.71 -0.50 -1.95 
CAND1-11 -0.78 0.50 3.88 0.12 0.37 -0.28 0.78 1.25 -1.15 -0.77 -0.68 -1.75 
CAND1-12 0.62 -0.09 -0.08 2.43 0.12 -1.01 0.25 0.15 0.82 0.50 0.11 0.66 
siAllStars 0.15 0.07 0.16 0.21 -0.03 0.14 -1.02 -0.13 0.04 -0.09 0.82 0.25 
siCellDeath 14.30 21.97 0.57 40.35 47.09 75.56 -1.04 -1.82 -1.34 -3.20 -1.90 -3.43 
siERG -0.46 -0.25 4.52 1.85 1.59 27.59 -1.39 -0.93 -1.21 -1.62 -1.09 -2.61 
CUL2-05 -0.30 1.48 2.40 -0.20 0.56 -0.70 1.40 -0.35 -0.18 0.22 -0.21 -0.24 
CUL2-06 0.23 -0.26 2.57 -0.83 -0.50 0.29 -0.70 -0.53 -0.35 1.08 -0.73 -0.24 
CUL2-07 0.75 3.88 -0.17 8.55 -1.43 22.35 -0.44 -0.45 0.14 -0.48 0.10 -1.93 
CUL2-08 0.54 1.17 0.07 -1.26 1.28 -0.48 0.87 0.01 0.43 1.05 -0.03 0.76 
CUL4B-05 -0.21 -0.94 -0.24 -0.14 -0.37 -0.97 1.10 0.94 0.69 1.21 0.04 0.96 
CUL4B-06 0.36 1.05 -0.62 -0.38 0.02 -0.35 -0.30 -0.65 1.97 0.26 -0.62 0.51 
CUL4B-07 -0.67 -1.13 -0.09 2.19 0.03 0.57 -0.41 1.49 0.89 0.54 -0.38 0.07 
CUL4B-08 -1.20 -0.05 -0.40 -0.46 -0.31 -1.20 1.58 0.60 0.90 1.23 0.18 0.74 
DCUN1D3-05 -1.41 0.45 2.80 0.77 -0.75 -0.81 0.63 0.22 -0.42 1.01 -0.02 -0.10 
DCUN1D3-06 4.02 19.39 8.63 1.21 6.06 34.89 1.39 -0.16 -0.56 -0.66 0.97 -2.56 
DCUN1D3-07 -0.49 1.47 -0.19 -0.27 -0.53 -0.84 0.84 1.11 0.43 0.84 -0.15 0.34 
DCUN1D3-08 -0.13 -0.45 -0.83 -0.37 -0.72 -1.08 -0.17 0.52 1.63 -0.38 0.41 0.93 
DCUN1D5-09 -1.19 0.13 -0.41 -0.18 -0.55 -0.79 0.89 -0.02 1.42 0.80 -0.16 0.69 
DCUN1D5-10 -0.73 0.16 -0.06 -0.56 -0.24 -0.77 0.31 0.24 1.21 1.35 -0.26 0.67 
DCUN1D5-11 0.75 0.35 1.32 0.21 7.77 1.07 -0.52 0.45 0.24 -0.47 -0.08 -0.84 
DCUN1D5-12 5.92 4.05 7.88 1.93 7.43 0.40 1.14 1.91 -0.97 -0.03 -0.26 -0.70 
HERC2-09 1.34 1.93 0.06 -0.30 6.21 1.82 0.80 -0.31 0.09 0.10 -0.08 -0.70 
HERC2-10 0.74 0.31 0.33 0.82 1.40 0.17 0.03 -1.31 -0.37 -1.05 0.02 0.94 
HERC2-11 -1.40 -0.87 -0.37 0.12 -0.36 0.20 -0.33 -0.27 0.15 -0.44 -0.99 0.81 
HERC2-12 -1.03 -0.43 0.62 -0.01 -0.20 -0.73 0.25 0.32 -0.71 0.21 1.11 1.23 
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HERC5-06 4.34 11.38 0.84 2.45 0.70 4.62 -0.25 -0.67 -0.64 -0.51 -0.46 -1.92 
HERC5-07 -1.43 0.31 1.27 -0.55 0.24 -0.87 0.14 -0.48 -0.50 0.86 0.65 0.58 
HERC5-08 -0.40 0.44 -0.07 0.32 0.09 0.07 -0.06 -0.65 0.71 -0.35 0.29 0.41 
HERC5-09 -0.18 -1.05 1.38 -0.29 0.54 -1.55 0.80 3.02 -0.45 -0.08 -1.08 0.76 
RBX1-07 -0.27 0.26 0.64 -0.03 0.05 -0.28 0.89 0.03 0.26 0.19 -0.45 -0.67 
RBX1-08 -0.74 -0.85 1.48 0.42 -0.38 0.03 0.58 0.64 -0.70 -0.31 -0.80 -0.91 
RBX1-09 -0.90 -0.31 -0.03 2.27 0.11 0.19 -0.96 -0.56 -0.31 -1.38 -0.88 -1.30 
RBX1-10 -0.96 -0.99 -1.04 0.51 0.01 0.17 0.33 1.03 1.82 -0.45 -0.89 -0.87 
RNF25-05 -0.70 -0.13 0.54 -0.26 -0.18 -1.02 0.22 0.24 0.06 -0.36 -0.67 1.02 
RNF25-06 -0.67 0.44 -0.54 -0.94 -0.51 -0.47 0.48 -0.19 0.54 1.08 0.08 0.41 
RNF25-07 -0.38 -0.23 0.09 -0.35 -0.41 -0.25 1.57 -0.22 0.22 0.97 0.29 0.32 
RNF25-08 -0.77 -0.46 -1.07 -0.43 -0.77 -0.79 -0.84 0.56 1.07 -1.00 0.54 1.17 
SAG-05 0.13 -0.81 -0.84 -0.07 -0.40 -0.75 -0.59 0.86 1.72 0.26 0.03 1.19 
SAG-06 0.06 -0.41 -0.12 -0.72 0.13 -0.80 1.06 0.10 0.20 0.81 -0.26 0.85 
SAG-07 -1.59 -1.06 -0.02 -1.01 -0.26 -0.35 0.38 0.80 -0.41 -0.72 -0.78 -0.27 
SAG-08 0.47 0.93 -0.10 0.10 -0.10 -0.26 0.33 0.39 0.19 0.85 0.58 0.54 
SPOP-08 0.48 0.74 -0.61 -0.24 -0.29 -0.56 0.00 0.08 0.57 0.82 -0.90 0.15 
SPOP-09 -0.72 -0.36 -0.19 -0.82 0.47 -0.74 0.38 0.80 -0.45 1.40 -1.35 0.58 
SPOP-10 -0.17 1.14 0.12 -0.28 0.48 1.40 -0.05 -0.98 0.83 0.06 1.62 0.30 
SPOP-11 -0.35 -1.22 1.21 -0.74 -0.70 -0.73 -0.17 2.16 -0.11 -0.54 -0.18 0.63 
UBA3-05 -1.47 0.65 3.12 -0.15 0.40 -0.35 1.68 0.22 -0.70 1.25 -0.73 -0.42 
UBA3-06 -0.54 -0.58 -0.49 -0.61 -0.20 -0.72 0.18 0.18 0.79 0.54 0.18 1.05 
UBA3-07 0.77 1.54 -0.59 0.01 -0.49 -1.06 0.19 -0.37 0.43 0.16 -0.09 -0.33 
UBA3-08 0.22 0.12 4.90 0.76 2.71 0.00 -0.63 0.08 -1.01 -0.41 -0.51 -0.97 
UBE2A-05 -0.46 -0.48 -0.54 -0.49 -1.12 -0.48 0.41 1.32 0.69 -0.03 6.73 0.74 
UBE2A-06 -0.77 -0.50 -0.39 -0.56 -0.73 -0.60 -0.17 1.52 0.53 1.07 0.15 0.58 
UBE2A-07 -0.82 -0.77 -0.94 -0.79 -0.69 0.16 0.06 0.42 0.18 -0.32 -0.26 -0.55 
UBE2A-08 -0.43 -0.81 0.01 -0.99 -1.25 -0.97 -0.07 -0.13 -0.53 -0.36 6.85 0.60 
UBE2D2-06 -0.37 -0.37 -0.81 -0.45 0.01 0.45 -0.71 -1.06 1.26 -0.36 -0.91 0.65 
UBE2D2-07 3.31 9.36 7.63 0.97 3.32 4.20 0.44 0.81 -1.03 -0.33 -0.70 -1.59 
UBE2D2-08 -1.10 -0.53 0.79 0.85 0.59 1.35 0.02 -1.61 -0.69 0.07 -0.80 -0.45 
UBE2D2-09 -0.20 -0.65 -0.52 2.44 -0.21 -0.17 0.31 0.94 1.32 -0.17 0.62 -0.10 
UBE2F-09 -0.47 0.08 0.00 0.81 -0.03 0.07 0.61 -0.50 1.04 0.44 0.46 0.13 
UBE2F-10 -0.57 -0.06 -0.61 0.17 -0.31 -0.38 -0.34 -0.64 0.84 0.15 0.14 0.29 
UBE2F-11 -0.23 0.62 1.78 1.57 -0.81 1.87 -1.84 -1.76 -1.21 -1.03 1.78 -1.66 
UBE2F-12 -0.70 -0.03 -0.33 -0.51 -0.68 -0.96 1.66 0.25 0.75 1.02 0.66 0.50 
UBE2G1-06 0.24 -0.49 0.67 -0.79 -0.52 -0.49 -0.33 -0.59 -0.24 0.48 -0.35 0.67 
UBE2G1-07 -0.67 -0.44 -0.31 -0.72 0.55 -0.76 0.43 0.51 0.89 1.04 -0.08 0.46 
UBE2G1-08 -0.01 -0.84 0.65 -0.38 -0.93 -0.02 0.36 0.15 0.65 1.14 1.03 -0.50 
UBE2G1-09 -0.07 -0.70 -0.52 0.14 -0.21 -0.30 -1.26 -0.31 0.32 0.63 1.98 -0.62 
UBE2H-05 5.54 13.95 4.35 0.42 1.77 2.19 1.91 0.76 -0.51 1.27 0.48 0.05 
UBE2H-06 -0.36 -0.68 -0.59 -0.12 -1.22 -0.18 0.90 0.68 0.89 0.54 5.43 0.37 
UBE2H-07 0.76 1.90 -0.09 -0.96 -0.09 -0.42 0.57 1.62 0.64 1.25 1.54 0.49 
UBE2H-08 0.91 -0.36 1.56 0.53 0.03 1.68 -0.52 0.52 -1.29 -1.12 1.12 -1.60 
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UBE2J1-05 -0.91 -0.77 -0.50 -0.43 -0.81 0.13 -0.22 0.11 0.07 -0.30 3.80 -0.38 
UBE2J1-06 0.40 -0.15 3.10 2.75 3.44 1.25 0.89 1.07 -0.97 -0.02 0.64 -1.44 
UBE2J1-07 -0.97 -0.10 1.14 0.12 0.26 9.31 1.47 -0.33 -1.16 0.14 -0.63 -1.64 
UBE2J1-08 4.13 0.29 -0.22 -0.56 0.05 0.93 -0.72 -0.59 0.51 -0.38 0.20 0.37 
UBE2QL1-09 -0.57 -0.36 -0.32 -0.53 -0.68 -0.77 0.34 -0.08 0.75 -0.12 0.12 0.02 
UBE2QL1-10 1.80 -0.08 2.97 -0.80 -0.44 0.25 0.81 1.96 0.58 0.21 1.51 -1.11 
UBE2QL1-11 -0.85 -1.21 -0.56 -0.11 -0.33 -1.06 0.42 0.20 0.73 1.33 1.04 0.53 
UBE2QL1-12 1.25 6.12 3.44 -0.43 10.99 2.32 0.43 -0.16 -0.22 -1.34 -1.84 -1.79 
UBE2S-05 2.69 1.07 0.38 0.35 -0.69 4.92 -0.59 0.45 -1.22 1.50 1.56 -1.84 
UBE2S-06 -0.02 -0.50 -0.43 1.25 -0.37 0.82 0.38 0.31 -0.20 0.34 5.58 -0.15 
UBE2S-07 0.28 1.46 1.45 0.32 0.35 -0.07 0.07 1.91 0.96 0.55 -0.08 -0.35 
UBE2S-08 1.47 1.40 -0.69 0.20 0.18 0.70 -0.83 -0.97 0.89 -0.17 -0.21 -0.69 
UBE2U-09 -0.94 -0.40 -0.35 0.41 -0.29 -0.54 0.94 1.00 0.94 0.45 0.63 0.37 
UBE2U-10 3.12 3.73 1.34 4.96 3.72 32.69 0.47 -0.47 -1.11 -1.25 -0.18 -1.95 
UBE2U-11 1.43 0.56 3.41 -0.61 -0.14 2.50 1.04 0.64 -0.80 1.23 -0.17 -1.09 
UBE2U-12 6.47 3.83 1.00 1.71 14.26 2.44 0.65 -0.50 -0.74 -0.53 -1.22 -1.73 
UBE2W-07 -0.40 -0.43 -1.04 1.11 -0.46 -0.10 -0.17 -0.89 1.43 0.27 0.05 -0.02 
UBE2W-08 5.60 1.76 4.22 2.20 7.27 6.11 0.05 -0.82 -1.01 0.91 -0.14 -0.42 
UBE2W-09 -0.24 -0.99 -0.55 -0.47 -0.37 -0.30 0.22 1.13 0.82 0.08 0.58 0.57 
UBE2W-10 -0.87 0.12 -0.38 -0.90 -0.36 -0.36 0.55 -0.19 1.05 0.83 1.31 0.20 
UBR1-06 0.07 0.05 0.41 -0.46 -0.46 -0.29 -1.05 0.25 0.17 0.17 0.93 -0.28 
UBR1-07 -0.46 0.44 -0.50 0.31 0.46 0.37 1.50 1.30 0.27 1.01 0.25 -0.10 
UBR1-08 7.37 6.75 0.18 2.12 0.95 0.47 -0.60 0.48 -0.48 -0.55 1.08 -1.30 
UBR1-09 0.00 0.77 -0.83 -0.10 -0.09 -0.42 1.14 -0.15 0.36 0.75 -0.03 -0.26 
UBR3-05 -0.31 -0.56 -0.89 -0.15 0.87 -1.00 -0.69 0.27 -0.19 -0.36 1.33 -0.46 
UBR3-06 -0.85 -1.06 -0.87 -0.67 -0.40 -0.85 1.41 0.45 0.82 1.15 -0.12 1.20 
UBR3-07 6.34 7.20 5.41 17.59 9.09 5.38 -0.35 -0.85 -0.87 -1.00 -0.18 -1.19 
UBR3-08 1.12 3.06 -0.36 -0.32 -0.19 -0.17 -0.27 -0.92 0.26 -0.19 0.24 -0.27 
UBR4-09 -0.46 -0.84 -0.85 0.08 0.63 0.04 -0.42 0.14 1.31 0.35 0.37 0.10 
UBR4-10 1.29 -0.40 -0.86 -0.03 0.20 -0.07 0.86 0.35 1.32 0.27 0.10 0.52 
UBR4-11 -0.44 -0.44 -0.74 -0.63 -0.28 -0.62 1.75 0.31 0.76 0.32 -0.30 0.64 
UBR4-12 0.32 -0.35 0.42 -0.53 -0.15 0.86 1.12 3.51 0.13 0.39 1.73 -0.85 
UBR5-06 -0.08 0.51 -0.18 -0.69 -0.85 -0.55 -0.31 -0.43 -0.16 0.17 0.09 -0.24 
UBR5-07 -0.99 -0.81 -0.95 0.13 -0.37 -0.60 -1.08 0.37 0.91 2.29 0.00 0.59 
UBR5-08 -0.12 -0.92 -0.81 0.31 -0.04 -0.90 0.02 0.52 0.76 0.09 -0.05 1.12 





Supplementary Table 7. Summary of secondary screens. Designations: numerics - number of hit siRNAs causing the 
same phenotype. 2 to 3: means 2 hit above the threshold, and 1 more just below the threshold. 1 (but 07): 1 hit with the 
'major' phenotype, but siRNA with catalogue number 07 is a hit in the other direction. In red - hits decreasing viability, 
in green - increasing viability. Colon “Overall” describes the “major” phenotype caused by the gene inhibition: death – 
more apoptosis, survival – less apoptosis, ↓/↑ in cells – decrease or increase of cell number comparing to control. 
Gene 
Overall Consensus VCaP 
VCaP 
(StdM) 





2 3 2 2 3 Extremely clear phenotype 
CAND1 death 




2 to 3 2 2 0 (but 07) 1 (but 08) 2 Potentially ERG-specific? 
CUL4B 
survival 








0 AND 3 
to 4 
0 (but 07) 
AND 2 
0 and 0 
2 AND 1 to 
2 
weak but clear 
UBE2A 
survival 
AND ↑ in 
cells 
All 
0 to 2 
AND 0 
0 to 2 
AND 2 
1 AND 0 
1 to 2 AND 
1 
2 to 4 AND 
2 
1 AND 0 weak but clear 
RBX1 
survival 
OR ↓ in 
cells 
Just VCaP 2 to 3 2 
1 (but 
08) OR 0 
0 (but 09) 
OR 1 
0 OR 2 to 
3 





0 to 1 3 2 
1 (but 08 
& 06) 
1 (but 07) 1 







1 to 2 
OR 2 
1 OR 1 2 OR 2 
1 OR 1 to 
2 
2 OR 0 
1 OR 0 to 
2 
2 siRNAs cause mostly apoptosis, 
and 2 others cause mostly 








2 0 1 1 (but 11) 
Only 1 siRNA is strong -> off-




1 to 3 1 to 2 3 1 (but 12) 2 2 (but 12) Specific for AR-sensitive cells? 
AREL1 no effect 
All             only si07 kills cells - off-target 








1 to 2 1 (but 3?) 
1 (but 
07,08) 
Only si06 definitely causes death -
> off-target? 
HERC2 no effect 
all             








3 1 0 
1 (but 07 
& 09) 
  
RNF25 no effect All               
SAG no effect All             Not very clear 
SPOP no effect All               





1 1 1 to 3 1 2 
Only si06 definitely causes death -
> off-target? 
UBE2F no effect all               






0 2 1 1 3   
UBE2W No effect 
all             
Only si08 causes death - off-
target? 
UBR1 No effect 
all             
Only si08 causes death - off-
target? 
UBR3 No effect 
all             
Only si08 causes death - off-
target? 
UBR4 No effect all               
UBR5 No effect 
all             
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The major aim of cancer therapy is to specifically suppress malignant 
neoplasm without detriment to normal cells. Modern therapeutic approaches 
exploit characteristic hallmarks of cancer cells, which render them 
susceptible to certain types of assault such as DNA damage, and mitotic and 
oxidative stress. Recently, the ubiquitin-proteasome system (UPS) has 
emerged as one of the principal cancer targets. In this work, a systematic 
approach, based on cascade organization, is described for screening the UPS. 
The effect of RNAi knockdown of individual UPS components on the 
viability of PCa cells was evaluated, with major focus on the TMPRSS:ERG-
positive cell line, VCaP, as a model of the prevalent phenotype of prostate 
cancer. Seven genes have been identified to be particularly important for the 
functioning of PCa cells. Among them, UBE2U was the strongest hit. This 
thesis provides the first evidence for UBE2U involvement in prostate 
carcinogenesis and describes initial characterization of UBE2U as a potential 
drug target. 
The prevalence of the components of the CRL/NEDD8 pathway in the hits 
(four out of seven) suggests the importance of neddylation to PCa biology. 
Two of these hits, CUL2 and RBX1, being specific to TMPRSS2:ERG-
positive cells, were potentially ERG-dependent. This study reveals the crucial 
role of the CRL-exchange factor, CAND1, in particular, when neddylation is 
compromised. Knockdown of CAND1 induces apoptosis in VCaP cells 
which is further potentiated by neddylation-specific inhibitor MLN4924. 
CAND1 is, therefore, a novel potential drug target. Furthermore, this study 
has found that the inhibition of the CRL/NEDD8 pathway in PCa cells has a 
complex outcome that strongly depends on cellular context. The MLN4924 
inhibitor induced apoptosis in all tested cell lines, though TMPRSS2:ERG 
positive cells were significantly more resistant. This study demonstrates that 
the increased resistance of VCaP cells reflects the plasticity of cancer cells is 
provided by the sophisticated interaction network ERG:NF-kB:c-Myc:Wnt/β-
cat:AR. Partial inhibition of neddylation triggered transcriptional 
reprogramming of the VCaP cells, leading to cell quiescence and inhibition 
of proliferation-dependent apoptosis. This was a result of the re-activation of 
the AR program and the induction of a differentiation-like state. We conclude 
that the CRL/NEDD8 pathway regulates one of the cancer transcriptional 
networks which underlie cancer cell plasticity. This knowledge may help in 
the search for better treatments for TMPRSS2:ERG-positive cancers. 
Finally, it was observed that neddylation inhibition changed the membrane 
properties and the morphology of VCaP cells. This was accompanied by 
dose-dependent changes in the level and localization of several membrane-
associated proteins, including occludin, N-cadherin, paxillin and FAK. We 
thus conclude that CRL/NEDD8 pathway might be involved in the 
sorting/trafficking of membrane proteins. This part of the work requires 
further investigation, since gaining an understanding of its underlying 
mechanisms would be of general importance and may uncover a new role of 
the CRL/NEDD8 pathway in the regulation of cellular functions. 
General conclusions: 
1.We have obtained a comprehensive dataset on the involvement of all the 
human E1-E2 UPS components in the regulation of viability of PCa cells. 
2.Our work has revealed new potential drug targets for PCa treatment: 
UBE2U and CAND1. 
3.We have demonstrated the role of CRL/NEDD8 pathway in the regulation 
of cancer cell plasticity and morphology. 
